Post on 22-Jun-2020
transcript
1. Greeting ������������������������������������������������������������������������������������������������������������������������������������������� 4
2. Overview of the Korean Pharmaceutical Industry ������������������������������������������������������������ 6
1) Current Status
2) Production Management System
3) Development of New Drugs
4) R&D Reinforcement
5) Biopharmaceuticals
6) Globalization
7) Korean Pharmaceutical Industry Vision - PHARMA 2020
Contents
3. Directory of Pharmaceutical Companies �������������������������������������������������������������������������� 13
· Regular Members(2015. 4)
A~D ���������������������������������������������������������������������������������������������������������������������������������������������������������������������������� 14
E~J ��������������������������������������������������������������������������������������������������������������������������������������������������������������������������� 66
K~P �������������������������������������������������������������������������������������������������������������������������������������������������������������������������� 110
R~Y �������������������������������������������������������������������������������������������������������������������������������������������������������������������������� 158
· Associated Members(2015. 4)
C~G ��������������������������������������������������������������������������������������������������������������������������������������������������������������������������� 200
4. Korean Pharmaceutical Company List ����������������������������������������������������������������������������� 206
Greetings to all! I am Kyeong-Ho Lee, Chairman of the Korea Pharmaceutical Manufacturers Association,
On behalf of about 200 KPMA member companies making efforts for continuous development of
Korean pharmaceutical industry and for better and healthier life of people, I would like to express my
welcoming message to all the readers of this book.
Korean pharmaceutical industry produces safe and quality medicines by strictly complying with
domestic Pharmaceutical Affairs law as well as international regulations including ICH guidelines from
developing stage of medicines to manufacturing, distributing and consuming stage.
As a result of the effort, the Ministry of Food and Drug Safety, Korean regulatory authority for safety and
quality management of medicines, joined the membership of PIC/S (The Pharmaceutical Inspection
Convention and Pharmaceutical Inspection Co-operation Scheme) in 2014 together with Japan, which
is a proof that the quality and safety of medicines made by Korea is globally recognized.
As of 2016, a total of 26 new drugs(New Chemical Entities) have been developed by Korean pharma
industry, and Korea ranks 10th in the world based on the standard of US FDA approval. Combined with
excellent biotechnology infrastructure and clinical study capability(Seoul is the best city in the world
based on the number of clinical study) and advanced IT technology, Korea now is one of the global
powerhouses in terms of biopharmaceuticals. The market size of Korean pharmaceutical industry
accounts for about 20 billion dollars and with this confidence, Korean pharma industry is knocking
on the global market though vigorous export and direct overseas investment such as constructing
manufacturing site overseas.
Welcoming Message
2016 Directory of Korea Pharmaceutical Industry4
The purpose of this directory book is to provide you with practical support for your business by
presenting the detailed information of competitive Korean pharma companies who are ready to go
global as well as brief picture of Korean pharma market. I truly understand that when trying to enter
into overseas market including Asian market, it is difficult to select appropriate potential partners and to
make a real contact with the person in charge.
Therefore, this directory consists of KPMA member company list, the actual contact point and main
business area, flagship product, technology, size and recent status of the company,
I hope this book helps you understand better of Korean pharma companies and also conduct business
exchange more actively.
Thank you
Dr. Kyeong Ho Lee
Chairman
Korea Pharmaceutical Manufacturers Association
5
Overview of the Korean Pharmaceutical IndustryKorea’s pharmaceutical market is worth approximately USD 17billion as of 2014, accounting for
about 1.5% of the global pharmaceutical market worth USD 1.06 trillion. As of 2014, the number
of pharmaceutical companies in Korea stands at 894. Among them, manufacturers of finished
pharmaceutical products are 285 with a combined workforce of 78,259 employees. The actual
output of pharmaceutical products, including finished pharmaceutical products (USD 12.2billion),
amounts to roughly USD 16 billion.
As of the end of 2014, Korea has manufactured 11,854 ETC drugs(worth USD 10,104.6 million) and
6,164 OTC drugs (worth USD 2,132 million). USD 15,801million
USD 15,801million
unit : USD 1million
Category 2010 2011 2012 2013 2014
Productrion 13,676 13,562 13,668 14,222 14,422
Export 1,555 1,707 2,029 2,036 2,223
Import 4,487 4,784 5,032 4,529 4,713
Trade balance -2,933 -3,077 -3,003 -2,492 -2,490
Market size 16,608 16,639 16,671 16,714 16,912
2016 Directory of Korea Pharmaceutical Industry6
USD 15,801million
Production Management SystemEquipped with production infrastructure conforming to CGMP regulatory standards
Joined PIC/S in 2014
The Korean pharmaceutical industry has invested over USD 2.6billion to build a production
infrastructure that conforms to U.S. CGMPs through the GMP advancement project initiated in
the mid-2000s. The joining of PIC/S (Pharmaceutical Inspection Convention and Pharmaceutical
Inspection Co-operation Scheme) by the Ministry of Food and Drug Safety in 2014 is also expected
to further increase the global standing of the Korean pharmaceutical industry and bolster its
exports.
Development of New Drugs26 new medicines(NCE) and 52 incrementally modified drugs
Through 2015, Korea has succeeded in developing 26 new medicines since the inception of Sunpla
Injection (SK Chemicals) in 1999, an anti-cancer medicine and Korea’s very first locally developed
new medicine.
As many as eight pharmaceutical products have been locally authorized as botanical drugs as of
late 2015. Korea also produces 52 incrementally modified drugs (through 2015), including Hanmi
Pharmaceutical Company’s Esomezol – a reflux esophagitis medicine and Korea’s first incrementally
modified drug that gained FDA approval in 2013 for sales in the U.S.
7
Biopharmaceuticals Developed the world’s first stem-cell therapy productProducing four of five globally commercialized stem-cell therapy products
Korea is rising as a global biopharmaceutical power based on its outstanding biotechnology
infrastructure, advanced clinical study, and world-class IT technology. Korea’s Hearticellgram-AMI
(Pharmicell) is the world’s first stem-cell therapy product to gain approval for marketing. In 2012,
Hunterase (Green Cross) became the world’s second medicine developed to treat Hunter syndrome
and has been designated as an orphan drug by FDA.
Currently, four out of five globally commercialized stem-cell therapy products have been developed
and manufactured by Korean companies (Hearticellgram-AMI, Cartistem, Cupistem, and Neuronata-R).
Korea also boasts advanced production facilities for biopharmaceuticals. The production facilities
within the Incheon Free Economic Zone, with a current capacity of 330,000 liters a year, will be
upgraded to an annual capacity of 510,000 liters by 2018. This upgrade is expected to help the
Incheon Free Economic Zone emerge as the world’s largest biopharmaceutical production base.
The Korean government has been providing strategic support for biopharmaceuticals, including its
investment of USD 291million in 2015, in an aim to release and commercialize five biopharmaceutical
products globally by 2017.
R&D ReinforcementA continued increase in R&D investment (8.25% of sales invested)A total of 671 products in the pipeline
The Korean pharmaceutical industry continues to expand its investment in R&D each year to boost
the development of new medicines.
The R&D expenses of Korean pharmaceutical companies equipped with labs and research-
dedicated departments have demonstrated continued growth. As of 2013, the ratio of R&D
expenses to sales stands at 8.25%, equivalent to USD 1.06billion. As a result, Korean pharmaceutical
companies have 671 new medicines currently in the pipeline (as of late 2013). Among these new
medicines, 25 have already been approved by FDA to begin clinical tests, completed all the steps to
gain final approval, or gained final approval for sales.
2016 Directory of Korea Pharmaceutical Industry8
GlobalizationExports reaching USD 2.4 billion Increased export of medicine development technologyDirect overseas investment reaching USD 150 million
The Korean pharmaceutical industry is advancing into the world in earnest as evidenced by its
increasing export of finished products, drug substances, and technology as well as its soaring
foreign direct investment (for the construction of production plants, etc.).
The total exports of pharmaceutical products sold in 188 countries in 2014 stand at USD 2.40349
billion, a 14% increase from the previous year. Pharmaceutical product exports have demonstrated
an impressive yearly growth rate of 19.7% since 2006. In 2016, pharmaceutical exports are projected
to exceed the USD 2.6 billion mark.
Since 2010, an average of 18.4 cases of technology export has been completed per year. In 2015,
a USD 4.2billion contract was concluded, representing the largest-scale single case of technology
export in the nation’s history. The total number of technology export contracts successfully signed
to this day stands at 164 (involving 32 companies).
9
unit : KRW 1million (USD 1million)
2011 2017 2020
Korean Market Size 18,000,000 (15,810)
27,000,000 (23,715)
37,000,000 (32,499)
Production Scale 15,400,000 (13,527)
30,000,000 (26,350)
50,000,000 (43,917)
Top 50 Global Pharmaceutical Companies - 1 2
Developing Global New Drugs - 4 10
R&D Investment 1,000,000 (878)
3,000,000 (2,635)
6,000,000 (5,270)
Overseas Export of Medicine 1,900,000 (1,669)
11,000,000 (9,662)
23,000,000 (20,202)
Road to becoming the 7th Largest Pharmaceutical Power in the World
Korean Pharmaceutical Industry Vision – PHARMA 2020To grow into a global top-seven pharmaceutical powerTo reinforce investment in R&D for new medicinesTo foster high-caliber pharmaceutical specialists
Korea is strengthening its foothold in the global pharmaceutical market and is emerging as an
advanced pharmaceutical producer as evidenced by its production infrastructure that conforms
to CGMP regulatory standards, the joining of PIC/S (Pharmaceutical Inspection Convention and
Pharmaceutical Inspection Co-operation Scheme), the development of 26 new medicines, and its
pharmaceutical exports worth over USD 2.2billion. Furthermore, Hanmi Pharmaceutical Company’s
cumulative exports of new medicine development technology recently totaled about USD 7billion.
As an extension of its efforts to expand its presence in the global pharmaceutical market and
thereby improve the quality of life for all humanity, Korea has established a vision and roadmap to
reinforce its investment in R&D, foster high-caliber specialists, and join the ranks of the global top-
seven pharmaceutical powers by 2020 and is working hard to achieve its vision.
2016 Directory of Korea Pharmaceutical Industry10
1. To enhance investment in R&D for developing new drugs :
expanding government R & D support by 200% (USD 2,640 million)
2. To boost financing for investment and loan: a cumulative USD 4,400 million in funding over 5 years
3. To attract and train core experts: to create 58,000 jobs and train 10,000 expexrts
4. To expand strategic overseas advance: to achieve USD 9,660 million in exports
5. To build an advanced level of infrastructure: to become the 5th-largest clinical trial country in the world
Source: Ministry of Health & Welfare ‘the world’s seven leading
pharmaceutical powerhouse enter’ Vision -related key indicators
11
2016 Directory of Korea Pharmaceutical Industry14
Ahn-Gook Pharm. Co., Ltd.JIN AUH
993-75 Daelim-dong, Yeongdeungpo-gu, Seoul, Korea
Sep. 1959
Pharmaceuticals, Diagnostic Medical Devices, Cosmetic
430
82-2-3289-4359
82-2-849-4123
www.ahn-gook.com
RepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Summary (1 Million Won)
Fiscal Year 2008 2009 2010
Sales 75,900 100,529 108,500
R&D Expenditure 4,326 6,434 8,799
Capital 69,400 85,300 99,600
Financial Figures
Historical Background : Ahn-gook Pharmaceutical co. LTD(AG) was established in Sep 1959
Nature of Business : AG is a korean leading pharmaceutical company specialising in the developing, markting and distribution of pharmaceutical specialty products and medical devices.
Mission Statement : AG has developed and supplied outstanding medicines for the last 50 years, dedicated to developing ‘advanced pharmaceutical products for health and happiness of the mankind.’
Main Focus : Since the establishment in 1959, we have accumulated experiences in pharmaceutical industry. We have been focusing on the respiratory, digestive and circulatory systems of human body.
Main Business areas : Pharmaceuticals, Diagnostic Medical Devices, Cosmetics and Export.
Company Profile
15
Main Products
Product (Ingredient) Use Exporting Countries
1. Anytin SR tab. (Trimebutine maleate 300mg)
Digestive
2. Levotension tab. (S-amlodipine 2.5mg)
Antichypertension
3. Anycough cap. (theobromine 300mg) Antitussive & Expectorant
4. Synatura Syrup. (Among 100mL Coptis Rhizoma Butanol Ext 87.5mg Ivy leaf 30% Ethanol Ext 262.5mg)
Antitussive & Expectorant SingaporeHongkong
5. Anyfen tab. (Dexibuprofen 300mg) Anti-inflammatory analgesic antipyreticPhilippines
Vietnam
6. Tobicom-S (Retinol, etc.) Honduras
7. Grandpaze-F Tab. (Trimebutine, etc.) Digestive Pakistan
8. Xaltrin xl Tab.(Alfuzosine HCl 10mg) Benign Prostatic Hyperplasia
9. HPVDNAChip kit Diagnosis of Human Papilloma virus which is risk factor of cervical cancer
10. Anyfen Syrup (Dexibuprofen 12mg/mL)
Antipyretic
New Active Substances
Product (Ingredient) Use Approval Date
Anycough cap. (Theobromine 300mg) Antitussive & Expectorant Jun. 2008
Synatura syrup (Among 100mL Coptis Rhizoma Butanol Ext 87.5mg Ivy leaf 30% Ethanol Ext 262.5mg)
Antitussive & Expectorant Mar. 2011
R&D Pipeline
Ingredient Use Stage of Development
AG NCA805 Asthma RS
AG NPN803 Nephritis Remedies RS
AG NPP709 Antitussive PII
AG SCT101 Antihypertension PI
AG SDT102 Urological agent PC
AG SFT201 Antihypertension PC
AG SPT201 Antiulcerant PIII
2016 Directory of Korea Pharmaceutical Industry16
Contact PersonContact PhoneContact E-mail
Doyoun Cho
82-2-2630-0728
dycho@ajupharm.co.kr
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 60,520 68,146 77,207
R&D Expenditure 2,000 2,500 2,700
Capital
Financial Figures
Established in 1953, Aju Pharm had been developed quality drugs to cure disease in Korean market.
We had separate cephalosporin site in our factory which also produce tablet, capsule and ampoule.
Also we are exporting more than 10 countries with amount of USD 2.5 Million.
Focus Area : Antibiotics, Cardiovascular and Olive Leaf products.
Company Profile
Aju Pharm Co., Ltd.Joongkil Kim
600 Gyeongin ro, Guro-gu, Seoul, Korea
1953
Antibiotics, Cardiovascular
about 310
82-2-2630-0728
82-2-2636-7519
www.ajupharm.co.kr
RepresentativeHeadquarter AddressFoundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
17
Product (Ingredient/Formulation) Use Exporting Countries Remarks
1. Ceftriaxone 1g Inj Antibiotics Cambodia, Vietnam OEM, ODM
2. Eperisone HCl 50mg Neuro-Muscular Vietnam
3. Ambroxol HCl 30mgAntitussive
ExpectorantsVietnam
4. Candesartan cilexetil 16mg Circulatory Phillippines
5. Olirex(Olive Leaf Ext spray) Sore throat China Food item
6. Cefotaxime 0.5g, 1g Antibiotics Yeman OEM
7. Cefuroxime 750mg Antibiotics Philippines
8. Amikacin 500mg/2ml Antibiotics Azerbaizan
Main Products
R&D Pipeline
Compound Name Code Use Stage of Development
Eperisone SR Muscular New product launch in
July, 2015
Zerocid (Omeprazole + NaHCO3)
PPIWill be launch in 3Q of
2015
2016 Directory of Korea Pharmaceutical Industry18
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 34,456 28,730 29,638
R&D Expenditure 1,821 1,695 1,783
Capital 1,112 1,112 1,112
Financial Figures
About 20 years, we Korea Arlico Pharm have been poured our energy into helping people to live healthier and happier based on the belief that life is precious and nature is the source of all life.
We value our quality through KGMP validation for better circumstance.
In the year 2010, we had 30% increase from 2009 and keep growing its sale record in 2011 and exports to 4 Countries as for April. 2011. In the near Future, we hope to find more countries to have a strong partnership.
Focus Area : NSAIDs, Anti-infective, Antihistamine & Respiratory, Dermatology, Gastrointestinal, Cardiovascular.
Company Profile
Arlico.co.Ltd.RepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Hang Gu Lee
Korea Arlico B/D, 7-21,Baumoe-ro 27-gil, Seocho-gu, Seoul, Korea
Oct. 1. 1992
Tablets, Ointments, Creams, Gels
200
82-43-535-8877
82-43-535-8175
www.arlico.co.kr
Contact PersonContact PhoneContact E-mail
Seung Chan Han
82-2-520-6945
schan@arlico.co.kr
19
Product (Ingredient/Formulation) Use Exporting Countries Remarks
1. Thioct HR Tab. (Thioctic Acid 600mg / Solid oral)
Relief and treatment of diabetic multiple
neuritis
VietnamMongol
2. Acrasone Cream 10g (Betamethasone Dipropionate 0.64mg, Clotrimazole 10mg, Gentamicin Sulfate 1mg)
Anti-inflammatory action and good antifungal action
VietnamTanzania
Hongkong
3. Cozasartan Tab. (losartan potassium 50mg)
Hypertension Renal disease in
diabetic patient with hypertension
4. Curazol Cap. (Omeprazole 20mg)
Duodenal ulcer, gastric ulcer, reflux
esophagitis etc.,Ecuador
Main Products
2016 Directory of Korea Pharmaceutical Industry20
Astellas Pharma Korea., Inc.Jeong Hai Do
GumHa B/D 6F 41-2 Chungdam-dong, Gangnam-gu, Seoul, Korea
Apr. 1. 2005
246
82-2-3448-0504
82-2-3448-0510
www.astellas.com/kr
RepresentativeHeadquarter Address
Foundation DateTotal StaffRepresentative PhoneRepresentative Fax Web
Summary (1 Million Won)
Fiscal Year 2008 2009 2010
Sales 105,800 132,300 150,400
R&D Expenditure
Capital 11,500 11,500 11,500
Financial Figures
Astellas Pharma Korea., Inc. is a local subsidiary of Japanese pharmaceutical corporate with superior R&D and worldwide sales network. It was founded in April 1st 2005 by merging of Fujisawa pharma Korea Co., and Yamanouchi pharma Korea Co., with 100% Japanese ownership
Company Profile
21
Main Products
Product (Ingredient) Use Exporting Countries
1. Harnal D (Tamsulosin HCI) benign prostatic hyperplasia Japan
2. Vesicare (Solifenacin Succinate) Overactive Bladder Netherland
3. Oldeca (Barnidipine HCl) Hypertension Japan
4. Berasil (Beraprost sodium) Peripheral Arterial Disease Japan
5. Protopic (Tacrolimus) Atopic Dermatitis Japan
6. Nasea (Ramosetron HCI) Nausea and Vomiting Japan
7. Prograf (Tacrolimus) Post-transplant rejection Ireland
8. Irribow (Ramosetron HCI) Irritable Bowel Syndrome Japan
9. Rapamune (Sirolimus) Post-transplant rejection
10. Perdipine (Nicardipine HCI) Hypertension
2016 Directory of Korea Pharmaceutical Industry22
BC World Pharm Co., Ltd.
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 25,496 30,375 35,692
R&D Expenditure 4,617 4,452 4,760
Capital 830 830 1,335
Financial Figures
BCWORLD PHARM is a R&D driven pharmaceutical company that has been committed to developing innovative formulations.
We are focusing on the development of niche buster products and highly marketable modified drugs.
BCWORLD PHARM not only has been certified as Korea Innovative Pharmaceutical Company (KIPC) by Korea Ministry of Health & Welfare but also designated as Advanced Technology Center (ATC) by Korea Ministry of Knowledge Economy.
Also, now we are constructing the EUGMP/cGMP facility.
Focus Area : Narcotics, Anti-TB, Carbapenem antibiotics.
Company Profile
RepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Sung Han Hong
Gyung Building, 78, Gaepo-ro, 22-gil, Gangnam-gu, Seoul, Korea
Jun. 10. 1980
DDS (Drug delivery system)
203
82-2-2182-0400
82-2-574-5064
www.bcwp.co.kr
Contact PersonContact PhoneContact E-mail
David Kim
82-2-2182-0452
tree365@bcwp.co.kr
23
Product (Ingredient/Formulation) Use Exporting Countries Remarks
1. Mepem Inj. (Meropenem 500mg, 1g, 2g / Injection)
Antibiotics Vietnam, Philippines
2. Sinraci Inj. (Imipenem 500mg+Cilastatin Sodium 500mg / Injection)
AntibioticsVietnam, Philippines,
Nigeria
3. BC Citicolin Inj. (Citicolin 500mg / Injection)
Central nervous system
Azerbaijan, Dominican Rep.
4. Tubes Tab. (Ethambutol+Isoniazid+Rifam
picin+Pyrazinamide / Tablet)Anti-TB
5. Tibare Inj. (Remifentanyl 1,2,5mg /
Injection)Narcotics
Main Products
R&D Pipeline
Compound Name Code Use Stage of Development
Anti-cancer BCWP-D001 Anti-cancer Formulation
Anti-cancer BCWP-D003 Anti-cancer Non-Clinical
Anti-cancer BCWP-D004 Anti-cancer Non-Clinical
Anti-cancer BCWP-D006 Anti-cancer Formulation
Schizophrenia BCWP-D009 Schizophrenia
Diabetes BCWP-D011 Diabetes Formulation
Anti-cancer BCWP-Y001 Anti-cancer Formulation
Anti-infective BCWP-Y002 Anti-infective Formulation
Antibiotics BCWP-A001 Antibiotics Clinical
Hyperlipidemia BCWP-C001 Hyperlipidemia Clinical
Antiemetics BCWP-E001 Antiemetics Launch
ADHD BCWP-E002 ADHD Formulation
BPH BCWP-E004 BPH Formulation
2016 Directory of Korea Pharmaceutical Industry24
Binex Co., Ltd.
Summary (1 Million Won)
Fiscal Year 2009 2010 2011
Sales 32,252 47,243 53,458
R&D Expenditure 4,349 706 4,663
Capital 7,800 8,357 9,379
Financial Figures
Binex is currently comprised of three main business sectors : biologics, chemicals, and cell therapy. As the only biologics CDMO in Korea, Binex plays the key role in solving the manufacturing bottleneck of biopharmaceutical industry with accumulated experience and US and EU-GMP facility.
Company Profile
RepresentativeHeadquarter AddressFoundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Myoung-Ho Jeong
368-3 Dadae-ro, Saha-gu, Busan, Korea
Mar. 21. 1985
biosimilar
about 300
82-32-850-3235
82-32-850-3299
www.bi-nex.com
25
Main Products
Product (Ingredient) Use Exporting Countries
1. Contract Development and Manufacturing Service - Binex manufactures client's products both in API and finished form based on clients' need. Products are manufactured at GMP quality with proficiency at reduced time and cost.
-
2. Human Growth Hormone Growth Hormone Deficiency -
3. Small Molecule Products Digestion, Ophthalmic Solution, Etc. -
R&D Pipeline
Ingredient Use Stage of Development
Infliximab (Remicade biosimilar)Rheumatoid Arthritis and other inflammatory conditions
Phase I in Korea and Japan for Rheumatoid Arthritis
2016 Directory of Korea Pharmaceutical Industry26
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 312,075 327,279 359,491
R&D Expenditure 9% 7.4% 7.2%
Capital 17,440 18,283 19,170
Financial Figures
Boryung Pharmaceutical Co., Ltd. has put a strong presence as TOP leading company in Korean pharmaceutical market since its foundation in 1963. Boryung has made its continuous efforts and investment on R&D to produce high-quality products in its specialty areas such as cardiovascular, gastrointestinal, antineoplastic, antibiotics drugs and API. Boryung has devoted itself to achieve the aspiration of company, “Dedicating to the health of mankind.”
In particular, Kanarb (Fimasartan, 8th ARB NCE for anti- hypertension ) has been already licensed out to 14 Latin countries including Mexico & Brazil, Russia and China (16 countries in total). Following the launch of Kanarb in Mexico in Sept. 2014, further global market development has been accelerated. In 2015, Kanarb is going to be licensed to APAC & MENA regions and be launched in Russia, Brazil, and China in a few years. Also, the projects heading to the reference countries such as EU & Japan have been carried out.
Following the remarkable success in Kanarb, Boryung is confident to make another success story with its next key pipeline, Lafutidine(new generation H2RA), Cilnidipine (4th generation CCB), and Gelfos (Top antacid in East Asia), with its best clinical values in class.
Focus Area : Cardiovascular, Gastro-intestinal, Antibiotics, Oncology, API synthesis.
Company Profile
Boryung Pharmaceutical Co., Ltd.RepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Tae-Hong, Choi
Boryung B/D, 136,Changgyeonggung-ro, Jongno-gu, Seoul, Korea
Oct. 1. 1963
Cardiovascular, Oncology
1,100
82-2-708-8000
82-2-744-0682
www.boryung.co.kr
Contact PersonContact PhoneContact E-mail
Micheal park or Jay Kim
82-2-708-8032 or 8051
jrpark@boryung.co.kr / jaykim@boryung.co.kr
27
New Active Substances
Product (Ingredient) Use Approval Date
Fimasartan Anti-hypertension Korea / 2011
Mexico / 2014Ecuador / 2014
Product (Ingredient/Formulation) Use Exporting Countries Remarks
1. Kanarb Tab. (Fimasartan) Anti hypertensionMexico, Brazil, Russia, China
NCE(New chemical entity)
2. Cilnidipine Tab. Anti hypertension 4th generation CCB
3. Lafutidine Tab. Gastric Ulcer, Gastritis new generation H2RA
4. Gelfos Susp. (ALPO4) Antacid China, TaiwanTop Antacid in East Asia
5. Pitavastatin Hyperlipimedia Japan API
6. Oncology InjectableAnticancer Chemotherapy
ASEAN, MENA
7. Cephalosporin Injectable Antibiotics Japan PMDA approved
Main Products
R&D Pipeline
Compound Name Code Use Stage of Development
Kanarb + CCB combo BKC002 Hypertension P3
Kanarb + Statin combo BKC003Hypertension
HyperlipimediaP3
Kanarb + CCB + Statin combo
BKC004Hypertension
HyperlipimediaP1
Incrementally modified drugs
BNT002 Dementia P1
New Chemical Entity BSN001Hypertension
Diabetes mellitusDiscovery
Gene therapy BCB002 Liver cancer P1
Vaccine BVN002 Vaccine P3
Vaccine BVN003 Vaccine PC
2016 Directory of Korea Pharmaceutical Industry28
Summary (1 Million Won)
Fiscal Year 2008 2009 2010
Sales 24,709 29,567 34,943
R&D Expenditure 1,623 1,502 1,296
Capital 39,514 39,875 42,237
Financial Figures
CHO-A PHARM.CO.,LTD. has put all efforts to develop and supply excellent medicine
under a corporate slogan, “Keep People Healthy and Happy Away from Diseases” since
establishment in 1988. With fast growth over the last 20 years, CHO-A PHARM, is one of the leading pharmaceutical company in Korea producing about 300 kinds of drugs
especially OTC products and health foods. CHO-A PHARM. began producing drinkable double-neck ampoule under technical cooperation with Laphal of France in 1994 and currently has 30 kinds of proudcts and exports them to Vietnam, Yemen and Guatemala.
After establishing a manufacturing factory in 1994, CHO-A has invested to improve quantity and maximize production capacity by obtaining an approval of KGMP in 1995 as well as ISO 9001 for the first time in the pharmaceutical industry in 1996. Through the CHO-A Bio technical R&D center, CHO-A succeeded producing a somatic-cell cloned pig for the first time in Korea and cloned a pig with EPO gene character coverted in 2005. Thereby CHO-A is expected to be a prominent biotech company of the next generation.
Company Profile
CHO-A PHARM. Co., Ltd.RepresentativeHeadquarter Address
Foundation DateTotal StaffRepresentative PhoneRepresentative Fax Web
Sung-Hwan Cho
1F Ace-Techno Tower, 12, Dangsan-ro 2-gil, Yeongdeungpo-gu, Seoul, Korea
1988
270
82-2-2166-4000
82-2-2166-4111
www.choa.co.kr
29
Main Products
Product (Ingredient) Use Exporting Countries
1. Uratonyl (L-Ornithine-L-Aspartate) Acute,Chronic Hepatic disease Vietnam
2. Hemopoly (Ferric hydroxide polymaltose complex)
Iron deficiencya anemia Vietnam
3. Calcitonic (Calcium Lactate) Calcium deficiency Vietnam
4. Elemmen (Adenosine, Thymidine) Acute, chronic hepatitis, anemia Vietnam
5. New Hem (Ferrous gluconate hydrate, Manganese gluconate, Copper gluconate)
Iron deficiencya anemia Yemen
6. Lyvitol (L-Lysine HCl, Inositol, Cyanocobalamin)
Nutrition disorder Vietnam
7. Ronalamin (Calcium Lactate) Calcium deficiency Vietnam
8. Manpos (L-Arginine-L-Aspartate) Physical mental asthemia Guatemala
9. BabycolcolReduction of symptoms resulting from
the cold Mongolia
10. Ginseng Korea (Korean Ginseng Ex.)Reduces fatigue, improve mental
conditions.Vietnam
2016 Directory of Korea Pharmaceutical Industry30
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 461,246 508,664 544,130
R&D Expenditure 50,494 61,174 74,727
Capital 32,625 23,523 23,523
Financial Figures
Chong Kun Dang Pharmaceutical Corporaiton (CKD) was spin-off from CKD Holdings on November 2, 2013. CKD is a new organization to manufacture, sales and market the pharmaceutical products, and has the excellent capabilities to develop new chemical entities (NCEs), incrementally modified drugs and generics. CKD has invested over 10% of annual revenues for R&D, and succeded to develop NCEs such as CAMTOBELL®, anti-cancer drug and DUVIE®, anti-diabetic drug. Currently, CKD has developed other NCEs including the targeted therapy for the treatment of cancer through clinical trials. Furthermore, since September 2014, CKD-732 for the treatment of Prader–Willi syndrome, an orphan disease has been developed under the clinical trial III in the United States.
Company Profile
CHONG KUN DANG PHARMACEUTICAL CORP.RepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Young-Joo Kim
8, Chungjeong-ro, Seodaemun-gu, Seoul, Korea
1941
Oncology, Immunology, Metabolism, Cardiovascular
1,858
82-2-2194-0300
82-2-2194-0369
www.ckdpharm.com
Contact PersonContact PhoneContact E-mail
Indy Baik
82-2-3149-7849
ihbaik@ckdpharm.com
31
New Active Substances
Product (Ingredient) Use Approval Date
Camtobell (belotecan) Ovarian cancer, SCLCOctober 22, 2003/Korea
Duvie (lobeglitazone sulfate) Type II diabetes July 4, 2013/Korea
R&D Pipeline
Ingredient Use Stage of Development
CKD-906 Dyslipidemia Phase III completed
CKD-732 Obesity Phase III
CKD-330 Hypertension Phase III
CKD-337 Dyslipidemia Phase III
CKD-391 Dyslipidemia Phase III
CKD-11101 Anemia Phase III
CKD-904 Benign prostatic hyperplasia Phase III
CKD-943 Pain, Uremic pruritus Phase III
CKD-516 Solid cancer Phase I completed
CKD-345 Hypertension+Dyslipidemia Phase I
CKD-519 Dyslipidemia Phase I
CKD-581 Lymphoma Phase I
CKD-841 Cancer Phase I
CKD-12201 Cervical cancer Phase I
CKD-12101 Neutropenia Pre-Clinical
Product (Ingredient/Formulation) Use Exporting Countries Remarks
1. Lipilou (atorvastatin calcium anhydrous)
Hyperlipidemia Asia
2. Dilatrend (carvedilol) Hypertension
3. Cipol-N (cyclosporine) Immunosuppressant Asia, S. America
4. Tacrobell (tacrolimus) Immunosuppressant Japan, Asia
5. Candemore plus (candesartan + HCTZ)
Hypertension Asia
6. Sarlotan (losartan potassium) Hypertension
7. Imotun (avocado-soya) Arthritis
8. Pregrel (clopidogrel resinate) Myocardial infarction
9. Avelox (moxifloxacin hydrochloride)
Antibiotics
10. Telminuvo (telmisartan, S-amlodipine)
Hypertension
11. Belloxa (oxaliplatin) Anticancer Asia
12. Gemtan (gemcitabine hydrochloride)
Anticancer Asia
Main Products
2016 Directory of Korea Pharmaceutical Industry32
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 449,000 414,000 430,000
R&D Expenditure
Capital
Financial Figures
CJ HealthCare started its business as Pharmaceuticals Business Unit at CJ CheilJedang Corporation from 1984.
CJ HealthCare first developed EPO[Epokine], ciprofloxacin injection[Citopcin] and simvastatin [Simvastar] pharmaceutical products in Korea. Now, CJ HealthCare has become a representative Korean pharmaceutical company in promising therapeutic areas such as oncology, cardiology, endocrinology and nephrology.
As of 1st April, 2014, CJHealthCare was spun off from CJ CheilJedang Corporation and became a separate pharmaceutical corporate entity with purpose of enhancement of expertise in pharmaceutical business to grow globally.
Focus Area : ETC (CVs, Antibiotics, IV Solution, Oncology, Endocrinology, Nephrology&Urology, Gastro Intestinal, Musculo skeletal, Respiratory, Others) & Health functional products
Company Profile
CJ HealthCare Corp.RepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Dal won Kwak, Chul ha Kim
CJ Cheiljedang Center, 330, Dongho-ro, Jung-gu, Seoul, Korea
Apr. 1. 2014
NCE , Biologicals, IMD
1,164
82-2-6740-2119
82-2-6740-2491
www.cjp.co.kr
Contact PersonContact PhoneContact E-mail
Kwang Hee Hong
82-2-6740-2181
khong@cj.net
33
Main Products
R&D Pipeline
Compound Name Code Use Stage of Development
Voglibose+Metformin (FDC) VogMet® Diabetes Launched (Korea)
pemetrexed Pemta® RTU Oncology Launched in 4Q 2015 (Korea)
UNDISCLOSED NEPA antiemetics Phase III
UNDISCLOSED CJ-12420* Gastric Acid-Related Disorders Phase III (Korea)Phase I (Completed, global)
UNDISCLOSED IBAT Inhibitor Gastric Acid-Related Disorders PC
UNDISCLOSED JAK Inhibitor arthritis DS
Atorvastatin+Metformin (FDC) CJ-30056 Type 2 Diabetes/Hyperlipidemia Phase II (Korea)
Pemetrexed Soln. CJ-30045 Oncology NDA
Candesartan+Amlodipine (FDC) CJ-30059 Hypertension Phase III (Korea)
Amlodipine+Valsartan+Rosuvastatin CJ-30060 Hypertension/
Hyperlipidemia PI
Amlodipine+Valsartan +Atorvastatin CJ-30061 Hypertension/
Hyperlipidemia PI
Darbepoetin CJ-40001 Anemia PI
UNDISCLOSED CJ-40002 2nd human Growth Hormone PI
UNDISCLOSED CJ-40010 Hand-Foot-Mouth Disease PC
UNDISCLOSED CJ-40012 Retinopathy (LUCENTIS Biosimilar) DS
Product (Ingredient/Formulation) Use Exporting Countries Remarks
1. Epokine Inj. (rh-EPO)The treatment of anemia of hemodialysis patients with end-stage renal disease
Southeast Asia, Africa, The Middle East, North Africa and CIS, Latin America
Biologicals
2. Leukokine Inj. (rh- G-CSF)
The chemotherapy in advanced cancer patients and in acute Leukemia patients can cause the Neutropenia.
Southeast Asia, Africa, The Middle East, North Africa and CIS, Latin America
Biologicals
3. Vancorin Inj. (Vancomycin)The treatment of serious, life-threatening infections by gram-positive bacteria
China Antibiotics
4. Tapocin Inj. (Teicoplanin) The treatment of serious infections by gram-positive bacteria
Southeast Asia, Latin America Antibiotics
5. Moveloxin I.V. solution bag (Moxifloxacin)
The treatment of acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, community acquired pneumonia and so on
Southeast Asia Antibiotics
6. Cinezolid I.V. solution bag (Linezolid)The treatment of vancomycin-resistant Enterococcus faecium infections
Southeast Asia Antibiotics
7. Calmtop Inj. (Irinotecan) The treatment of colorectal cancer Southeast Asia Oncology
8. Pemta Inj. (Pemetrexed) The treatment of pleural esothelioma and non-small cell lung cancer Southeast Asia Oncology
9. CONDITION (Fruit extract of Hovenia dulcis, Natural Herbal Extracts, Taurine) Anti-hangover drink China, Japan, Vietnam
10. HongSamJin Gold (6-yeared red ginseng drink) Red Ginseng drink Vietnam
11. OmapOne Lipid Inj. Soybean oil, Olive oil, Fish oil, Medium-Chain Triglycerides Southeast Asia Parenteral
Nutrition
12. OmapOne Peripheral Inj. Lipid, Amino acid, Glucose Southeast Asia Total Parenteral Nutrition (TPN)
2016 Directory of Korea Pharmaceutical Industry34
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 16,009 20,402 22,753
R&D Expenditure 419 6,499 4,242
Capital 33,013 3,313 43,313
Financial Figures
CMG Pharma is the ODF manufacturing company in Korea. CMG Pharma is an affiliate company of Cha Health Group which has esteemed general hospitals and bio research centers in Korea and also in US. By the fund and support of mother company, CMG Pharma is thriving to develop global leading ODF products.
Focus Area : R&D and Manufacturing of OTF Products.
Company Profile
CMG PHARMA Co., LTDRepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Jeong Ho Kim
14, Dosan-daero 66-gil, Gangnam-gu, Seoul, Korea
Aug. 1. 2001
Oral Dissoluble Film
164
82-31-881-7663
82-31-732-1856
www.cmgpharma.co.kr
Contact PersonContact PhoneContact E-mail
Chloe Cho
82-31-881-7663
chloe@cmgpharma.co.kr
35
Product (Ingredient/Formulation) Use Exporting Countries Remarks
1. Tadalafil ODF (10mg, 20mg) Erectile dysfunction -
Be test completed succesfully in Korea
2. Entecavir ODF (0.5mg, 1mg) Hepatitis type B -
Be test completed succesfully in Korea
3. Aripiprazole ODF Schizophrenia -
- Be test completed succesfully in Korea
- IND submission to FDA in 1Q, 2015
4. Montelukast ODF Asthma -Be test in June, 2015
Main Products
R&D Pipeline
Compound Name Code Use Stage of Development
Confidential CMG-14011 Nocturia Formulation Research
Confidential CMG-14012 OTC Product Formulation Research
Confidential CMG-14013 Anti-emetic Formulation Research
Confidential CMG-14014 Anti-migrain Formulation Research
2016 Directory of Korea Pharmaceutical Industry36
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 129,800 123,400
R&D Expenditure 2,730 1,690
Capital 125,400 150,500
Financial Figures
CTCBIO is a Korean pharmaceutical company which holds top 50 domestic pharmaceutical companies as solid clients and is involved in co-operative partnership with international pharmaceutical companies. Its pharmaceutical business covers development and production of super-generics with drug formulation and delivery technology. We are specialized in micro-encapsulation using fluid bed and OSF formulation. CTCBIO is capable of manufacturing various types of oral dosage forms and has business capabilities starting from formulation development and all the way to commercial production.
Company Profile
CTCBIO, IncRepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Ho Yeon Cho
13, 40-gil, Jungdae-ro, Songpa-gu, Seoul, Korea
Jun. 1993
Finished Formulations
258
82-1661-8800
82-2-449-3886
www.ctcbio.com
Contact PersonContact PhoneContact E-mail
Chae Young Ban
82-70-4033-0233
ban@ctcbio.com
37
Product (Ingredient/Formulation) Use Exporting Countries Remarks
1. Sildenafiltreatment of erectile
dysfunctionLebanon, Iraque,
Taiwan, Japan etc.
Main Products
R&D Pipeline
Compound Name Code Use Stage of Development
Donepezil free base CDFF0212Treatment of
Alzheimer's diseaseNDA applied
Desmopressin CDFF0612Treatment of primary
enuresis, nocturnal enuresis
Bioequivalence test / review of specification and test method completed
Entecavir CDFF0511Treatment of chronic
hepatitis B virusNDA applied
Tadalafil CDFF0213Treatment of erectile
dysfunction
20mg: approved5mg, 10mg : NDA applied
Clomipramine/sildenafil CDFR0812Treatment of premature
ejaculationIND (phase II) applied
Omeprazole/sodium hydrogen caronate
CDFR0209
Treatment of duodenal and gastric ulcer, GERD
and symptoms of gastroesophageal reflux
disease
NDA applied
Sodium picosulfate etc. CDFR0613Eathartic for colonology
and preoperatic treatment
Phase I
2016 Directory of Korea Pharmaceutical Industry38
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 14,680 15,362
R&D Expenditure 1,314 1,813
Capital 2,477 2,777
Financial Figures
A research oriented pharmaceutical company which has focused on developing new drugs and medicines ever since 1998 of its establishment
1. Proven R&D technology in Bio-chemistry
Applied for 45 patents for drug manufacturing-related substances and methods.
2. Stable growth foundation through drug manufacturing business
Growth foundation prepared by continuous surplus management since 2005.
Obtained may types of drugs and OTC drugs.
OEM business run paralled based on KGMP production facilities and excellent manfuactufing capacity
3. New growth engine prepared through continuous R&D
Development of Peptide Drugs , Unnatural Amino Acids Drugs , Green Technology (development of ionic liquids and establishment of refinement technology).
Focus Area : Peptide Drugs, Unnatural Amino Acids, Green Technology(Ionic Liquid)
Company Profile
C-TriRepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Kim Wan-ju / Kim Woon-jang
27, Gyeonggang-ro, Namyangju-si, Gyeonggi-do, Korea
Apr. 23. 1998
New drug/drug manufacture business, ionic liquid business
145
82-31-557-0001
82-31-557-6622
www.c-tri.co.kr
Contact PersonContact PhoneContact E-mail
Eun-ji Jeong
82-31-560-7125
jej@c-tri.co.kr
39
Product (Ingredient/Formulation) Use Exporting Countries Remarks
1. Citrelin Oral Disintegrating Tablet (Taltirelin hydrate / OD Tab.)
Spinocerebellar degeneration
The nation’s first licensed
2. Pliclan Tablet (1000mg / 625mg / 500mg) (Amoxicillin hydrate, Potassium clavulanate, diluted / Tab.)
Penicillins Cambodia
3. MOSAPIA Tablet(Mosapride citrate / Tab.)
GI Tract Regulators & Antispasmodics
4. BROMETIN SOFT Capsule(Bromelain, Dehydrocholic Acid, Pancreatin, Simethicone, Trimebutine maleate / Cap.)
Digestants
5. CTRI CIMETIDINE Tablet (Cimetidine / Tab.)
H2 Receptor Blockers
6. Losartin Tablet (Losartan Potassium / Tab.)
Angiotensin II Receptor Antagonists
7. CIFLUCO Capsule (Fluconazole / Cap.)
Antifungal Agents
8. PRIMOX Tablet (Amoxicillin, Pivoxyl sulbactam / Tab.)
Penicillins
9. FENLEX Tablet (Loxoprofen Sodium / Tab.)
Nonsteroidal Anti-Inflammatory Drugs
10. Pramax Cream (Pramoxine Hydrochloride / Cream)
Hemorrhoidal, Phlebitis & Varicose Preparations
Main Products
R&D Pipeline
Compound Name Code Use Stage of Development
Peptide drugs CTB-001 anticoagulant 1stage clinic
Peptide drugs Desmopressinenuresis,
diabetes insipidusdrug development
Peptide drugs eptifibatide etc. drug development
Antiviral drugs tamiflu derivatives drug development
Antiviral drugs relenza derivatives etc. drug development
green & bio technology ionic liquids and battery
New Active Substances
Product (Ingredient) Use Approval Date
Citrelin Oral DisintegratingTablet(Taltirelin hydrate / OD Tab.)
Spinocerebellar degeneration 2015.02.06 / Korea
2016 Directory of Korea Pharmaceutical Industry40
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 36,025 41,479 46,448
R&D Expenditure 1,414 1,547 1,180
Capital 24,141 27,205 24,246
Financial Figures
Since its founding in 1976, Daewoo Pharmaceutical has endeavored to promote the public health with 3 business principles - sincerity, correctness, research.
We have focused on the business of ethical drugs in the past 30 years in Korea. With the business experience, Daewoo has effort on continuous research, development and investment about facilities and human resources.
Now, Deawoo is preparing to become a global pharmaceutical company with new-drugs pipline, particularly anti-angiogenesis and anticancer drug for the next 10 years. We are investing for world class product facilities to increase oversea business and accomplish R&D projects in Daewoo R&D institute. Daewoo has committed Contract Manufacturing Organization(CMO) business with sufficient technical and marketing resources.
Even in challenging internal and external enviroment, Daewoo will be a competent global pharmaceutical company with recognized ability.
Focus Area : Opthalmic Products / Cancer Drugs / Generic Drugs
Company Profile
Daewoo Pharmaceutical Co., LTDRepresentativeHeadquarter AddressFoundation DateResearch Focus
Total StaffRepresentative PhoneRepresentative Fax Web
Yong-Hoon Ji
153 Dadae-ro, Saha-gu, Busan,Korea
Apr. 1976
1) Ophthalmic product formula modification & customization 2) Development of targeted cancer drugs with inhibition of
angiogenesis
280
82-51-204-3831
82-51-202-3397
www.daewoopharm.com
Contact PersonContact PhoneContact E-mail
Ji-Hoon Suh
82-2-3477-1731
shortyj8@daewoopharm.com
41
Product (Ingredient/Formulation) UseExporting Countries
Remarks
1. Original Relief Eye Drops (Tetrahydrozoline HCl 0.5mg/Ophthalmic Eye Drops)
Relieves red, Irritated eyes
USAOTC (USA
OEM)
2. Advanced Relief Eye Drops (Tetrahydrozoline HCl 0.5mg + Dextran 70 1mg + Polyethylene glycol 400 10mg + Povidone 10 mg/Ophthalmic Eye Drops)
Relieves red, Irritated eyes, Hydrating
moisturizerUSA
OTC (USA OEM)
3. Hyalsan Eye Drops1) Single-use disposable type 0.8 mL
(Sodium hyaluronate 0.8mg/Ophthalmic Eye Drops)2) Multi-use type
(Sodium hyaluronate 1mg/Ophthalmic Eye Drops)
Keratoconjunctival epithelial disorder
Vietnam
4. Tobeson Eye Drops (Tobramycin 3mg, Dexamethason 1mg/Ophthalmic Eye Drops)
Eye steroids,Antiallergics
Vietnam
5. Taspen-ER Tablet (Acetaminophen 650mg/Tablet, Extended Release)
Other Analgesics, Antipyretics
6. Eperisone Tablet (Eperisone HCl 50mg/Tablet)
Skeletal muscle relaxants
Vietnam, Thailand
7. Simvasterol Tablet (Simvastatin 20mg/Tablet)
Antilipidemic agents
8. Pantezol Tablet (Pantoprazole sodium sesquihydrate 45.1mg, as Pantoprazole 40mg / Tablet)
H+ Pump inhibitors
9. Pseudoephedrine Tablet (Pseudoephedrine HCl 30mg / Tablet)
Decongestants, Nasal prep
10. Romicin Tablet (Roxithromycin 150mg / Tablet)
Macrolide antibiotics Vietnam
Main Products
R&D Pipeline
Compound Name Code Use Stage of Development
Macrolactin A
Int. CL.:A61K 31/335:A61K 35/74:C12P 7/62:A61P 29/00Application number:10-2010-0029016
Anti-inflammatory Non-clinical
Macrolactin A and its derivatives
Int. CL.:A61K 31/335:A61P 19/02:A61P 19/00Application number:10-2011-0012707
Anti-angiogenesis Non-clinical
Macrolactin Compounds
Int. CL.:A61K 31/335:A61K 31/365:A61P 1/00:A61P 29/00Application number:10-2012-0011924
The prevention or treatment of inflammatory bowel
diseaseNon-clinical
Macrolactin Compounds
Int. CL.:A61K 31/335:A61K 31/365:A61P 35/00Application number:10-2013-0089955
Anticancer Drug Non-clinical
2016 Directory of Korea Pharmaceutical Industry42
Summary (1 Million Won)
Fiscal Year 2008 2009 2010
Sales 48,385 57,468 66,971
R&D Expenditure 1,036 703 839
Capital 43,065 51,848 53,693
Financial Figures
DAEHWA has been steadily endeavoring to meet your expectation to have a healthful life and escape from a hazard of disease. We supply the best quality pharmaceutical products to the people who earnestly need them, and realize the dignity of human life through our research and development. “Nothing is more precious and valuable than life.” is our permanent spirit and goal.
And, DAEHWA was established in 1984 and has been doing our best for the health of the People through supplying best quality products to the market. And with the completion of the c-GMP facilities in 2009, we are striving to produce high quality pharmaceutical products from “Raw Material” to “Finished Products”.
Company Profile
Daehwa Pharm. Co., Ltd.RepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Han Koo Lee
1056-16 Namhyeon-dong, Gwanak-gu, Seoul, Korea
Jan. 19. 1984
API, TDDS Product, etc.
350
82-2-586-6451
82-2-587-0566
www.dhpharm.co.kr
43
Main Products
Product (Ingredient) Use Exporting Countries
1. PROTASE Tab. (Bromelain 40mg, Crystallized Trypsin 1mg)
Fracture, sprain, internal, external and incarcerated hemorrhoid after proctoptosis and a hemorrhoidal surgery, stagnant breast, mammitis, hematoma and thrombosis
Myanmar, Vietnam, Cambodia
2. Top-Roll S.Cap. (Korea Ginseng 100mg and multivitamins etc.)
Tonic, nutritive supplement : weak, fatigable, lacking physical strength during or after disease, having febrifacient and exhaustive diseases and pregnant and lactating woman.
Myanmar, Vietnam, Cambodia, Ghana,
Bolivia
3. ALMETAMIN Tab. (Betamethasone 0.25mg, Dexchlorpheniramine maleate 2mg)
Urticaria, hay fever, allergic rhinitis, drug hypersensitivity reaction, chronic bronchial asthma, atopic dermatitis, eczema, contact dermatitis, allergic conjunctivitis
Ethiopia, Vietnam, Cambodia
4. DEMACOT Cream (Batamethasone dipropionate 0.64mg,
Clotrimazole 10mg, Gentamicin sulfate 1.0mg(potency)
Allergic dermatitis, alopecia areata, first degree burn, dermatomycosis
Vietnam, Bolivia, Cambodia, Ghana,
Mongolia
5. DICLONIC Tab. (Clonixin lysinate 125mg or 250mg)
Neuralgia, rheumatoid arthritis, myalgia. headache, toothache, menorrhalgia
Bolivia
6. BIDICA Tab. (Biphenyl dimethyl dicarboxylate 25mg)
Treatment for chronic persistent and active hepatitis that is associated with a high SGPT level or drug-induced high transaminase level
Vietnam, Ecuador, Cambodia, Mongolia
7. KEBANON Plaster (Ketoprofen 30mg)Traumatic inflammation of muscles, strains and sprains. Relief of symptoms of muscular pain.
Bolivia, Cambodia, Hongkong,
Vietnam
8. LOXONA Plaster (Loxoprofen 56.7mg)Traumatic inflammation of muscles, strains and sprains. Relief of symptoms of muscular pain.
Cambodia, Hongkong
9. RESNALIN Patch (Tulobuterol 0.5 / 1/2mg)
Respiratory distress caused by airway obstruction of bronchial asthma, acute bronchitis, chronic bronchitis, or emphysema
Myanmar, China
10. FAMOCID Tab. (Famotidine 20mg)
Gastric and duodenal ulcer, reflux esophagitis, hemorrhage of upper digestive tract, zollinger-Ellison syndrome
Ethiopia
R&D Pipeline
Ingredient Use Stage of Development
PaclitaxelBreast cancer, Gastric cancer, Non-small cell lung cancer,
Ovarian cancer
Clinical Study Phase IINew formulation(Oral Solution)
CetrizinePerennial allergic rhinitis,Seasonal allergic rhinitis,
Urticaria, chronic New formulation
Sildenafil Erectile dysfunction New formulation
Voglibose Diabetes mellitus New formulation
Isomers Pre-Clinical Study
2016 Directory of Korea Pharmaceutical Industry44
Summary (1 Million Won)
Fiscal Year 2008 2009 2010
Sales 90,659 111,930 144,696
R&D Expenditure 4,425 4,935 5,683
Capital 5,944 5,944 6,454
Financial Figures
Being a partner for healthy life of human on Customers’ trust
Daewon Pharm.Co.,Ltd. is a state-of-the-art pharmaceutical company that has achieved success in commercializing Pelubi tablet and Aquafol injection. We are developing new follow-up medicines such as anti-hepatitis and anti-asthma. Now, Daewon Pharm seeks to leap forward and become a world-class global pharmaceutical company that improves human health based on advanced technologies and global expertise of over a half century of experience.
Daewon Pharm.Co.,Ltd., as a specialized company manufacturing medicines to cure various diseases, has tried to make the lives of human beings much happier and healthier. We at daewon pharm.Co.,Ltd. continue to invest in R&D, production facility and quality improvement to meet customers’ various needs.
Since it was completed in 1988, the Hyangnam factory of Daewon Pharm.Co.,Ltd. is equipped with superior manufacturing and quality control management system, and has produced over 100 kinds of medicines, i.e. solid dosage medicines, liquied dosage medicines, injectable medicines, sex hormone medicines and etc. In particular, Daewon Pharm.Co.,Ltd. has improved its competitiveness with its updated Hyangnam factory, installed with the cutting-edge systems to meet cGMP levels in Apr. 2009
Company Profile
Daewon Pharm. Co., Ltd.RepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Seung Ho Baek / Seung Ryel Bae
229-3 Yongdap-dong, Seongdong-gu, Seoul, Korea
Jan. 1958
New Chemical Entity
520
82-2-2204-7000
82-2-498-9108
www.daewonpharm.com
45
Main Products
Product (Ingredient) Use Exporting Countries
1. Oramin Cap. (Korean Ginseng + Mulitivitamins + Minerals)
Korean Ginseng Multivitamin25 countries include Myanmar (Latin America, Asia, Africa, CIS, Middle East)
2. Megex-I Susp. (Megestrol Acetate) Anorexia, cachexia of cancer or AIDSDominican Rep., Guatemala, Peru, Panama
3. Naphine Inj. (Nalbuphine HCl) Potent AnalgesicsPhilippines, Domincan Rep. etc.
4. Rizine Tab. (Cetirizine) SympathomimeticsAsia, Latin America, Middle East
5. Codaewon Tab. (dihydrocodeine bitartrate etc.)
Potent AntitussivesHong Kong, Cambodia, Vietnam. etc.
6. Pantyrase Tab. (Pancreatin etc.) Digestives Asia, Latin America
7. Trigel Susp. (Oxethazaine etc.) AntacidsAsia, Latin America, Middle East
8. Metran Cap. & Metran Inj. (Mecobalamin)
Peripheral neuronic disorderDominican Rep., Africa, Pakistan, Afganistan
9. Forend Tab. (Alendronate) OsteoporosisPhilippines, Hong Kong, Vietnam, Guatemala
10. Wontiam Inj. (Cefotiam HCl) Cephalosporins China
New Active Substances
Product (Ingredient) Use Approval Date
Pelubi Tab. (Pelubiprofen) Alagesic & Lumbago 2008
2016 Directory of Korea Pharmaceutical Industry46
Daewoong Pharmaceutical is the pharmaceutical company with the No. 1 sales of prescription drugs in the Korean market.
Established in 1945 in Seoul, South Korea, Daewoong Pharmaceutical offers high-quality and innovative pharmaceutical products and is one of the top market leaders in Korea. For over 60 years, Daewoong Pharmaceutical has been providing better health for people through its total dedication to healthcare. Daewoong has built strong core competency for new drug development to meet diverse medical needs and enhance human life. Building on our core strength, Daewoong Pharmaceutical has involved in becoming a global healthcare group by operating our foreign branches in SE Asia and by collaborating with global partners. We have an inspiring mission to become a top 50 global healthcare company which contributes to improving the quality of life for people worldwide.
The reinforcement of the R&D capacities through the establishment of R&D center in the USA, China and India.
Daewoong Lifescience Research Institute has been focused on developing new chemical entities, biologics, incrementally modified drugs and high-value added APIs. Daewoong has also been studying to find solutions for the unmet therapeutic needs of neuropathic pain disease, Alzheimer’s disease as well as other innovative programs like anticancer gene therapy. Daewoong is operating several overseas offices in China, Vietnam, Indonesia, Thailand, Philippines, USA, and India and has R&D centers in China, India and America.
Focus Area : GI
Company Profile
Daewoong Pharm. Co., Ltd.RepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Jongwook Lee
Bongeunsa-ro 114-gil 12, Gangnam-gu, Seoul, Korea
1945
Biologics, value added generics, generics, medical device
1,700
82-2-550-8800
82-2-550-8400
www.daewoong.co.kr
Contact PersonContact PhoneContact E-mail
Doyoung Brian Kim
82-2-550-8936
doyoung.kim@daewoong.co.kr
47
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 706,600 674,000 737,000
R&D Expenditure 70,000 67,000 73,000
Capital 28,215 28,966 28,966
Financial Figures
Product (Ingredient/Formulation) UseExporting Countries
Remarks
1. Nabota (Botulinum toxin type A / injectable)
Glabellar lines
Thailand, Latin American countries
Contracted to export more than 90 countries including USA and EU
2. Novosis (BMP-2 / bone grafting material)
Dental sinus lifting, spinal fusion
Thailand, Philippines
3. Easyef (Epidermal growth factor / spray)
Diabetic foot ulcer, oral mucositis, acute wound healing)
Vietnam, Thailand, Philippines
Contracted to export to countries in Russia, Middle East, Latin America
4. Caretropin (Human growth hormone / injectable)
Growth hormone deficiency
Philippines, Vietnam, Iran
Contracted to export to countries in Middle East, South East Asia, and Latin America
5. Eposis (EPO, injectable)Anemia in end stage renal diseases
Vietnam, Philippines, Thailand
Contracted to export to countries in Middle East and South East Asia
6. Olostar (Olmesartan, rosuvastatin/ fixed dose combination)
Concomitant hypertension and dyslipidemia
Contracted to export US and Canada
7. Ursa (Ursodeoxycholic acid/ tablet & capsule)
Liver & bile disease including cholestasis, Gallstone, etc
Preparing to enter USA and Australia
8. Albis (Bismuth, sucralfate, ranitidine/ tablet)
Gastric & duodenal ulcer, gastritis
Vietnam
9. Luphere depotProstate cancer, Endometriosis, precocious puberty
Philippines, Vietnam
Registration process ongoing in Russia, Mexico, and US
10. Medicloreedical device for anti-adhesion
Thailand
Main Products
R&D Pipeline
Compound Name Code Use Stage of Development
Fungicidal DWJ205 Oral fungicidal program Research
APA DW206 Antiulcer program Research
Ion channel blocker DWJ208Neuropathic pain, Cancer pain
Research
PRS inhibitor DW209Lung Cancer, pancreatic cancer
Research
2016 Directory of Korea Pharmaceutical Industry48
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 96,562 106,802 111,709
R&D Expenditure 1,041 91,649 67,880
Capital 3,000 3,000 3,000
Financial Figures
DAI HAN PHARM.Co.,Ltd makes Good Pharmaceutical Products in the GMP plant, We make Infusions(Bag, Glass), Injections(Glass, PE, PP), Solutions for external use, and We have exported the product since 2005.
Focus Area : Infusions for PN, Injectable solutions
Company Profile
Dai Han Pharm. Co., Ltd.Yoonwoo Lee
3 Seonyu-ro 45-Gil Yeongdeungpo-gu, Seoul, Korea
Oct. 14. 1945
551
82-2-2678-8445
82-2-2671-9636
www.daihan.com
RepresentativeHeadquarter Address Foundation DateTotal StaffRepresentative PhoneRepresentative Fax Web
Contact PersonContact PhoneContact E-mail
George Kim
82-2-2620-8952
hskim@daihan.com
Product (Ingredient) Use Exporting Countries Remarks
1. Iohexol Inj. 300
Myelography, angiography, urography, Computerized-tomography(CT)-contrast enhancement
VietnamExpect to be
exported
2. Iohexol Inj. 350
Myelography, angiography, urography, Computerized-tomography(CT)-contrast enhancement
VietnamExpect to be
exported
3. Luminal 10% Inj.Sedation (if urgently required), epilepsy and status epilepticus
Vietnam
4. Lefquin Infusion
pneumonia, acute pyelonephritis, multiple urinary tract infection, acute sinusitis, infection of skin and tissue, etc.
Philippines, Vietnam
Main Products
49
5. Lidocaine HCL 2%
1. Anesthesia : epidural anesthesia, nerve block, infiltration anesthesia and surface anesthesia.2. Internal medical use: ventricular arrhythmia.
Hong Kong, Philippines
Expect to be exported
6. Pan-B-Comp Inj.Supply of vitamins and prophylaxis of deficiency of vitamin B series
Cambodia
7. Vitamin K1 Inj.1. Prophylaxia and treatment of
hemorrhage disease for a newborn2. Hypoprothrombinemia
Iran, Vietnam, Philippines, Myanmar
8. Orni Inj.Hepatic coma, Treatment of precoma
Vietnam, Azerbaijan, Uzbekistan
9. Heparogen Inj.Detoxication of liver disease (hepatitis and sequela, tissue damage, hepatic cirrhosis)
Vietnam, Azerbaijan
10. Tranexamin Inj. 500mg
Hemorrhage(by leukemia, aplastic anemia, purpura, cancer, pulmonary hemorrhage, renal hemorrhage, genital bleeding, etc.)
Vietnam, Philippines, Myanmar
11. Tranexamin Inj. 250mg
Hemorrhage(by leukemia, aplastic anemia, purpura, cancer, pulmonary hemorrhage, renal hemorrhage, genital bleeding, etc.)
Vietnam, Philippines, Myanmar
12. Ketorolac tromethamine Inj. Severe pain Philippines
13. Sod. Bicarbonate Inj. 8.4% Acidosis, Acute pruritus Iraq
14. Piroxicam Inj.Rheumatic arthritis, osteoarthritis, ankylosing spondylitis etc.
Vietnam
15. Statirin Inj.Disturbance of consciousness by head trauma and surgery of brain etc.
Vietnam, Myanmar
16. Ciprofloxacin Inj.
Respiratory tract, ENT infections, renal or urinary tract infections, genital infection including gonorrhoea, GI infections, bone or joint infections, etc.
Philippines
17. Aminohex Inj.
Supply of amino acids in following cases (Hypoproteinemia, hypoalimentation, and before/after surgery)
Vietnam
18. Amicomplex Inj.
Supply of amino acids in following cases (Hypoproteinemia, hypoalimentation, and before/after surgery)
Mongolia
19. Hepavia Inj.
Improvement of encephalopathy due to acute / chronic hepatic impairment, supply of amino acids to a patient with hepatic impairment
Vietnam
20. Eyecon Sol.Rinsing and cleaning of contact lens
Japan
2016 Directory of Korea Pharmaceutical Industry50
Summary (1 Million Won)
Fiscal Year 2008 2009 2010
Sales 36,300 50,200 56,700
R&D Expenditure
Capital
Financial Figures
Daiichi Sankyo Korea.,Ltd. is the Korean subsidiary of Daiichi Sankyo Japan, a global Pharmaceutical enterprise. Consolidation of the Daiichi Pharmaceuticals Co.,Ltd. and Sankyo Co. Ltd., gave birth to Daiichi Sankyo Korea Co.,Ltd. in April 2007, which since its launch has expanded its domain of expertise from anti-inflammatory area to cardiovascular area. Daiichi Sankyo Korea offers a fluoroquinolone antibacterial agent named Cravit, an anti-hypertension agent Olmetec and sevikar as well as an anti-dyslipidemia agent Mevalotin. The company will continue to make strides forward to secure a leading status in the pharmaceutical industry by leveraging and further diversifying its product offerings.
Daiichi Sankyo
The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging market. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabloic therapies. Furthermore, the Daiichi Sankyo Group has created a “Hybrid Business Model” which will respond to market and customer diversity and growth opportunities across the value chain. For more information, please www.daiichisankyo.com
Company Profile
Daiichi Sankyo Korea Co.,Ltd.RepresentativeHeadquarter AddressFoundation DateTotal StaffRepresentative PhoneRepresentative Fax Web
Dae Jung Kim
19F, 47 Jong-ro, Jongno-gu, Seoul, Korea
Jul. 16. 1990
122
82-2-3453-3300
82-2-3452-9756
www.daiichisankyo.co.kr
51
Main Products
Product (Ingredient) Use Exporting Countries
1. Olmetec (Olmesartan) Anti Hypertension Imported
2. Olmetec plus (Omesartan + Hydrothiazide) Anti Hypertension Imported
3. Mevalotin (Pravastatin) Anti dislipidemia Imported
4. Sevikar (Olmesartan+amlodipine) Anti Hypertension Imported
5. Cravit (Levofloxacin) Antibiotics Imported
6. Sunrythm (Pilsicainide HCI) Antiarrhythmic agent Imported
7. Effient (Prasugrel) Antiplatelet agent Imported
2016 Directory of Korea Pharmaceutical Industry52
Summary (1 Million Won)
Fiscal Year 2008 2008 2010
Sales 17,019 18,637
R&D Expenditure 828 744
Capital 500 500
Financial Figures
Dalim BioTech has been recognized as the best domestic pharmaceutical manufacturing/marketing firm for the treatment drugs in the field of endocrinology and Ob/Gyn with its solid sales organization covering the entire nation.
Company Profile
Dalim Biotech Co., Ltd.RepresentativeHeadquarter AddressFoundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Jong-Sup Chung
4, Jandari-ro 3-gil, Mapo-Gu, Seoul, Korea
2001
Diabetes, OB/GY, Surgery
163
82-2-335-1656
82-2-3140-3777
www.dalimpharm.co.kr
53
Main Products
Product (Ingredient) Use Exporting Countries
1. Glupa Tab (Metformin HCI) 250mg / 500mg / 800mg / 1000mg
Non insulin depedent diabetes -
2. Glupa Combi Tab 500mg / 80mg (Metformin HCI, Gliclazide)
Non insulin depedent diabetes -
3. Diaryl Tab 2mg / 3mg / 4mg (Glimepiride)
Non insulin depedent diabetes -
4. Garcon Inj. (Glucagon 1mg, Sterile Water 1ml)
Hypoglycemia (insulin shock) -
5. Evoprim Soft Cap. (Evening Primrose Oil)
Diabetic neuropathy, Atopic eczema, Breast pain
-
6. Lipo-A HR Tab. 600mg (Thioctic acid) Diabetic multiple neuropathy -
7. DicaMax 1000 Tab. (Calcium carbonate 1,250mg Cholecalciferol Concentrate Powder 1,000 IU)
Bone health -
8. DicaMax D Tab. (Calcium carbonate 250mg, Cholecalciferol Concentrate Powder 1,000 IU)
Bone health -
9. Premina Tab. 0.3mg /0.625mg (Conjugated equine estrogen)
Postmenopausal syndrome -
10. Norpin Inj. 4ml / 10ml / 20ml (Norepinephrine bitartrate)
Acute hypotension or shock Thailand
2016 Directory of Korea Pharmaceutical Industry54
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 21,870 26,850 32,566
R&D Expenditure 181 245 342
Capital 7,490 44,914 56,716
Financial Figures
DHP KOREA was created for the purpose of being an special company in the field of ophthalmic drugs. As the leading ophthalmic drugs company in Korea, DHP KOREA seeks to be a world-class that continuously tries to meet customer’s need by offering safe and stable drugs. Also, we make constantly effort to comfort demand of various customers, through ceaseless produce and offer more developed products.
Focus Area : Ophthalmic Drugs
Company Profile
DHP Korea Co., Ltd.RepresentativeHeadquarter Address
Foundation DateResearch Focus
Total StaffRepresentative PhoneRepresentative Fax Web
Dae Hoon Yoeu
1106 starvalley, 99, Digital-ro 9-gil, Geumcheon-gu, Seoul, Korea
Aug. 30. 2005
Ophthalmic Drugs (Dry eye, Anti-glaucoma, Anti-allergy/inflammatory/infective, etc)
110
82-2-2027-0078
82-2-2027-0079
www.dhpkorea.co.kr
Contact PersonContact PhoneContact E-mail
Jin-Sook Ko
82-43-230-0304
jsko@dhpkorea.co.kr
55
Product (Ingredient) Use Exporting Countries Remarks
1. Tearinfree EYE DROPS (Sodium Hyaluronate 0.1%) Keratoconjuntival epithelial disorder with
symptoms following :1. Endogenous disease: Sjogren syndrome,
Dry eye syndrome.2. Enthetic disease: Drug-induced trauma
after operation, Enthetic disease due to wearing contact lenses.
N/A
·Preservative-free, 30 Single Dose Units per Box·6 mL Multi Dose Bottle
2. TearinS EYE DROPS (Sodium Hyaluronate 0.18%)
N/A·Preservative-free, 30
Single Dose Units per Box
3. TearinF EYE DROPS (Sodium Hyaluronate 0.3%)
N/A·Preservative-free, 30
Single Dose Units per Box
4. Dr.Fresh EYE DROPS (Sodium Carboxymethylcellulose 0.5%)
·For the temporary relief of burning, irritation, and discomfort due to dryness of the eye or exposure to wind or sun. ·May be used as a protectant against
further irritation.
N/A·Preservative-free, 30
Single Dose Units per Box
5. DryFree EYE DROPS (Cyclosporine 200ug)
·For the increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca.
N/A·Preservative-free, 30
Single Dose Units per Box
6. Tearsopt Free EYE DROPS ( Dorzolamide HCl 22.26mg Timolol Maleate 6.83mg)
·Open angle glaucoma·For the reduction of elevated intraocular
pressure in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blocker.
N/A·Preservative-free, 10
Single Dose Units per Box
7. Floson EYE DROPS (Fluorometholone 1mg)
·To treat eye inflammation N/A·Preservative-free, 10
Single Dose Units per Box
8. Flotera EYE DROPS ( Fluorometholone 1mg, Tetrahydrozoline HCl 250ug)
·For the allergic, noninfectious conjunctivitis & keratitis, severe swelling & hyperaemia, noninfectious inflammation of the anterior segment of the eye (including anterior uveitis, episcleritis & scleritis) and post-operative conditions. ·Inflammation after operation
(glaucoma, cataract)
N/A·Preservative-free, 10
Single Dose Units per Box
9. LevoFresh EYE DROPS (Levofloxacin 0.5%)
·To treat by helping to kill the bacteria which are causing the infection.
N/A ·6mL Multi Dose Bottle
10. SmileO2Tears EYE DROPS ( Sodium Chloride 5.5mg, Potassium Chloride 1.5mg)
·Tired Eyes·Dryness·Contact Lens Discomfort·Dimed Eyes
N/A
·Preservative-free, 30 Single Dose Units per Box·15 mL Multi Dose Bottle
Main Products
Code Use Stage of Development
DHPNP01 Dry Eye Plant scale process development
DHPNP02 Dry Eye Plant scale process development
DHPNP03 Glaucoma Lab-scale process development
DHPNP04 Glaucoma Formulation development
DHPNP05 Allergic conjunctivitis Formulation development
DHPNP06 Cataract Formulation development
R&D Pipeline
2016 Directory of Korea Pharmaceutical Industry56
Summary (1 Million Won)
Fiscal Year 2008 2009 2010
Sales 39,976 60,842 77,515
R&D Expenditure 1,298 1,473 1,485
Capital 8,639 11,138 9,732
Financial Figures
Dong Koo Pharm. Co, Ltd. is a local pharmaceutical company leading Dermatology market in Korea. (Top sales company in Dermatology area)
We are a manufacturer and distributor in South Korea, located in Seoul.
We are equipped with factory under GMP guideline for oral solid forms including tablet, hard cap., soft cap., ointment and cream production lines.
Our sales turnovers recorded more than 70 Million USD in 2011. We have 110 MRs and especially we have a very strong sales/marketing power for Dermatology and Urology field. We have a lot of customers in Dermatology and Urology area such as hospitals, clinics, esthetics and so on.
Company Profile
Dong Koo Pharm. Co., Ltd.RepresentativeHeadquarter AddressFoundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Cho Yong-Joon
222, Gochuk-ro, Guro-gu, Seoul, Korea
May. 1970
Generics, Branded generics, NCE, Neutraceuticals
260
82-2-2688-9611
82-2-2681-1880
www.dongkoo.co.kr
57
Main Products
Product (Ingredient) Use Exporting Countries
1. Dermotasone MLE cream/lotion (mometasone furoate 1mg/g)
dermatological agent
2. Allestine tablet(epinastine HCI 10mg) antihistamine agent
3. Sponex capsule(itraconazole 100mg) antifungal agent
4. Famclover tablet(famciclovir 250mg) antiviral agent
5. Cordicare lotion 2.5% (hydrocortisone 10mg/g)
dermatological agent
6. Boneaid tablet (alendronate Na 91.37mg (70mg as alendronate))
bone modulating agent hongkong
7. Alvista soft capsule (alverine citrate 60mg, Simethicone 300mg)
gastrointestinal agent hongkong
8. Dongkoo levofloxacin tablet 100mg (levofloxacin 100mg)
Chemotherapeutic agent hongkong
9. Urofa SR tablet 0.2mg (tamsulosin HCI 0.2mg)
urological agent
10. Zansi-Q tablet (ranitidine HCI 168mg (150mg as ranitidine))
gastrointestinal agent
R&D Pipeline
Ingredient Use Stage of Development
Alprostadil Erectile dysfunction Clinical trial
Herbal extract Atopic dermatitis Preclinical trial
Antifungal agent Mycosis Preclinical trial
Pollen extract combinationBenign
prostatic hyperplasiaPreclinical trial
Pollen extract FBenign
prostatic hyperplasiaPilot test
FlurbiprofenAnti-inflammatory
AnalgesicPilot test
Amlodipine, Valsartan Hypertension Formulation
IbuprofenAnti-inflammatory
AnalgesicPilot test
DexibuprofenAnti-inflammatory
AnalgesicPilot test
Saw palmettoBenign
prostatic hyperplasiaFormulation
Acetaminophen combination Antipyrectics Formulation
2016 Directory of Korea Pharmaceutical Industry58
Dongkook Pharmaceutical was founded in 1962 and from the early stage since its foundation, Dongkook has concentrated on R&D and technology innovation.
We, Dongkook Pharmaceutical is well known for its OTC products boasting of high brand values in Korea.
Besides OTC products, Dongkook has developed and produced outstanding therapeutic products through various clinical trials, e.g. Pofol Injection, intravenous anesthetic agent, Pamiray, the contrast medium produced using independently synthesized API as the first attempt in Korea, and Lorelin Depot, an anti-cancer agent, earning raves in both domestic and overseas markets.
In 1999, Dongkook completed its registration in PMDA of Japan regarding approval for the finished product in relation to Pamiray; its API, Iopamidol acquired COS (Certificate of Suitability), and Teicoplanin acquired COS in 2009 from EDQM. Bellast Injection as cross-linked hyaluronic acid filler acquired ISO certificate and CE mark from EVPU, and launched in European market. Furthermore, Dongkook completed the GMP approval in Japan for Antibiotic agent, contrast media, anesthetic agent and so on, and also completed the GMP approval in TGA of Australia in 2010.
Currently, Dongkook Pharmaceutical exports finished pharmaceutical products and API to over 50 countries around the world. It seeks to grow into a global leading pharmaceutical company that is trusted and loved by all domestic and overseas customers backed by the greatest global competitiveness.
Focus Area : Nano-emulsions, Long-acting release, Contrast media, HA dermal filler, etc.
Company Profile
Dong Kook Pharm. Co., Ltd.RepresentativeHeadquarter Address
Foundation DateResearch Focus
Total StaffRepresentative PhoneRepresentative Fax Web
Hung Joo, Oh / Young Wook, Lee
7, Teheran-ro 108-gil, Gangnam-gu, Seoul, Korea
Jul. 14. 1962
Nano-emulsions, Long-acting release, Contrast media, HA dermal filler, etc.
658
82-2-2191-9800
82-2-2191-9869
www.dkpharm.co.kr
Contact PersonContact PhoneContact E-mail
Eugene Jang
82-2-2191-9800
jeg@dkpharm.co.kr
59
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 191,571 210,830 222,770
R&D Expenditure 7,967 9,841 9,621
Capital 147,746 162,238 172,834
Financial Figures
Product (Ingredient) Use Exporting Countries Remarks
1. Profofol Injection General Anaesthesia
Japan, Brazil, Uruguay, Russia, Georgia, Iran, UAE, Iraq, Philippines, Thailand, etc.
2. Leuprolide Acetate InjectionProstatic Cancer Endometriosis
Brazil, Mexico, Peru, Uruguay, India, Iran, Pakistan, Kazakhstan, etc.
3. Iopamidol InjectionX-ray contrast media CAT Scanning
Armenia, Georgia, Honduras, Myanmar, Peru, Philippines, Syria, Ukraine, Yemen, etc.
4. Gadopentetate Meglumine Injection
MRI contrast mediaArmenia, Georgia, Jordan, Nigeria, Syria, Ukraine, Vietnam, etc.
5. Octreotide LAR lnjectionAcromegaly Carcinoid Tumors
Chile, Mexico, Peru, etc.
6. Streptokinase Injection Thrombolytic agentDominica, Uruguay, Egypt, Syria, Vietnam, Yemen, etc.
7. Cross-linked Hyaluronic Acid Injection
Injectable implant for filling wrinkles and folds in skin
Poland, Hungary, Peru, Indonesia, Philippines, Syria Turkey, etc.
8. Iopamidol(API) X-ray contrast mediaAustria, Germany, Japan, Tunisia, Turkey, etc.
9. Gadopentetate Meglumine (API)
MRI contrast mediaJapan, Turkey, Tunisia, Iran
10. Teicoplanin(API) Antibiotics
Austrailia, Japan, Begium, Brazil, Greece, Turkey, Tunisia, Ukraine, etc.
Main Products
2016 Directory of Korea Pharmaceutical Industry60
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 223.372 220.241 213.472
R&D Expenditure 10,897 12,317 11,771
Capital 27,931 27,931 27,931
Financial Figures
Dong Wha Pharm, as Korea’s first and oldest pharmaceutical company, is pursuing the ultimate goal of pharmaceutical industry, which is the development of new drugs.
Whal Myung Su, Korea’s first western-style medicine, by integrating the advantages of Western medicine into the royal court’s secret recipe in 1897, the first year of The Great Korean Empire. Furthermore, many pharmaceutical products such as Fucidin ointment, Lacteol and Pancold A etc., have been developed after Dong-Wha Pharmaceutical Research Institute was founded in 1973. Since present state-of-the-art laboratory building was built in 2010, it is now set to become a global hub for new drug development. The Chungju Industrial Complex (established in 2009) is equipped with equipment and facilities that satisfy Current Good Manufacturing Practice (cGMP) Regulations of US FDA In addition, the plant has been evaluated as a world-class pharmaceutical company by the installment of high-tech plant automation system. Utilizing multi-component resources, Dong Wha strategizes to develop numerous superior medicines, the most advanced drugs and new pharmaceutical products.
Focus Area : Diabetic nephropathy, allergic rhinitis, Anti-infectives, etc
Company Profile
Dong Wha Pharm. Ind. Co., Ltd.RepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Doh Joon Yoon
19F, STX Namsan Tower, 98, Huam-ro, Jung-gu, Seoul, Korea
Sep. 25. 1897
NCE (New Chemical Entity)
719
82-2-2021-9300
82-2-776-7873
www.dong-wha.co.kr
Contact PersonContact PhoneContact E-mail
Yoon Kyung Kim
82-2-2021-9341
yoonkyung.kim@dong-wha.co.kr
61
Product (Ingredient) Use Exporting Countries Remarks
1. Gas Whal Myung Su-Q (Herbal extracts, Solution)
Indigestion, Nausea and vomitting,Abdnominal digesion, Anorexia
US OTC
2. Pancold (Acetaminophen etc, Solution)
Symptoms of cold(runny/ blocked nose, sneezing, cough, sputum, fever, shivering, headache, muscle ache, joint pain
US OTC
3. Each (myrrh, chamomile, ratanhia,
Paste)
Gingivitis, symptoms of pyorrhea alveolaris(gingival flare/swelling/bleeding/pus)
- OTC
Main Products
Product (Ingredient) Use Approval Date / Country
Zabofloxacin Acute exacerbation of COPD 2015. 3. 20. / Korea
New Active Substances
Compound Name Code Use Stage of Development
Zabofloxacin DW224
Acute exacerbation of COPD,
Community Acquired Pneumonia
Phase III completed(KFDA APPROVAL)
(FDA PHASE III IND)
DW-1029M DW-1029M Diabetic nephropathy Phase II
DW-2006 DW-2006 allergic rhinitis phase II
R&D Pipeline
2016 Directory of Korea Pharmaceutical Industry62
Summary (1 Billion Won)
Fiscal Year 2012 2013 2014
Sales 594.6 568.1
R&D Expenditure 525 627
Capital 925.7 1,077.9
Financial Figures
Dong-A ST focuses on drugs, such as domestically developed new drugs like Stillen, Zydena, and Motilitone, medical devices, diagnosis, and overseas businesses.
With its optimized research infrastructures such as its world-class, sophisticated research center completed in 2011, as well as its excellent researchers, Dong-A ST is furthering its efforts to develop global new drugs. Also, with the backing of these infrastructures, Dong-A ST vows to positively explore overseas markets, to expand its overseas exports, and to establish itself as a global pharmaceutical company, operating beyond the domestic market.
Focus Area : Manufacture of ETC drug, overseas business, medical equipments and diagnostics
Company Profile
Dong-A STRepresentativeHeadquarter AddressFoundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Chan-il Park
64 Cheonhodaero, Dongdaemun-gu, Seoul, Korea
Mar. 2013
New drugs
1,582(R&D Personnel : 212)
82-2-920-8114
82-2-926-9400
www.donga-st.com
Contact PersonContact PhoneContact E-mail
Geunsung Kim
82-2-920-8366
e2110576@donga.co.kr
Product (Ingredient) Use Exporting Countries Remarks
1. GrowtropinⅡ®inj / AQ / cartridge (somatropin/injection)
Human growth hormone
Brazil, Iran, Peru, Colombia, Mexico
Bio-pharmaceutical
2. Eporon®inj. / PFS (erythropoietin/injection)
Renal anemia treatment
Turkey, Thailand, Chile, vietnam, Pakistan
Bio-pharmaceutical
3. AtorvastatinHyperlipidemia
treatmentJapan APIs
Main Products
63
Product (Ingredient) Use Approval Date
Zydena(Udenafil) Erectile Dysfunction Dec. 2005/Korea
Sivextro(Tedizolid) Infection: ABSSSI Jun. 2014/USA / Apr. 2015/Korea
New Active Substances
Ingredient Code Use Stage of Development
Udenafil DA-8159 Erectile DysfunctionLaunched(Korea),
Ready to NDA(USA)
Udenafil DA-8159 Benign Prostatic Hyperplasia PhⅡcompleted(USA)
Udenafil DA-8159Pulmonary Arterial
HypertensionPhⅡ(Korea)
Tedizolid DA-7218 Infection: ABSSSILaunched(USA), NDA
approved (EU)
Tedizolid DA-7218 Pneumonia: HA/VAP Ph III(Global)
Evogliptin DA-1229 Type2 diabetes NDA submitted(Korea)
5-Hydroxytryptamine4 agonist DA-6886Irritable Bowel Syndrome-
ConstipationPh I completed(Korea)
M3 receptor antagonist DA-8010 Overactive bladder Non-clinical(Korea)
SARM (selective androgen receptor modulators)
DA-4210 Sarcopenia Non-clinical(Korea)
GPR119 agonist DA-1241 Type 2 diabetes Non-clinical(Korea)
Herbal extract DA-9701 Functional dyspepsiaLaunched(Korea), PhⅡ
planned(USA)
Herbal extract DA-9801 Diabetic neuropathyPhⅡcompleted(Korea), PhⅡcompleted(USA)
Herbal extract DA-9803 Alzheimer's disease Non-clinical(Korea)
Herbal extract DA-9805 Parkinson's disease Non-clinical(Korea)
Recombinant Follicle Stimulating Hormone DA-3801Controlled Ovarian Hyper-
stimulation in Assisted Reproductive Technology
Launched(Korea)
Recombinant Follicle Stimulating Hormone DA-3801Ovulation induction in
anovulatory womenNDA submitted(Korea)
R&D Pipeline
4. CycloserineTuberculosis
treatmentIndia APIs
5. TerizidoneTuberculosis
treatmentSouth Africa APIs
6. Closerin® (Cycloserine/Capsule)Tuberculosis
treatmentEurope Ethical drug
7. Zydena® (Udenafil/Tablet)Erectile
DysfunctionBrazil, Turkey, Russia,
Malaysia, IndiaNCE
8. Monotaxel®inj. (Docetaxel anhydrous/Injection)
Anti-Malignant tumor Drug
EU approval Ethical drug
9. Bacchus® (Taurine, Royal Jelly and others/Drink)
Energy Drink Cambodia
2016 Directory of Korea Pharmaceutical Industry64
Summary (1 Million Won)
Fiscal Year 2008 2009 2010
Sales 62,231 68,724 71,926
R&D Expenditure 1,133 1,265 1,337
Capital 124,570 128,167 127,808
Financial Figures
Since its founding in 1957, Dong Sung has advanced technologically, while at the same time developing the highest quality products and strengthening its position as one of Korean leading pharmaceutical companies.
We continuously Produce and develop the variety products such as Hair Care Products > Pharmaceutical Products (ETC, OTC), > Cosmetics, > Health Food and Beverage.
Currently, we possess Korean largest production facilities, hold 40 percent of the domestic hair dye market and are renowned for the safety, efficacy and quality of our pharmaceutical products.
Our success reflects the exceptional teamwork and commitment of the Dong Sung team to delivering the highest quality service to you, our customers. It also reflects your belief and support in Dong Sung.
Company Profile
Dongsung Pharm. Co., Ltd.RepresentativeHeadquarter AddressFoundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Lee Yang-Gu
683, Dobong-ro, Dobong-gu, Seoul, Korea
Nov. 25. 1957
OTC
306
82-2-6911-3600
82-505-191-6908
www.dongsung-pharm.co.kr
65
Main Products
Product (Ingredient) Use Exporting Countries
1. Dong Sung Cheong Ro Hwan (In 1 pill Creosote 44.4mg, Cyperus rhizome powdered 16.6mg, Coptidis rhizoma powder 22.2mg, Glycyrrhiza powder 22.2mg, Citrus unshii pericarpium 22.2mg)
Dyspepsia, watery stool , vomiting and diarrhea
U.S.A
2. Dong Sung Cheong Ro Hwan (Sugar Coated Tablet) (In 1 tab. Creosote 22.5mg, Pulvis phellondendri corticis 33.75mg, Pulvis geranil herbae 25mg)
Dyspepsia, watery stool , vomiting and diarrhea
U.S.A
3. Teethrol (In 1 tab. Zea mays L. extract 35mg,)
Parodontopathy, Gingivitis, Parodontosis U.S.A
4. Teethran (In 1 cap. Tocopherol acetate 50% 10mg, Carbazochrome 2.0mg, Lysozyme chloride 30.0mg, Ascorbic acid coated 96% Type SC 156.3mg)
periodontal disease, pyorrhea alveolaris(erythema, swelling, hemorrhage, pus etc.)
U.S.A
5. Livermarine (In 1 cap. Carduus marianus L. seeds extract 200mg, Calcium pantothenate 8mg, Cyanocobalamin 1.2㎍ Nicotinamide 12mg, Pyridoxine hydrochloride 4mg, Thiamine nitrate 4mg)
chronic liver disease, fatty liver, liver cirrhosis, toxic liver disease
U.S.A
6. EMg, (In 1 cap. Tocopherol acetate 500mg, Magnesium oxide 250mg)
Improvement of muscle spasm that runs out of magnesium
U.S.A / Cambodia
7. GinKolin (In 1 cap. Ginko leaf extract 120mg)
Organic brain dysfunction accompanying athymia symptoms such as tinnitus, headache, memory impairment, attention impairment, depression, vertigo
U.S.A
8. You Green F (In 1g Urea 250mg)
keratodermia tylodes palmaris progressive (housewife`s eczema), keratodermia , ichthyosis, senile xeroderma, lichen pilaris, atopic dermatitis
U.S.A
9. Syan (In 1 Cap. Retinol palmitate 2mg, Ergocalciferol 200IU Copper Chlorophyll 0.3mg, Snake oil 296.7mg)
Construction feeling of eye, Bone defectiveness, Night blindness, Rickets prevention, Vitamin A and D supplies
U.S.A / Cambodia
10. Vaso-Q (In 1 cap. Crataegus oxyacantha fruit dried extract 50mg, Garlic oil 150mg, Ginkgo Biloba Leaf Extract 5mg, Melissa leaf extract 10mg)
Problems with the circulation of the blood : decreasing of memory, enervation, and concentration becomes worse, dizziness, chronicity tiredness
U.S.A
2016 Directory of Korea Pharmaceutical Industry66
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 5,107 4,756 6,591
R&D Expenditure 68 270 490
Capital 1,000 1,000 1,000
Financial Figures
Elyson Pharm. was founded in 2011, on a foundation of improving quality of human life and the breakthrough research & development of novel products in mind.
Company Profile
Elyson Pharmaceutical Co. Ltd.RepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Eul Won Dhong
2F, Kyungpoong B/D, 788-26, Yeoksam 2-dong, Gangnam-gu, Seoul, Korea
Oct. 2011
Cardiovascular disease
27
82-31-8059-4706
82-31-8059-4708
www.elyson.co.kr
Contact PersonContact PhoneContact E-mail
Min Jung Kwon
82-2-6342-7001
elyson@elyson.co.kr
67
Main Products
Product (Ingredient) Use Exporting Countries
1. NiferonCR 40mg (Nifedipine) Hypertension
2. Molsiton 2mg / 4mg (Molsidomine) Anti-anginal Drug
3. Oxiklorin 100mg / 200mg (Hydroxychloroquine sulfate)
Rheumatoid arthritis, Malaria and malaria prophylaxis
4. Conbloc 1.25mg/2.5mg/5mg (Bisoprolol fumarate)
Hypertension, angina, Treatment of stable chronic heart failure with reduced systolic left ventricular function
5. Nebistol 2.5mg/5mg (Nebivolol hydrochloride)
Essential Hypertension, Chronic heart failure
2016 Directory of Korea Pharmaceutical Industry68
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 715,597 793,754 854,258
R&D Expenditure 69,209 71,065 74,160
Capital 50,655 58,433 58,433
Financial Figures
Green Cross is a leading Pharmaceutical company in the biotechnology industry in Korea. Starting from the nation’s first production and sales of Plasma Fractions in 1970, which required sophisticated technology, Green Cross has striven to develop ethical drugs that are hard to produce but essential to patients. Subsequently, it is now an internationally recognized biotechnology company in blood derivative products, vaccines, and recombinant products.
• 1974-Started manufacturing the AHF, an antihemophilic factor
• 1983-Succeeded in developing the world’s third Hepatitis B vaccine
• 1988-Succeeded in developing the world’s first vaccine against the epidemic hemorrhagic fever (Hantavax)
• 2010-Launched Recombinant Factor VIII for Hemophilia A (Green Gene F)
• 2011-The influenza vaccine GC FLU became the fourth in the world to obtain Pre-Qualification approval from the WHO
• 2012-Developed Hunterase (the world’s second treatment of Hunter syndrome).
• 2013-contract with the Thai Red Cross for plasma fractionation plant project (Construction and Tech-transfer).
• 2015-Launched Neulapeg (PEG-GCSF)
Company Profile
Greencross CorporationRepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Eun-Chul Huh
107, Ihyeon-ro 30 beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do, Korea
1967
Biological Products
about 1,700
82-31-260-9300
82-31-260-9413
www.greencross.com
69
Main Products
Product (Ingredient) Use Exporting Countries
1. Human Albumin SolutionFor general use in conditions which require plasma or serum
Asia, Middle-East, South/Central America
2. Human Intravenous Immunoglobulin
a-/hypo-gammaglobulinemina, bacterial or vial infections, idiopathic thrombocytopenic purpura, guillain barre syndrome, Kawasaki Syndrome
Asia, Middle-East, South/Central America
3. Human Hepatitis B Immunoglobulin
- For prophylaxis of hepatitis B after exposure to HBsAg- For prophylaxis of hepatitis B in neonates
Asia, Middle-East, South/Central America
4. Human Tetanus Immunoglobulin
To provide passive immunization against infection caused by clostridium tetani
Asia, Middle-East, South/Central America
5. Varicella Zoster Immunoglobulin
Passive immunity to varicella zoster virus for post-exposure prophylaxis of immunodeficiency children
Asia, Middle-East, South/Central America
6. Human Blood Coagulation Factor VIII
For the treatment of hemophilia AAsia, Middle-East, South/Central America
7. Recombinant Coagulation Factor VIII
For the prevention and control of bleeding episodes and preoperative management in hemophila A
Asia, Middle-East, South/Central America
8. Split Virion Inactivated Influenza Vaccine
For the prophylaxis against InfluenzaAsia, Middle-East, South/Central America
9. Live Attenuated Varicella Vaccine
For the prophylaxis against varicellaAsia, Middle-East, South/Central America
10. Idursulfase betaFor treatment (Enzyme Replacement Therapy) of Hunter Syndrome (Mucopolysaccharidosis II)
Asia, Middle-East etc.
11. PEG-GCSF For treatment of Neutropenia during cancer chemotherapy
Asia, Middle-East, South/Central America (under registration)
12. Shinbaro (Dried Extract Herbal Medicine)
For treatment of Osteoarthritis Asia (under registration)
R&D Pipeline
Ingredient type Use Stage of Development
GC 3110A (Quadrivalent flu vaccine)
vaccine Seasonal Influenza Clinical Phase III
MG 1109 (AI) vaccine Pre-Pandemic Flu Clinical Phase III
GC1107 vaccine Tetanus, Diphtheria Clinical Phase III
GC1109 vaccine Anthrax Clinical Phase II
GC3111A (TdaP) vaccine Tetanus, Diphtheria, Pertussis
Pre-Clinical
MG1111 vaccine Varicella Clinical Phase I
GC3106A (Cell culture) vaccine Seasonal Influenza Clinical Phase I
GC1102Hepatitis B
immunoglobulinChronic HBV infection after liver transplantation
Clinical Phase II
MG4101 Allogenic NK cell Cancer Clinical Phase I
GC1118A EGFR target Anti cancer Colon Cancer Clinical Phase I
MGAH22Fc-optimized
monoclonal antibodyBreast Cancer Clinical Phase II
GC6101A Natural Herbal Drug Gastritis Clinical Phase II
GC2107 Factor Xa inhibitor Anti-thrombotics Clinical Phase I
2016 Directory of Korea Pharmaceutical Industry70
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 56,592 59,253 57,137
R&D Expenditure 1,795 1,856 2,091
Capital 13,189 14,788 15,960
Financial Figures
GUJU PHARM. CO. LTD. is a specialized pharmaceutical manufacturer considering human life the most important value in the world.
Focus Area : Chronic metabolic disease
Company Profile
Guju Pharm. Co., Ltd.RepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Kim Woo Tae
River Tower officetel 12F, 50, Beodeunaru-ro, Yeongdeungpo-gu, Seoul, Korea
Dec. 23. 1974
Final Product (Medicine)
270
82-2-2672-1122
82-2-2679-7569
www.gujup.co.kr
Contact PersonContact PhoneContact E-mail
Jeoung Seob Kim
82-2-2672-1122, Ext. 400
kim3548@hanmail.net
71
Main Products
Product (Ingredient) Use Exporting Countries Remarks
1. Clif cap.(Cefaclor) Antibiotics
2. Atorix Tab. (Atorvastatin Calcium hydrate)
Treatment for Hyperlipidemia
3. Unazol cap.(Fluconazole) Antifungal agents
4. Bronkid syrup.(Hederae Helix Fluid) Expectorants
5. Rabiem Tab. (Rabeprazole Sodium) Proton pump inhibitor
6. Neocatin tab.(Acetyl Carnitine HCl) Cholinergic drugs
7. Neotidine tab.150mg(Ranitidine HCl) H2-blocker
8. Anicid cap.(Omeprazol) Proton pump inhibitor
9. Talimed Tab.(Talniflumate) NSAID
10. Diacerhein Cap.(Diacerhein)Treatment of Osteoarthritis
2016 Directory of Korea Pharmaceutical Industry72
Summary (1 Million Won)
Fiscal Year 2008 2009 2010
Sales 91,900 98,700 106,900
R&D Expenditure 10,831 10,928 10,651
Capital 18,500 18,500 18,500
Financial Figures
HanAll is a top 20 Korean-based R&D pharmaceutical company established in 1973. Our company initially started R&D with the development of over 30 different combinations of cardiology products through its innovative and proprietary XC Hybrid Combination formulation technology. With the acquisition of Nautilus Biotech and strengthened bio-therapeutics pipeline, we are currently developing engineered protein therapeutics via amino acid replacement engineering and mAb fragment via domain engineering which will provide superior PK/PD profile. We also focus on the treating autoimmune disease with bio-therapeutics.
Not only do we focus on bio-therapeutics, but also strive to develop new chemical entities for the treatment of cancer due to high global needs. It is important to provide effective and safe anti-neoplastic agents with minimized adverse drug events which can significantly increase patient’s quality of life. Recently, preclinical and clinical data are emerging for a beneficial effect of Metformin which may affect cancer cell’s proliferation and apoptosis. Hence, we are presently developing new chemical entity of biguanide derivatives as an effective and safe anti-neoplastic agent.
Company Profile
Hanall Bio Pharm. Co., Ltd.RepresentativeHeadquarter Address
Foundation DateResearch Focus
Total StaffRepresentative PhoneRepresentative Fax Web
Sung-Wuk Kim
Daewoong B/D 9F, 12 Bongeunsa-ro 114-gil, Gangnam-gu, Seoul, Korea
Nov. 20. 1973.
Bio-therapeutics(Biobetter & antibodies), CV Combinations, AMPK activator, Anti-Atopic dermatitis.
446
82-2-2204-1753
82-2-414-8046
www.hanall.co.kr
73
Main Products
Product (Ingredient) Use Exporting Countries
1. Reposporen inj.(Cefazedone) Antibiotics
2. Tomiporan inj.(Cefbuperazone Sod.) Antibiotics
3. Normix tab.(Rifaximin) Antibiotics
4. Hanall Glimepiride tab.(Glimepiride) Antidiabetes Vietnam
5. Glucodown OR tab.(Metformin HCl) Antidiabetes
6. Hanall tramadol inj.(tramadol HCl) NSAIDS
7. Levod tab.(Levosulpiride) Prokinetic agent
8. Hanall Fluconazole cap.(fluconazole) anti-fungal drug
9. Lenvard tab.(Rebamipide) antiulcer agent
10. Hanall finasteride tab. 5mg(Finasteride) 5alpha-reductase inhibitor Vietnam, Philippines
New Active Substances
Product (Ingredient) Use Approval Date
Spelear(Fudostein) antitussive agent 2005-01-19
R&D Pipeline
Ingredient Use Stage of Development
HL009(Adenosylcobalmin) Atopic dermatitisKOR Phase II completed
US Phase II IND approved
HL008(amlodipine, losartan) HypertensionKOR Phase I completed
US IND preparation
HL040(losartan, atorvastatin) Hypertension, HyperlipidemiaKOR Phase III preparation
US IND preparation
HL156(Biguanide derivative NCE) Anti-cancer Lead optimization
HL032(oral hGH) Growth hormone deficiency KOR Phase I ongoing
HL143(sc IFN) Hepatitis C US Phase I ongoing
HL036(anti TNF-alpha) Rheumatoid arthritis Lead optimization
HL161(FcRn) Autoimmune disease Lead optimization
2016 Directory of Korea Pharmaceutical Industry74
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 314,648 327,936 348,311
R&D Expenditure 17,600 19,100 17,859
Capital 5,800 5,800 6,297
Financial Figures
HANDOK, a leading innovation-driven pharmaceutical/health-care company in Korea, develops, manufactures and distributes healthcare solutions to improve the health and quality of human life. Handok has a core business focus in diabetes, cardiovascular, muscular skeletal, psychoneurotic disease, human vaccines, medical devices, diagnostics and consumer health. Handok, founded in 1954, grew as a joint venture with Hoechst/Aventis/Sanofi from 1964 to 2012. Handok has also established strategic collaborations in several areas with multiple multinational pharmaceutical companies.
Focus Area : diabetes, cardiovascular, muscular skeletal, psychoneurotic disease, human vaccines, medical devices, diagnostics and consumer health
Company Profile
Handok Inc.RepresentativeHeadquarter Address
Foundation DateResearch Focus
Total StaffRepresentative PhoneRepresentative Fax Web
Young-Jin Kim
132, Teheran Street, Gangnam-Gu, Seoul, Korea
Apr 27. 1954
Diabetes & Metabolic disorders, Oncology, Eye disorders, Quality of life products, Orphan disease
896
82-2-527-5114
82-2-527-5001
www.handok.co.kr
Contact PersonContact PhoneContact E-mail
So-Hyun Kwon
82-2-527-5316
sohyun.kwon@handok.com
75
Main Products
Product (Ingredient) Use Exporting Countries Remarks
Amaryl M (Glimepiride+Metformin/Tablet)
Anti-diabetic drug
14 countries (Taiwan, Indonesia, Philippines, Hungary, Russia, Dubai, South Africa etc.)
The first fixed dose combination of glimepiride and metformin HCl in Korea
Amaryl Mex (Glimepiride+Metformin/Sustanined – release Tablet)
Anti-diabetic drug
6 countries (Singapore, Hungary, Croissy, Philippines, Kazakhstan etc.)
applied by DRM technology (Dual Release Micro-coating Technology)
Ketotop (Ketoprofen/plaster)Arthritis and muscle pain
4 countries (Singapore, Malaysia, Vietnam etc.)
No.1 plaster in Korea
R&D Pipeline
Compound Name Code Use Stage of Development
HL5201 DiabetesPreclinical
development
HL5945 Alopecia discovery
HL5128 Orphan discovery
HL5226 Cancer discovery
HL3501 Glaucoma discovery
HL5171 Cancer discovery
HL3715 Diabetes discovery
HL2351Auto-inflammatory
disordersPhase I
HL2356Growth Hormone
DeficiencyPhase II
HL2353 Factor VII Discovery
HL1513 Diabetes NDA
2016 Directory of Korea Pharmaceutical Industry76
Summary (1 Million Won)
Fiscal Year 2008 2009 2010
Sales 20,384 21,687
R&D Expenditure 646
Capital 2,100
Financial Figures
We have a lot of specialized technologies in the natural medicine field, such as Korean traditional medicines. Since our modern Korean traditional medicines, resulting in many accomplishments in the biotechnology sector. Those accomplishments includes development of anticancer substances as well. In 1984, we produced and supplied successfully Korean traditional medicine solutions(i.e., Galgeuntang, Sipjeondaebotang, Sosihotang etc.) to the market. In 1992, we saw another success for development of the anticancer substance having a brand of MESIMA.
Company Profile
Hankooksinyak Pharm. Co., Ltd.RepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Sang Wook Han
805-15 Jungsan-ri, Yangchon-myeon, Nonsan-si, Chungcheongnam-do, Korea
Feb. 27. 1961
Korean traditional herbal medicine
260
82-41-740-8900
82-41-740-8849
www.hsp.co.kr
77
Main Products
Product (Ingredient) Use Exporting Countries
1. Chunsim heart disease, hypotension, etc. -
2. Keopoongshibodan stroke -
3. Woohwangchongshim-won stroke, atherosclerosis, hypertension, etc. Japan
4. Mankyungdan stroke, sciatica, etc -
5. Mesima gastrointestinal cancer Japan
6. Yukmihwan urinary difficulty -
7. Ickbodan fortifying, kidney-essence -
8. Shinbanwan diabetes -
9. Oakbihwan constipation -
10. Chongwidan stomach catarrh, indigestion -
New Active Substances
Product (Ingredient) Use Approval Date
MESIMA Immuno-stimulating drug 1990.2.28
R&D Pipeline
Ingredient Use Stage of Development
Korean medicine GST anti-atopic dermatitis Evaluation of GST
2016 Directory of Korea Pharmaceutical Industry78
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 99,567 116,792 130,347
R&D Expenditure 8,655 10,312 11,327
Capital 7,700 9,255 9,255
Financial Figures
With the corporate mission of protecting the precious human life from various forms of diseases, Hanlim has consistently endeavored to improve the health standards of people over 30 years, and with your warm encouragements we have grown to become one of the leading companies in the ethical drug market in Korea.
In 1993, the future-oriented GMP factory was completed together with the founding of the Central Research Center. As a part of the long-term investment scheme of the company, we continue to make a great investment in accumulating advanced technologies and securing outstanding research team to perfectly assist the development of new drugs.
Hanlim will do our best in the future to enhance the health of mankind as a leading pharmaceutical company.
Lastly, we would like to express our sincere appreciation to the people of every fields, including doctors and pharmacists who have encouraged us to come this far.
Focus Area : Alimentary Drugs, Cardiovascular Related Agents, Antianemics, Restoratives, Hemostatics, Allergy&ENT Disease Related Agents, Endocrine&Metabolism related agents, Ophthalmologic drugs, Antineoplastics&Adjuvants, Psychoneural Drugs, Corticosteroids.
Company Profile
Hanlim Pharm. Co., Ltd.RepresentativeHeadquarter Address
Foundation DateTotal StaffRepresentative PhoneRepresentative Fax Web
Jae-Yoon Kim
42, Seocho-daero 52-gil, Seocho-gu, Seoul, Korea
Sep. 1974
350
82-2-3489-6000
82-2-3489-6101
www.hanlim.com
Contact PersonContact PhoneContact E-mail
Sung-dae Kim
82-2-3489-6127
sdkim@hanlim.com
79
Main Products
Product (Ingredient) Use Exporting Countries Remarks
1. Dages Cap (Pepsine, Papain, Diastase, Cellulase, Pancreatin, Pancrelipase, UDCA)
Alimentary Drugs China
2. Heparin Inj. (Heparin Sodium)Hemostatics, Anticoagulants
and related agentsVietnam,
Singapore
3. Easy-DROP Eye drops (Hydroxypropylmethylcellulose, Glycerin, Polyethyleneglycol400)
Ophthalmologic DrugsUSA, Cambodia,
Nigeria
4. NUMAREN EYE DROPS (Hydropropylmethyl cellulose, Dextran 70)
Ophthalmologic Drugs
USA, Myanmar, Cambodia, Hongkong,
Vietnam, Mongol
5. POSOD EYE DROPS (Potassium Iodide, Sodium Iodide)
Artificial eye drops Vietnam, Hong
Kong, Singapore, Nigeria
6. QUINOVID Ophthalmic ointment (Ofloxacin)
Ophthalmologic Drugs Vietnam
7. QUINOVID Ear drops (Ofloxacin) Ophthalmologic Drugs Vietnam
8. DESONA Nasal spray (Budesonide)
Allergy&ENT Disease Related agent
Cambodia, Vietnam, Mongol,
Cambodia, Guatemala
9. PEPTAZOLE Inj. (Pantoprazole Sod. sesquihydrate)
Alimentary Drugs Vietnam
10. PROTAMINE SULFATE Inj. (Protamine Sulfate)
Hemostatics, Anticoagulants and related agents
Iran, Mongol
R&D Pipeline
Compound Name Code Use Stage of Development
HL-PIF mixed hyperlipidemia phase III
HL301 Bronchitis phase II
HL-SAS hypertension phase I
HL-CER osteoarthritis phase I
HL-217 AMD phase I
HL-HAS dry mouth IND
HL-BRO allergy IND
2016 Directory of Korea Pharmaceutical Industry80
Summary (1 Billion Won)
Fiscal Year 2012 2013 2014
Sales 674 730 761
R&D Expenditure 91 116 153
Capital 20 21 24
Financial Figures
Hanmi Pharmaceuticals is a Korea-based global pharmaceutical company focused on the development and commercialization of new pharmaceutical products.
Focus Area : Biologics , Anti-Cancer Drug
Company Profile
Hanmi Pharm. Co., Ltd.Lee Gwan Sun
14, Wiryeseong-daero, Songpa-gu, Seoul, Korea
1973
Biologics / NCEs
1,824
82-2-410-9114
82-2-410-9259
www.hanmipharm.com
RepresentativeHeadquarter AddressFoundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
81
Main Products
Product (Ingredient) Use Exporting Countries Remarks
1. Amosartan(Amlodipine + Losartan / Tablet)
Hypertension
Southeast Asia, MSD(Russia, Mexico, Vietnam, Colombia, Costa Rica, Dominican Republic, El Salvador, Guatemala, Honduras, Malaysia, Panama, Philippine, Ecuador)
2. Esomezol (Esomeprazole / Capsule)
GERD US
3. Ceftriaxone (FDF) (Ceftriaxone / injectable)
AntibioticsEurope, Middle east, Nigeria, Singapole
4. Fontiam (Cefotiam / injectable)
Antibiotics China
5. Ceftriaxone (API) AntibioticsEurope, Middle east, Mexico, Pakistan
6.Cefotaxime (API) AntibioticsEurope, Middle east, Turkey, Mexico
7.Ceftazidime (API) AntibioticsEurope, Middle east, Mexico
8.Ceftizoxime (API) Antibiotics Japan
9.Cefixime (API) Antibiotics Europe, Japan
10.Cefpodoxime (API) Antibiotics Europe, Japan
R&D Pipeline
Compound Name Code Use Stage of Development
LAPS Exendin 4 HM11260C Diabetes Phase II
LAPS GCSF HM10460A Neutropenia Phase II
LAPS hGH HM10560A Growth hormone Phase II
LAPS Insulin 115 HM12470 Diabetes Phase I
LAPS GLP/GCG HM12525A Diabetes Phase I
LAPS Combo Combination Diabetes Pre clinical
Poziotinib(Pan her) HM 781 36B Lung cancer Phase II
Oraxol Gastic cancer Phase II
EMSI HM61713 Lung cancer Phase II
Luminate ALG-1001 Retina disease Phase II
BTK inhibitor HM71224 RA Phase I
RAF Inhibitor HM95573 Solid tumor Phase I
KX2-391 Solid tumor Phase I
Oratecan Solid tumor Phase I
2016 Directory of Korea Pharmaceutical Industry82
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 45,317 46,038 47,500
R&D Expenditure 35 36 38
Capital 3,436 3,436 3,436
Financial Figures
Han Wha Pharma (HWP) is a pharmaceutical company based in Seoul, Korea. HWP is well established in manufacture, distribution, marketing/sales and export of pharmaceutical products. HWP is recognized to doctors and pharmacists as a specialized company that has ethical products in certain therapeutic areas such as alimentary, cardiovascular, genito-urinary, neuro-muscular, and respiratory system. Aiming to become a global enterprise, HWP has introduced global marketing techniques through an organic partnership with several overseas companies. As a result, HWP has continued making record growth in sales by successfully launching new products in the domestic market to meet customer needs based on market research. In sales activities, HWP has grown into a most trusted company among customers by successfully supplying high-quality and superior medicines to hospitals and clinics. HWP has expanded its business area to dietary supplements. HWP family consists of NaturaLife, a subsidiary focused on nutrition supplements, NaturaLife Asia, a subsidiary focused on Asia business, and Weider Asia, a subsidiary focused on sports nutrition business in Asia.
Focus Area : Gastro-intestinal system, Respiratory system, Central nervous system etc.
Company Profile
Hanwha Pharma. Co., Ltd.RepresentativeHeadquarter AddressFoundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Kyoungrak Kim
76 Hwarang-ro 32-gil, Sungbuk-gu, Seoul, Korea
Jul. 4. 1976
Respiratory diseases etc.
300
82-2-959-3161
82-2-959-3621
www.hwpharm.com
Contact PersonContact PhoneContact E-mail
Jong Hoon Kim
82-2-959-3161
hw@hwpharm.com
83
Main Products
Product (Ingredient) Use Exporting Countries Remarks
1. Antibio Probiotics Vietnam
2. Ramnos Probiotics Malaysia
3. Muteran Mucolytics -
4. Wingli-M Anti-diabetics -
5. Winexge Anti-hypertension -
6. Telmiam Anti-hypertension -
R&D Pipeline
Compound Name Code Use Stage of Development
YJP-14 Cardiovascular agent Phase II
YJP-40 Respiratory agent Phase III
YJC-10592 Anti-atopic dermatitis Preclinical
YJC-50018 Anti-rheumatoid arthritis Preclinical
2016 Directory of Korea Pharmaceutical Industry84
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 6,190,651 5,865,021 5,320,896
R&D Expenditure 78,894 35,727 49,028
Capital 5,777,685 5,254,988 5,915,659
Financial Figures
Hawon believes that “To contribute to the health and happiness of people through developing good medicines”. We will keep the level of global standards of competition and place high priority on R&D for devised out new products and raw materials of new brand.
Focus Area : Antibiotic Drug etc
Company Profile
Hawon Pharm. Co.RepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Dae-ho Kooh
2~4F, Time B/D 312 Nonhyun-ro, Gangnam-gu, Seoul, Korea
May. 4. 1981
Natural Medicine
158
82-70-8260-6030
82-2-554-4557
www.hawonpharm.co.kr
Contact PersonContact PhoneContact E-mail
R&D Department
82-70-8260-6030(#3)
hawon342@hawonpharm.co.kr
85
Main Products
Product (Ingredient) UseExporting Countries
Remarks
1. Fazidone Inj. 1g,2g (Cefazedone sodium 1g,2g)
- urinary tract infection, cholangitis, intrauterine infection, adnexitis
2. Hawon Ceftriaxone Inj. 1g,2g (Ceftriaxone Na 1g,2g)
- pneumonia, bronchitis and breathing device infection
- ear, nose and throat infection- nephritis and urinary tract infection- sepsis- bone and joint infection- skin, laceration and soft tissue
infection- peritonitis, cholecystitis, cholangitis- meningitis
Mongolia
3. Ciploxacin Inj. 200mg (Ciprofloxacin 2mg)
- Respiratory Infections- ENT infections, Oral, Teeth, jaw
infections - kidneys, urinary tract infection
4. Myal Inj. (Sodium hyaluronate/10mg)
- Osteoarthritis of the knee , shoulder treatment
5. Coxicam Cap. (Meloxicam 7.5mg)
- perceived exercise barrier- Symptomatic treatment of
rheumatoid arthritis- Symptomatic treatment of poker
back
Vietnam
6. Furoxetil Tab. (Cefuroxime axetil 300.72mg (cefuroxime axetil(as cefuroxime) 250mg ))
- upper airway infection : otitis media, tonsillitis, pharyngitis
- lower respiratory tract : acute bronchitis and chronic bronchitis, pneumonia
- urogenital system infection : nephropyelitis, cystitis, urethritis
7. Remist Tab. (Rebamipide 100mg)
- Ulcer- Gastric mucosal lesions in the
following diseases ( erosion , bleeding , redness, swelling) improvement of acute gastritis , acute exacerbation of chronic gastritis group
8. Fronan Cap. (Fluconazole 50mg)
- Acute or recurrent vaginal candidiasis
- Hand , nail fungus , athlete's foot ( foot ringworm ) , tinea corpus , wanseon ( groin ringworm ), Skin and skin fungal infections , including candida eorureogi
9. Lipitrol Tab. (Atorvastatin calcium 10.35mg)
- Reduced risk of myocardial infarction- Reduced risk of stroke- Vascular regeneration and reduce
the risk of chronic stable angina
10. Mosadin Tab. (Mosapride citrate 5.29mg)
- Functional due to poor digestion digestive symptoms ( heartburn , nausea, vomiting )
2016 Directory of Korea Pharmaceutical Industry86
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 11,704 23,544 29,200
R&D Expenditure 1,916 1,832 2,602
Capital 2,042 2,304 3,158
Financial Figures
We, humedix, have platform technology for application of biocompatible polymers just like hyaluronic acid and PEG.
And then, we are trying to research and develop the improvement of drugs with biocompatible polymers.
We’ve rapidly grown up recently due to our products developed with hyaluronic acid and have been listed in korean stock market(KOSDAQ),
Focus Area : application of biocompatible polymer as hyaluronic acid and PEG etc.
Company Profile
Humedix. Co., Ltd.RepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Bong-Yeol Chung
Unit 603 Mega Valley, 268, Hagui-ro, Dongan-gu, Anyang-si, Gyeonggi-do, Korea
2003
Biomaterials & Applications
79
82-70-7492-5618
82-31-421-5623
www.humedix.com
Contact PersonContact PhoneContact E-mail
Jong Oh Lee
82-70-7492-5609
jolee@humedix.com
87
Main Products
Product (Ingredient) Use Exporting Countries Remarks
1. Sodium Hyaluronate (Sodium Hyaluronate/Powder)
Remedies for Arthritis Worldwide -
2. High Hyal Plus Inj. (Sodium Hyaluronate/Injection)
Remedies for Arthritis Worldwide-
3. High Hyal Inj. (Sodium Hyaluronate/Injection)
Remedies for Arthritis Worldwide -
4. High Eye Inj. (Sodium Hyaluronate/Injection)
Ophthalmological surgical aids Worldwide -
R&D Pipeline
Compound Name Code Use Stage of Development
cross-linked hyaluronic acid improvement of osteoarthritis pre-clinical
conjugated Vit. D derivative whitenning pre-clinical
scFv macular degeneration pre-clinical
2016 Directory of Korea Pharmaceutical Industry88
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 122,059 131,050 156,508
R&D Expenditure 8,146 8,785 9,849
Capital 4,744 5,322 5,650
Financial Figures
Huons, started as Kwang Myung Pharm in 1965, has grown to a competent global company, producing original and effective essential medicine and medical products, through continual challenges and innovation over 50years.Huons is putting a ceaseless effort for human healthy life without disease.Our goal is to achieve 1billion USD in 2020 and aiming to be the TOP 10 global company at the industry in Korea.To prepare the future, Huons built new factory in 2009. Huons has constructed state-of-the art manufacturing facility in compliance with Korea, US and cGMP. Huons is increasing the investment on innovative research and development. Huons, having obtained many patents as the results of its research, is not becoming complacent and is working hard for development of new medicines, with the global pharmaceutical market entrance. Focus Area : - Manufacturing Pharmaceuticals (including Injections, Dental Anesthetics, Plastic Ampoules, Eye Drops)- Well-being Products- Medical Devices - CMO
Company Profile
Huons Co., LtdRepresentativeHeadquarter Address
Foundation DateTotal StaffRepresentative PhoneRepresentative Fax Web
Jae Kap, Jun
C-901 PangyoInoBelly, 621 Sampyeong-dong, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea
Jul. 30. 1965
540
82-2-854-4700
82-2-6455-0740
www.huons.com
Contact PersonContact PhoneContact E-mail
Taek Keun, Yoo
82-70-7492-5080
intbiz@huons.com
89
Main Products
Product (Ingredient) Use Exporting Countries Remarks
1. Lidocaine and Adrenaline injection
Dental anesthetics20countries including Japan
2. Heparin sodium 25000unit Injection
Essential Hypertension Pakistan, Georgia, Mongolia, Vietnam
3. Norepinephrine bitartrate injection
Myocardial infarction, Shock by sepsis
Venesuela, Chile, Philippines
We have started to register it in KSA.
4. Sodium chloride injection
Flushing compatible intravenous tubing system and in dwellling intravascular access devices.
USA510K Approval in US FDA
5. Cyclosporin 0.05% eye- drop
Dry eye syndrome Iran, etc.
We have made distribution agreement for Iran and other conturies.
New Active Substances
Product (Ingredient) Use Approval Date
Clacier Eye drop (Cyclosporin 0.05%) Dry eye syndromeMarch, 2015 / Korea(Modified generic)
R&D Pipeline
Ingredient Code Use Stage of Development
HL-09 Magnoliae Cortex Ext. HU002 Fatty Liver Phase II
HSP23 Lonicera Japonica T. Ext. HU003 Sepsis Phase I
Cyclosporine combination HU007 Dry eye syndrome Pre-clinical
Honeybush HU018 Wrinkle reduction Pre-clinical
HU017(NCE) HU017 IBD Pre-clinical
Ultracet + Eperisone HU016 Analgesic Pre-clinical
Peptide HU015 Decubitus ulcer Phase I
Botulinum toxin type A HU014Temporary improvement of
glabellar linesPre-clinical
acid α-glucosidase HU023 Pompe disease Pre-clinical
2016 Directory of Korea Pharmaceutical Industry90
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 101,116 106,627 107,837
R&D Expenditure 8,083 8,368 8,243
Capital 14,000 14,000 14,000
Financial Figures
We, Hyundai Pharm. with corporate philosophy in “Contribute to public health promotion” which embodies humanistic philosophy in improving public health and quality of life and CEO’s philosophy focused in transparent enterprise spirit, implements organization’s vision and value and actively handle fast changing business are in order to have a new leap forward in 21st century.
Focus Area : Caridovascular, CNS, Oncology support, Women’s Health Care, Respiratory
Company Profile
Hyundai Pharm. Co., Ltd.RepresentativeHeadquarter Address
Foundation DateResearch Focus
Total StaffRepresentative PhoneRepresentative Fax Web
Han Koo Lee
Hyundaipharm Bldg, Bongeunsa St 135, Gangnam-Gu, Seoul, Korea
1965
Pharmaceutical products, Health food drinks, Medical equipment & device
Over 400
82-2-2600-3951
82-2-2693-7628
www.hyundaipharm.co.kr
Contact PersonContact PhoneContact E-mail
Yuna Chae
82-2-2600-3883
yuna.chae@hdpharm.co.kr
91
Main Products
Product (Ingredient) Use Exporting Countries Remarks
1. Surfolase Capsule (Acebrophylline 100mg)
Acute, chronic respiratory disease, acute, chronic bronchitis, bronchial asthma, paranasal sinustis, dried rhinitis
China IND submission
2. Minoxyl solution 5% (Minoxidil 5g/100mL )
Main pattern baldnessHong Kong, Vietnam, Cambodia, Myanmar
Preparation, Approval, Submission, Approval
3. Hyundai Moolpas-F Solution (Methyl salicylate, dl-camphor, etc)
Antiinflammatory analgesic, pernio
Hong Kong, USA, Mongolia
Approval, Registration, Approval
4. Bumooly-S Solution (Diphenhydramine HCl, Dibucaine HCl, etc)
Eczema, dermatitis, erosion, miliaria, rhus dermatitis, pruritus, pernio, insect bite, hives
USA Approval
5. Varosc Tablet (Amlodipine besylate 5mg)
Hypertension, coronary artery disease
Vietnam, Cambodia Approval, Approval
6. Olanpin Tablet (Olanzapine 5mg, 10mg)
Treatment of schizophrenia, bipolar disorder
Hong Kong, Macao Approval, Preparation
7. Mirtapin Tablet (Mirtazapine 15mg)
Treatment of episodes of major depression
Hong Kong, Macao Approval, Preparation
8. Mirap SR tablet (Pramipexole HCl)
Idiopathic parkinson's disease
Thailand Submission
2016 Directory of Korea Pharmaceutical Industry92
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 9,122 9,347 14,930
R&D Expenditure 309(3%) 372(4%) 305(2%)
Capital 10,111 12,930 14,997
Financial Figures
Icure Pharmaceutical Inc. is a privately held specialty drugs company with its HQ located in Seoul, R&D Center in Pyeongtack-si and KGMP approved manufacturing facility in Anseong-si in Korea. Icure’s business strategy is to develop innovative transdermal drug delivery systems for local, systemic and device aided delivery of drugs. Icure is developing the transdermal formulations that enhance therapeutic value of the drugs by reducing side effects, enhancing efficacy and promoting patient compliance.
The company has successfully developed and commercialized several pharmaceutical plasters and patches for the treatment dementia associated with Alzheimer’s Disease, rheumatic arthritis pain, nicotine replacement therapy.
These products have been licensed to several leading Korean Pharmaceutical firms for sales in Korea.
Focus Area : Central nervous system, Respiratory, Nicotine Replacement Therapy, Pain management, Skin care
Company Profile
Icure Pharm. Inc.RepresentativeHeadquarter AddressFoundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Young Kweon Choi
7, Saimdang-ro 1-gil, Seocho-gu, Seoul, Korea
May. 29. 2000
TDDS(Transdermal Drug Delivery System)
93
82-2-6959-6909 (Ext.232)
82-2-2-6959-8509
www.icure.co.kr
Contact PersonContact PhoneContact E-mail
Tom Chung
82-70-5038-3399
global@icure.co.kr
joebu@icure.co.kr
93
Main Products
Product (Ingredient) Use Exporting Countries Remarks
Rivaderm Patch(Rivastigmine)
Treatment of mild to moderate dementia
of the Alzheimer’s and Parkinson’s disease
Exoderm Patch (Nicotine)
Nicotine replacement therapy
NSAIDs Plaster(Ketoprofen/ Diclofenac Sodium, diethylammonium/ Flurbiprofen/ Indomethacin /Felbinac/ Loxoprofen)
Relief for Rheumatic arthritis pain
Russia, Hong Kong, Bolivia, India
Lidogesic Cataplasma(Lidocaine)
Local anesthetics
Tulobuterol Patch (Tulobuterol)
Treatment of bronchial asthma and chronic
obstructive pulmonary disease (COPD)
Teeth whitening strips(Hydrogen perxide)
Teeth whitening treatment
Taiwan, Finland
Cosmetics Patch and Facial mask
Anti wrinkles, Whitening, Moisturizing
Several countries
Skin care Product Anti wrinkles,
Whitening, Moisturizing
R&D Pipeline
Ingredient Code Use Stage of Development
Donepezil Patch Treatment of mild to moderate dementia
associated with Alzheimer`s disease and
Parkinson`s disease
Clinical study Phase I
Ropinirole Patch Formulation phase
Fentanyl PatchRelief for Severe cancer
painBE Study phase
Granisetron Patch Prevention for nausea
and vomiting caused by cancer chemotherapy
2016 Directory of Korea Pharmaceutical Industry94
Summary (1 Million Won)
Fiscal Year 2008 2009 2010
Sales 6,020 7,416 8,359
R&D Expenditure - 31 47
Capital 3,900 4,700 4,700
Financial Figures
Based on our ideology ‘adding life’ for the people, IKSU keeps trying to be trustworthy
and reliable company respecting human beings. Since foundation in 1970 IKSU developed ‘Kohohwan’ for treatment of neuralgia & ar thritis and ‘Woohwangchungsimwon’ which is acknowledged as traditional miracle drug for life-saving. Recently IKSU has got preliminary GMP which is the first in herbal liquid preparation thereby having a chance to get more reliable and diverse products launched such as ‘Banhasasimtang liquid’.
Company Profile
Ik-Su Pharm. Co., Ltd.RepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Yong jin Jung
3F, Iksu B/D, 315, Gucheonmyeon-ro, Gangdong-gu, Seoul, Korea
Mar. 10. 1986
Herbal medicine
97
82-2-416-1115
82-2-426-1112
http://www.iksu.co.kr
95
Main Products
Product (Ingredient) Use Exporting Countries
1. Yongpyo wonbang woohwang chungsimwon pill/liquid
Cerebral apoplexy (total paralysis, hemiplegia, speech defect, coma, lethargy condition, facial paralysis), hypertension, palpitation, anxiety neurosis, acute & chronic convulsion, autonomic imbalance, insensibility
2. Yongpyo woohwangchungsim won pill/liquid
Cerebral apoplexy (total paralysis, hemiplegia, speech defect, coma, lethargy condition, facial paralysis), hypertension, palpitation, anxiety neurosis, acute & chronic convulsion, autonomic imbalance, insensibility
3. Iksu banhasasimtang liquid
Following symptom of the person with stuffiness of epigastrium, nausea, anorexia, soft stools or diarrhea : acute&chronic gastric catarrh, fermental diarrhea, dyspepsia, gastric ptosis, gastraneuria, weak stomach, hangover, heartburn, stomatitis, nervousness
4. Cheers liquidMaldigestion, vomiturition, thirst, headache caused by heavy drinking
5. Iksu kalgeuntang liquidCommon cold, coryza, headache, pain of shoulder and hands
6. Yongpyo ansinhwan pill/liquidInsomnia, unrest, anxiety, thirst, palpitation, neurasthenia, shortness of breath, amnesia
7. Iksu kohohwan pill Neuralgia, arthralgia, myalgia
8. Iksu samsoeum liquid Headache, fever, cough caused by cold
9. Iksu chungkantang liquidFollowing symptom of the person with liver damage, being easily angry : nervousness, eye fatigue
10. Atomoms liquid Xeroderma : use when skin is dried and chapped
2016 Directory of Korea Pharmaceutical Industry96
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 346,030 378,247 401,330
R&D Expenditure 31,102 35,326 37,585
Capital 318,869 321,860 328,399
Financial Figures
Founded in 1941, ILDONG PHARMACEUTICAL CO., LTD has been contributing to healthier and happier lives of mankind for more than 70 years. We are developing innovative and outstanding products by utilizing all knowledge and know-how that we have piled up. We are mainly manufacturing anticancer, probiotics, HA and antibiotics in our state-of-the art plants.
Focus Area : Anti-cancer medicine, Antibiotics, Hyaluronic acid, Probiotics and Vitamins
Company Profile
Il Dong Pharm. Co., Ltd.RepresentativeHeadquarter AddressFoundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Jung-chi Lee
2, Baumoe-ro 27-gil, Seocho-gu, Seoul, Korea
Mar. 14. 1941
ETC, OTC, Neutrient food
1,449
82-2-526-3114
82-2-526-3030
www.ildong.com
Contact PersonContact PhoneContact E-mail
Nathan Ahn
82-(0)2-526-3500
export@ildong.com
97
Main Products
Product (Ingredient) Use Exporting Countries Remarks
1. Capecitabine Anti-cancer AsiaThe 1st approved product by MFDS
2. Imatinib Anti-cancer CIS -
3. Levofloxacin Quinolons Asia, Japan FDF / API
4. Hyaluronic acid Osteoarthritis Russia FDF / API
5. Aronamin series Vitamin B complex Asia -
6. Biovita Probiotics Asia, Latin- America, -
7. Sulbutiamine Vitamins Latin-America -
R&D Pipeline
Ingredient Code Use Stage of Development
Besifovir - hepatitis B Phase III
Product A ID1201 dementia Phase II
Product B IDP73152 refractory Infections Phase I
Product C IDF11774 antineoplastics Phase I
Product D IDV12002 viral infections Phase I
Product E IDX-1197 antineoplastics Preclinical
Product F GX-G6 diabetes Preclinical
Product G - antineoplastics Research
Product H - arthritis Research
Product I - diabetes Research
Product J - antineoplastics Research
2016 Directory of Korea Pharmaceutical Industry98
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 77,161 62,807 62,829
R&D Expenditure 1,903 1,402 1,213
Capital 318,059 322,744 328,683
Financial Figures
ILSUNG Pharmaceuticals is one of the well-known pharmaceutical companies in Korea. ILSUNG has been focused on antibiotics, anesthetics and contrast media and is expanding to GI, CV, CNS and other areas. ILSUNG is famous for its in-licensing activities with global partners such as GSK (UK), Bracco (Italy), Abbott / Baxter (USA), Ono / Teijin (Japan). ILSUNG is selling various kinds of the branded products such as Augmentin, Suprane, and Rytmonorm. In addition to this, ILSUNG is interested in exporting business for contrast media and CMO business for antibiotics based on well organized KGMP manufacturing facilities approved by PMDA for contrast media and antibiotics.
Focus Area : Antibiotics, Anesthesia, Contrast Media, GI, CV, CNS
Company Profile
Ilsung Pharm Co., Ltd.Suk Keun Yoon
44-7 Wonhyoro1-ga, Yongsan-gu, Seoul, Korea
Feb. 15. 1961
Antibiotics, Anesthesia, Contrast Media
245
82-2-3271-8705
82-2-718-7239
www.ilsung-ph.co.kr
RepresentativeHeadquarter AddressFoundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Contact PersonContact PhoneContact E-mail
Ji Young Lee
82-2-3271-8824
jiyounglee@ilsung-ph.co.kr
99
Main Products
Product (Ingredient) Use Exporting Countries Remarks
1. Raypam Injection (Iopamidol)
CT Contrast Media
2. Sevoprane Inhalation (Sevoflurane)
Anesthesia
3. Augmentin (Amoxicillin + lavulnate)
Antibiotics
R&D Pipeline
Ingredient Code Use Stage of Development
Iohexol CT Contrast Media
Iopromide CT Contrast Media
Ioversol CT Contrast Media
Iomeprol CT Contrast Media
Meglumine Gadoterate MRI Contrast Media
Gadobutrol MRI Contrast Media
2016 Directory of Korea Pharmaceutical Industry100
IL-YANG Pharmaceutical Co., Ltd. has been exerting its intended efforts to manufacture superior pharmaceutical products for the last half a century and it is still going on. Since it took the first step to supply pharmaceutical products in Korea, since 1946, IL-YANG has been advancing into a top-ranking pharmaceutical company in the world with developing in the area of Gastrointestinal, Hematology, Vaccine, and Virology. IL-YANG established vaccine plant in April 2011 with production capacity of 60mil doses per year. IL-YANG has been exporting a variety of pharmaceuticals to approximately 30 countries including USA and Europe. IL-YANG established two branches in China, YANGZHOU IL-YANG PHARM. Co., Ltd. and TONGHUA IL-YANG HEALTH PRODUCTS Co., Ltd. for manufacturing and distribution of finished pharmaceuticals in China. Since their establishment, the sales and business are expanding enormously. In Sept. 2014, YANGZHOU IL-YANG had completion ceremony for newly built CGMP plant which is compliance to EU-GMP standard.
Focus Area : Gastroenterology, Urology, Oncology, Virology, Biopharmaceutical
Company Profile
Il-Yang Pharm. Co., Ltd.RepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
D. Y, Kim
110, Hagal-ro, Giheung-gu, Yongin-si, Gyeonggi-do, Korea
Jul. 1. 1946
Gastroenterology, Oncology, Virology
620
82-2-570-3700~7
82-2-570-3708~9
www.ilyang.co.kr
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 146,460 147,731 210,000
R&D Expenditure 15,564 16,440 12,400
Capital 45,850 45,850 45,850
Financial Figures
Contact PersonContact PhoneContact E-mail
Sun Park
82-2-570-3787
spark@ilyang.co.kr
101
Product (Ingredient/Formulation) Use RemarksSupect Cap Radotinib 2nd line of CML-CP New Drug
Noltec Tab Ilaprazole Gastric Ulcer, Deodenal Ulcer, Erosive Esophagitis New Drug
Il Yang Flu Vaccine Pre-filled
Syringe inj
Trivalent purified inactivated influenza
virus antigenInfluenza Vaccine Generic
Rosatan Tab Losartan potassium Hypertetion Generic
Nizaractine Cap Nizatidine H2-blockers Generic
Neusilin A Tab Magnesium Aluminum Silcate Antacid, Absorbent Generic
Andilac-S Cap Lactobcillus Acidophillus Digestive Generic
Mutacil Powder Psyllium husk Habitual constipation, irritable bowel syndrome Generic
Motive Tab Mosapride Cirtate Anticonvulsive Generic
Etive Tab Itopride HCI Anticonvulsive Generic
Montidin Tab Levosulpiride Anticonvulsive Generic
Telmisartan Tab Telmisartan ARB Generic
Betaprol Tab Bisoprolol β-blockers Generic
AmBP Tab Amlodipine Mesylate Monohydrate CCB Generic
Furix Tab Furosemide Diuretics Generic
Indapam Tab Indapamide Diuretics Generic
Atrovastatin Tab Atorvastatin Hyperlipidaemic Generic
Pista Tab Pitavastatin Hyperlipidaemic Generic
Actigli Tab Pioglitazone Hypoglycemic agent Generic
Hinechol Tab Bethanechol Chloride Autonomic nervous system Generic
Poverin Tab Propiverine HCI genitourinary, Urinary frequency, urinary incontinence Generic
Sildenafil Tab Sildenafil citrate Erectile dysfunction Generic
Arthalgyl Inj Aspirin lysine Fever reducer, Pain reliever Generic
Nutrix Tab Acetly-L-Carnitine Improvement of brain metabolism Generic
Bonaring A Tab Dimenhydrinate Motion sickness, Vomiting, Nausea, Meniere’s disease Generic
Alvorin Tab Levocetirizine Antihistamine Generic
Epinastine Tab Epinastine HCI Antihistamine, Antiallergy Generic
Kukuratum Syrup Pelagonium sidoides Acute laryngitis Generic
Ambosol Inj Amino acid Amino acid Generic
Ibandronsan Tab Ibandronic Acid Osteoporosis Generic
Clopidogrel Tab Clopidogrel CVA, Cardiac infarction, Peripheral artery disease Generic
Glimed Tab Glimepiride non-insulin dependent diabetes mellitus Generic
Finasterid Tab Finasteride Neurogenic bladde, r Nervous pollakiuria Generic
Cefadroxil Cap Cefadroxil Pyelonephritis, Cystitis, Urethritis Generic
Nofaxin Tab Levofloxacin Antibiotic Generic
Aldrin Tab, Susp* Almagate Antacid action Generic
Noigel Susp* Aluminium magnesium silicate 1g Antacid action Generic
Main Products
Product (Ingredient) Use Approval Date
Noltec (Ilaprazole) Anti-ulcer agentDec. 2007 / ChinaOct. 2008 / Korea
Supect (Radotinib) Anti-CML agent Jan. 2012 / Korea
New Active Substances
Ingredient Use Stage of Development
Ilaprazole NERD, H.Pylori Phase III
Radotinib CML-CP 1stline Phase III Completed
IY7640 Anti-viral Phase I
Flu Vaccine Quadvalent Flu Vaccine Phase I
R&D Pipeline
* Exporting Countries : Vietnam, Cambodia, Mongolia, Etc.
2016 Directory of Korea Pharmaceutical Industry102
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 5,583 8,164 7,097
R&D Expenditure 2,269 4,202 4,293
Capital 5,621 6,396 6,939
Financial Figures
Since 2001, ISU Abxis has established its own platform technologies and product pipelines with a desire of being an axis of all therapeutic antibody industry as its name stands (ABXIS=AntiBody + aXIS). Beginning with the successful development and market-launch of Korean first therapeutic antibody in 2006, ISU Abxis has led Korean biopharmaceutical industry specialized in biosimilars and biobetters. Consequently in 2013 and 2014, ISU Abxis launched two biotherapeutics for orphan diseases of Gaucher and Fabry. ISU Abxis has accumulated the world class manufacturing and QC/QA management through the full development and manufacturing experiences in the globally harmonized compliance.
Focus Area : Orphan drug, Anti-cancer drug
Company Profile
Isu Abxis Co., Ltd.RepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Daeseong Kim
Global R&D Center C-5F, 22 Daewangpangyo-ro, 712 beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea
Mar. 28. 2001
Oncology, Metabolic disorder
93
82-31-696-4700
82-31-696-4690
www.abxis.com
Contact PersonContact PhoneContact E-mail
Juneyoung Park
82-31-696-4620
jpark@isu.co.kr
103
Product (Ingredient/Formulation) Use Exporting Countries Remarks
1. Clotinab®(Abciximab)Adjunct to Percutaneous Coronary Intervention (PCI)
Twelve countries including India, Turkey, Columbia, Venezuela and etc.
The first therapeutic antibody developed in Korea and the world’s second Abciximab
2. Abcertin®(Imiglucerase)Enzyme Replacement Therapy (ERT) for Gaucher disease (GD)
Under the registration in around 20 countries
The first drug for GD developed in Korea and the world’s second Imiglucerase
3. Fabagal®(Agalsidase beta)Enzyme Replacement Therapy (ERT) for Fabry disease (FD)
Launched only in Korea in 2014
The first drug for FD developed in Korea and the world’s second Agalsidase beta
Main Products
Ingredient Code Use Stage of Development
Recombinant Factor IX ISU304 Hemophilia B Non-clinical study (Toxicity)
Novel drug (mAb) ISU104 Breast cancer Non-clinical study (Efficacy)
Trastuzumab ISU103 Breast cancer Non-clinical study (Ready)
Eculizumab ISU305Paroxysmal nocturnal hemoglobinuria (PNH)
R&D
R&D Pipeline
2016 Directory of Korea Pharmaceutical Industry104
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 426,819 451,968 512,736
R&D Expenditure
Capital 241,405 237,602 235,213
Financial Figures
Since foundation in 1959, JEIL has made efforts with a sense of mission to contribute to pharmaceutical industry and our society by development of superior medicines for promoting people’s happiness and health.
JEIL established own central research laboratory for formulation and synthesis of drugs, followed by successive construction of KGMP factory in 1986. JEIL’s chemical production facilities are entirely controlled by BGMP according to GMP guideline for bulk chemical production related to general, special, and aseptic pharmaceuticals. In 2012. JEIL completed Anti-cancer Plant and Cephalosporin Plant according to cGMP standard and obtained GMP approval.
We are specialized in developing and producing patent terminated products to make first generic in exportable countries and trying to reach customer’s needs with current products.
Focus Area : cardiovascular drug, urologic drug, antibiotics API
Company Profile
Jeil Pharm. Co., Ltd.Suk Je Sung
343, Sapyeong-daero, Seocho-gu, Seoul, Korea
Mar. 7. 1959
1,044
82-2-549-7451
82-2-549-4045
www.jeilpharm.co.kr
RepresentativeHeadquarter AddressFoundation DateTotal StaffRepresentative PhoneRepresentative Fax Web
Contact Person
Contact Phone
Contact E-mail
International Business Dept. (Export), Bussiness Development & Licensing Dept. (License in/out)
export : +82-2-549-7451 (내선) licensing : +82-2-549-7451 (520)
export@jeilpharm.co.kr (export) pjkim@jeilpharm.co.kr (licensing)
105
Product (Ingredient/Formulation) Use Exporting Countries Remarks
1. Cefditoren Pivoxil Antibiotic
2. Cefcapene Pivoxil Antibiotic
3. Imipenem Cilastatin Mix. Antibiotic
4. Rosuvastatin Cardiovascular
5. Ketoprofen Plaster TDS
6. Imipenem/Cilastatin Inj. Antibiotic
7. Cool Pap TDS
8. Sany Plaster TDS
9. Epinastine HCl Respiratory
10.Valtra Tab. Antiviral
Main Products
Ingredient Code Use Stage of Development
JPI-289 (NCE) JPI-289 PARP-1 inhibitor / Stroke Phase Ib
JPI-283 (NCE) JPI-283 oncology preclinical
JLP-1310 JLP-1310 hyperlipidemia + type 2 DM FDC phase I
JLP-1207 JLP-1207 BPH/LUTs FDC phase I
JLP-1401 JLP-1401 hypertension + type 2 DM FDC phase I
R&D Pipeline
2016 Directory of Korea Pharmaceutical Industry106
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 37,144 40,234 45,236
R&D Expenditure 3,393 2,241 2,913
Capital 6,000 6,000 6,000
Financial Figures
Jin Yang Pharmaceutical Co., Ltd. was established in 1971 and has been staying ahead of the pharmaceutical industry in Korea with our full automatic production system in the most modern and up-to-date plant and by being designated as a company conforming to KGMP (Korea Good Manufacturing Practice). We have also been leading the development of the pharmaceutical industry in Korea through cooperation with the world’s premier pharmaceutical companies. In July 2000 our company joined in the KOSDAQ Listed Companies Association so that we laid the groundwork for the more stable company, and furthermore, one of the most excellent companies in the 21st century. For more than forty years, based on the principle of honesty and sincerity, all the staffs and employees of our company has been putting all their efforts into building a better world with the aim of developing good quality drugs for health and happy life of the people and with the faith of managing the company in a profound respect for humanity. We promise to be a company that keeps on doing research and development for the improvement of life quality of the people and clients can give their confidence to our company. We will contribute to healthy life of the people by bending over backwards to help you not to lose your healthy body and happy life.
Focus Area : Cardiovascular, Gastronitestinal
Company Profile
Jin Yang Pharm. Co., Ltd.Jae-Joon, Choi
31, Hyoryeong-ro, Seocho-gu, Seoul, Korea
Jul. 1. 1971
IMD, Generic
220
82-2-3470-0300
82-2-3470-0390
www.jinyangpharm.com
RepresentativeHeadquarter AddressFoundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Contact PersonContact PhoneContact E-mail
Chul-Ho, Han
82-2-3470-0371
overseas@jyp.co.kr
107
Product (Ingredient/Formulation) Use Exporting Countries Remarks
1.Clivix tab.(Clopidogrel)Antithrombotics,
Antiplatelet AgentsVietnam
2. Eszol Caps.(Esomeprazol) Antiulcerants Vietnam
3. Gynodron Tab.(Alendronate) Osteoporosis Vietnam
4. Nacton Tab.(Nabumetone) NSAIDs Vietnam
5. Gyno-plus Tab. (Black cohosh, Hyperici)
Hormone & Synthetic Agents
VietnamMalaysia
6. Cloxin tab.(Clonixin) NSAIDsVietnamBolivia
7. Ramista tab.(Rebamipide) Antiulcerants Vietnam
8. Dapid tab.(Indapamide) Essential hypertension Hong-Kong
9. Miary tab.l(Glimepiride) Anti-diabetics Malaysia
10. Freegra ODF(Sildenafil) Erectile Dysfunction Nigeria
Main Products
Ingredient Code Use Stage of Development
Entecavir Antiviral Agents Launch expected
Celecoxib NSAIDs Launch expected
Atorvastatin Antilipidemic AgentsFormulation development &
BE study
Rosuvastatin Antilipidemic AgentsFormulation development &
BE study
Esomeprazole(magnesium trihydrate)
Antiulcerants Formulation development
Vitis viniferaTreatment of venous
insufficiencyFormulation development
R&D Pipeline
2016 Directory of Korea Pharmaceutical Industry108
Summary (1 Million Won)
Fiscal Year 2008 2009 2010
Sales 437,648 455,147 443,276
R&D Expenditure 19,942 22,173 24,231
Capital 23,033 23,774 24,487
Financial Figures
Since its foundation, JW Group has led the hospital market based on respect for life and the pioneering spirit, and is now being reborn as a global healthcare company to lead the industry into the 21st century.
Based on leading competitiveness in the ethical drug market, JW Pharmaceutical has built up strong sales network across the country and superior pipelines in I.V solutions, antibiotic, cardiovascular, gastrointestinal, nephrology, anticancer and neuropsychiatry. And now, it is pioneering the rapidly growing new field such as diabetes and so on. It has been striving to produce and provide innovative new technologies and services heading for healthy lives of human beings on the basis of its founding spirit of “Respect for life”.
Company Profile
JW Pharmaceutical CorporationKyung Ha Lee
2477, Nambusunhwan-ro, Seocho-gu, Seoul, Korea
1945
Anti cancer, Formulation research
1,872
82-2-840-6777
82-2-841-1213
www.jw-pharma.co.kr
RepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
109
Main Products
Product (Ingredient) Use Exporting Countries
1. Carbenem Antibiotics (Imipenem/Cilastin)
Infection byGram - positive
bacteria
· Japan, China · EU (Spain, Germany)· South-East Asia (Hongkong, Indonesia, Malaysia, Mongol, Parkistan, Philippines, Syria, Thailand, Vietnam, Yemen, Nigeria, India, Bangladesh etc.)· CIS (Russia, Kazakhstan, Belarus, etc.)· Latin America (Brazil, Mexico, Argentina etc.)
2. I.V SolutionsSupply
electrolytes and trace elements
· South-East Asia (Vietnam, Cambodia, etc.)
3. Antifungal Agents (Itraconazole, ketoconazole)
Infection by fungi· Japan· South-East Asia (Indonesia, Parkistan etc.)
4. Other antibiotics (Cefmetazole, amikacin)
Various infection· Japan· South-East Asia (Vietnam etc.)
5. Anticancer drugs (Cytarabine, Alkyloxan, 5-FU)
Care for variouscancer including
hematologicalcancer
· South-East Asia (Turkey, Malaysia, Bangladesh etc.)
New Active Substances
Product (Ingredient) Use Approval Date
Q-ROXIN (Balofloxacin) Antibiotics100mg: 6th, May, 1993200mg: 7th, Jul, 1995
Zepeed (Avanafil) Erectile Dysfunction 17th, Aug, 2011
R&D Pipeline
Ingredient Use Stage of Development
WnT Hematological Malignancy Phase I clinical trial approved by FDA in April, 2011
Oxaliplatin (Oral formulation)
Metastatic Colorectal Cancer Pre-clinical study for IND application
Montelukast Anti-AsthmaBUSH-Tab® Tech (Formulation research)
To be launched in January, 2012
2016 Directory of Korea Pharmaceutical Industry110
Summary (1 Million Won)
Fiscal Year 2008 2009 2010
Sales 16,003,885,516 15,520,406,585 13,049,056,754
R&D Expenditure 840,026,917 597,463,118 365,380,138
Capital 23,821,672,987 13,818,671,875 13,603,417,008
Financial Figures
Since its foundation in 1997, KMS PHARM CO., LTD. has devoted itself to provide high-quality pharmaceutical and herbal medicines to the local pharmacies and hospitals, and overseas customers such as Vietnam, Myanmar, Hongkong, etc. KMS PHARM has successfully accomplished a whole production line in compliance with KGMP (Korea Good Manufacturing Practice) compatible with WHO GMP and , has been providing quality medicines.
Company Profile
KMS Pharm Co., Ltd.RepresentativeHeadquarter Address
Foundation DateTotal StaffRepresentative PhoneRepresentative Fax Web
Kyung joo Lee
232, Sinwon-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do, Korea
Jul. 1997
60
82-31-215-5456
82-31-215-5925
www.kmspharm.com
111
Main Products
Product (Ingredient) Use Exporting Countries
1. L-Viem Tab(Lysozyme 90mg) Enzyme Vietnam
2. Trirog Tab(Trimebutine maleate 100mg) Indigestion Vietnam
3. Hepaphil S.C(DDB 3mg) Hepatic protector Vietnam
4. Mipisul Tab(Levosulpiride 25mg) Indigestion Vietnam
5. KMS Losartan potassium Tab (Losartan potassium 50mg)
Hypertension Vietnam
6. Yuraf Tab (Tramadol HCI 37.5+Acetaminophen 325mg)
Anti-inflammatory Vietnam
7. KMS Domperidone maleate Tab (Domperidone maleate 12.72mg)
Indigestion Vietnam
8. KMS Ciprofloxacin HCI Tab. (Ciprofloxacin HCI 582mg)
Antibacterial antibiotics Vietnam
9. Ketrazin Tab(Levocetirizine 2HCI 5mg) Antihistamins Hong Kong
10. Suzyme Tab(Lysozyme 90mg) Enzyme Myanmar
2016 Directory of Korea Pharmaceutical Industry112
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 177,779 267,881 439,080
R&D Expenditure 7,418 11,997 17,200
Capital 9,742 9,742 10,550
Financial Figures
Since founded in 1990 as a joint venture company with Nihon(Japan) Kolmar, Kolmar has grown to the biggest Korean Pharmaceutical contract manufacturer.
Kolmar Korea has extended our business to pharmaceutical business from 2002. And provide specialized production system with total outsourcing service on development and production of pharmaceutical and quasi-drug.
Kolmar Korea has provided customized contract manufacturing service with customers who want to outsource their pharmaceutical products, cosmetics and healthcare foods to be more competitive and to develop new formulations feasible in the market.
Focus Area : CMO (Contract Manufacturing Organization), Generic drug
Company Profile
Kolmar Korea Co.,Ltd.RepresentativeHeadquarter Address
Foundation DateTotal StaffRepresentative PhoneRepresentative Fax Web
Cho Hong Koo
12-11, Deokgogae-gil, Jeonui-myeon, Sejong, Korea
May. 15. 1990
650
82-2-3485-0497
82-2-515-1532
www.kolmar.co.kr
Contact PersonContact PhoneContact E-mail
M.S.Pyo
82-2-3485-0397
mspyo@kolmar.co.kr
113
Product (Ingredient/Formulation) Use Exporting Countries Remarks
1.Painless Tablet Anti inflammatory Philippines EU-GMP 추진품목
2.Hiforge Tablet Hypertensive Ajerbaijan
3.Cerephone Dry Syrup Anti-biotic Vietnam
4.Azithrobiotic Dry Syrup Anti-biotic Vietnam
5.Romaryl Cream Anti-fungi HongKong
6.Levocetirizine HCl Tab. Anti-histamine The Philippines
7.Minoxidil solution Male pattern
alopeciaJapan
Main Products
Ingredient Code Use Stage of Development
Tadalafil Erectile dysfunction BE
Amlodipine + Olmesartan
Hypertension BE
Celecoxib Antiinflammatory BE
Atorvastatin Calcium Hyperlipidemia BE
Entecavir Treatment of HBV BE
R&D Pipeline
2016 Directory of Korea Pharmaceutical Industry114
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 61,674 65,104 71,820
R&D Expenditure 3,962 2,175 2,922
Capital 24,430 20,229 21,747
Financial Figures
KOLON Pharma has been producing and supplying outstanding medicines and health functional foods to promote national health.
Our company will proceed to develop as an exceptional pharmaceutical company with excellence in technologies, labor force, and customer-oriented product development.
Focus Area : Pediatric Respiratory Drug etc
Company Profile
KOLON PHARMARepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Woo Seok Lee
Kolon Tower Annex 6th Floor, 13, Kolon-ro, Gwacheon-si, Gyeonggi-do, Korea
Oct. 5. 1958
Pediatric Respiratory Diseases
378
82-2-2120-8300, 8400
82-2-2120-8301
www.kolonpharm.co.kr
Contact PersonContact PhoneContact E-mail
Seok Jung Yun
82-2-2120-8346
alomek@kolon.com
115
Product (Ingredient/Formulation) Use Exporting Countries Remarks
1. COMY (Chlorpheniramine maleate, Phenylephrine hydrochloride / Syrup, Tablet)
Improvement of all symptoms due to common cold or allergic rhinitis, Cough
2. FOSTER 100/6 HFA (Formoterol fumarate dihydrate, Beclometasone dipropionate / Inhaler)
Regular treatment of asthma where use of a combination product (inhaled corticosteroid and long-acting beta2-agonist), severe COPD(Chronic Obstruction Pulmonary Diseases) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators
3. TOPISOL MILK LOTION (Methylprednisolone aceponate / Lotion)
Eczema(atopic dermatitis, psoriasis eczema, etc.)
4. CUROSURF INJ. (Poractant alfa / Injection)
Treatment of Respiratory Distress Syndrome (RDS) in newborn babies. Prophylactic use in premature infants between 24 and 31 weeks estimated gestational age at risk from RDS or with surfactant deficiency.
5. COUGHJIN (Ammonium chloride, Chlorpheniramine maleate, Dihydrocodeine tartrate, Dl-methylephedrine HCl / Syrup)
Cough, Sputum
6. KOFXIME (Cefpodoxime proxetil / Tablet, Dry Syrup)
Treatment of susceptible acute, community-acquired pneumonia caused by S.pneumoniae or nonbeta-lactamase producing H.influenza acute uncomplicated gonorrhea caused by N. gonorrhoeae; uncomplicated skin and skin structure infections caused by S.aureus or S.pyogenes; acute otitis media caused by S.pneumoniae, H.influenzae, or M. catarrhalis; pharyngitis or tonsillitis; and uncomplicated urinary tract infections caused by E. coli, Klebsiella, and Proteus
7. BICOGREEN (Aloe capensis, Aloe extract, Bisacodyl, Chelidonii Herba, Curcuma Root, Frangula extract, Rhubarb Extract, enna leaf / Tablet)
Constipation, improvement of symptoms (anorexia, abdominal distention,intestinal putrefaction, hemorrhoid)
Main Products
2016 Directory of Korea Pharmaceutical Industry116
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 11,517,041 12,124,578 12,100,153
R&D Expenditure 402,665 213,818 177,080
Capital 17,356,368 17,457,246 18,287,237
Financial Figures
Established in 1982, Korea Otsuka Pharmaceutical Co.,Ltd. is a joint-stock company that provides excellent and innovative medicines as part of its mission of contributing to the Korea healthcare industry. We have large-scales production facilities in Korea for the consistent production of finished goods from synthesis of life. Moreover our products have help treat patients in Korea and improve quality of life. Moreover our products been exported Europe, Asia and the Middle East contributing to the taken an active part in international clinical studies, and strived to expand our business starting with the healthcare business in 2012.
Focus Area : CNS, Neurology, Cardiology, Gastroenterology.
Company Profile
Korea Otsuka Pharmaceutical Co., Ltd.Sungho Moon
226 Yeoksam-ro, Gangnam-gu, Seoul, Korea
Jul. 9. 1982
340
82-2-3287-9000
82-2-3287-9019
www.otsuka.co.kr
RepresentativeHeadquarter AddressFoundation DateTotal StaffRepresentative PhoneRepresentative Fax Web
Contact PersonContact PhoneContact E-mail
Taejin Kim
82-2-3287-9124
paran2010@otsuka.co.kr
117
Product (Ingredient/Formulation) Use Exporting Countries Remarks
1. ABILIFY Tab. Anti-psychotic agentHong-Kong, Philippines, Thailand, Indonesia
2. ABILIFY ODT Anti-psychotic agent OPEL(Europe)
3. PLETAAL Tab. Anti-platelet agentHong-Kong, Philippines, Thailand, Vietnam, Malaysia
4. PLETAAL SR Cap Anti-platelet agent
5. MUCOSTA Tab. Anti-ulcer agentPhilippines, Thailand, vietnam, Cambodia, Malaysia
6. SAMSCA Tab. Aquaretic agent Philippines, Thailand
7. Meptin Tab. Anti-asthmatic agent
8. Meptin swinghaler Anti-asthmatic agent Philippines, Indonesia
9. OBUCORT swinghalerAnti-asthmatic agent(Inhalation)
Philippines, Thailand, Indonesia
10. Mikelan Tab. Anti-arrhythmic agents
11. Busulfex IVHSCT (hematopoietic stem cell transplantation)Conditioning agent
12.Lorelco Tab.Anti-hyperlipidemic agent
Main Products
2016 Directory of Korea Pharmaceutical Industry118
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 44,744 50,046 54,829
R&D Expenditure 1,010 1,350 1,453
Capital 3,300 4,200 4,200
Financial Figures
Korea Pharma Co., Ltd.(KP) established in 1974, have acquired KGMP as we have safe and stabilized production systems. KP maintain the production process to assure the efficacy, safety and stability of all our products such as oral solid forms, oral liquid forms, topical liquid forms, ointment etc. We have built up perfect Q.C. systems, and we are supplying our products to the domestic markets, and exporting to over 16 countries to be widely recognized the manufacturing and technological achievements in the world.
Focus Area : CNS Drug, Colon Cleansing Agent, Alimentary Preparation etc.
Company Profile
Korea Pharma Co., Ltd.RepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Jae Don Park
8F, 58, Nonhyeon-ro 85-gilm Gangnam-gu, Seoul, Korea
Sep. 3. 1974
Developing innovative new medicines
242
82-2-558-1277
82-2-558-1678
www.koreapharma.co.kr
Contact PersonContact PhoneContact E-mail
Jin Wook Lee
82-70-4742-8845
koreapharma@hanmail.net jinwook.lee@koreapharma.co.kr
119
Product (Ingredient/Formulation) Use Exporting Countries Remarks
1. VASTIA Tab. 5mg/10mg (Donepezil HCl 5mg, 10mg)
Central nervous system agent
Hong Kong
2. ALBIX Tab. 10mg (Memantine HCl 10mg)
Central nervous system agent
Hong Kong
3. KOTASE Tab. (Bromelaine 40mg & Crystalline Trypsin 1mg)
Anti-tumefacient enzyme preparation
Myanmar, Vietnam
4. BAB Chewable Tab. (Hydrous dibasic calcium phosphate 100mg, Calcium lactate 25mg, Vitamins, etc.)
Alimentary preparation
Myanmar
5. AMOROLFINE Nail Lacquer (Amorolfine HCl 5g)
Topical antifungal agent for
onychomycosis
6. CRICOLON Tab. (Dibasic Sodium phosphate anhydrous 398mg, Monobasic Sodium phosphate monohydrate1,102mg)
Tablet type colon cleansing agent
7. RISDON Tab. 1mg/2mg (Risperidone 1mg, 2mg)
Central nervous system agent
8. PAROXETINE Tab. 20mg (Paroxetine HCl 22.8mg)
Central nervous system agent
Main Products
2016 Directory of Korea Pharmaceutical Industry120
Summary (1 Million Won)
Fiscal Year 2008 2009 2010
Sales 35,145 43,544 60,233
R&D Expenditure - - -
Capital 1,950 2,150 2,150
Financial Figures
KOREA PRIME PHARM. CO., LTD. is specializes in manufactures and sales of pharmaceutical drugs(ETC) and Hospital doctors prescribe medications, and going to achieve higher growth rate of 30% per year rather than the average growth rate of the pharmaceutical industry.
Furthermore, domestic pharmaceutical companies are noticed to a big change by Korea-US FTA agreement recently. Therefore, Our company cope with the policy changes of the domestic pharmaceutical industry and the opening of the global pharmaceutical market, and we think to develop new products as a top priority in order to grow as a global company, and are focusing on doing business making new drugs(improved new drugs, Biomedicine, drug formulation development, and so on) by R&D cooperation.
In particular, our company awarded “2009, Korea Health Industry Award”, and “Grand Prize”in the part of independent medium venture company. With this opportunity, we will increasingly continue to work hard with the responsibility of the development of domestic pharmaceutical health industry.
Company Profile
Korea Prime Pharm. Co., Ltd.RepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Kim Dae Ik
7~9F, Daein B/D, 211 Jungang-ro, Dong-gu, Gwangju, Korea
May. 31. 1995
Medicine
253
82-62-233-1110
82-62-233-3296
www.koreaprime.co.kr
121
Main Products
Product (Ingredient) UseExporting Countries
1. Denical Tab. ( Calcium lactate pentahydrate 271.8㎎
Calcium Gluconate 240㎎ Precipitated Calcium Carbonate 240㎎ Dried Ergocalciferol 0.118㎎)
In case of calcium shortage/supplyVietnam
Cambodia
2. Throgin Tab.(Roxithromycin 150mg)Pharyngolaryngitis, acute bronchitis, tonsillitis, bacterial pneumonia, otitis media, sinusitis, periodontitis, etc.
VietnamCambodia
3. Rocin Tab.(Ciprofloxacin 250mg)Respiratory tract infection, infections in ear, nose, throat, mouth and tooth, renal and urinary tract infection, etc.
VietnamCambodia
4. Anflaim Tab.(Ofloxacin 100mg)respiratory tract infections, urinary tract infections, dermatological infections, gynecological infections
VietnamCambodia
5. Simbidan Tab.(Simvastatin 20mg)hyperlipidemia, prophylactic use in hypercholesterolaemic patients with ischaemic heart disease
Vietnam
6. Loxorofen Tab. (Loxoprofen sodium 68.1mg) (60mg as anhydrous)
1. Anti-inflammation and analgesia in the following diseases and symptoms : Chronic rheumatoid arthritis, osteoarthritis, low back pain, scapulohumeral periarthritis and neck-shoulder-arm syndrome.
2. Anti-inflammation and analgesia after operation, trauma or tooth extraction.
3. Anti-pyresis and analgesia in the following diseases : Acute upper respiratory tract inflammation (including acute upper respiratory tract inflammation accompanied by acute bronchitis)
VietnamCambodia
7. Talpain Tab.(Talniflumate 370mg)
Rheumatoid arthritis, osteoarthritis, (degenerative arthritic disease), sciatic neuralgia, amenorrhoeic pain, pain caused by trauma, inflammation and pain after surgery, tendosynovitis, sprain, adnexitis, pharyngitis, tonsillitis, otitis, sinusitis
VietnamCambodia
8. Exad Cap. (Nizatidine 150mg)Duodenal ulcer, gastric ulcer, Gastric oesophageal reflux disease
VietnamCambodia
9. Borad Tab.(levosulpiride 25mg)
Alleviation of the following symptoms due to functional dyspepsia: abdominal fullness, epigastric discomfort, and stomach soreness, belching, nausea and vomiting
VietnamCambodia
10. Apepsia-m Tab. (Domperidone maleate 12.72mg) (10mg as Domperidone)
Following diseases and dyspepsia in case of drug administration nausea, vomiting, anorexia, abdminal Distension, abdominal pains, flatulence, etc.
VietnamCambodia
R&D Pipeline
Ingredient Use Stage of Development
Sildenafil citrate Treatment for erectile dysfunction. Bioequivalence Test completion
2016 Directory of Korea Pharmaceutical Industry122
· Business Activities : Manufacture, Marketing & Sales of Pharmaceuticals and Other Healthcare Products
· Number of registered products : about 224 items
· Investment in R&D : 12.6% of net sales (2013’)
· Market Sales : $136M (2014’)
· Growth Rate from 2013 to 2014 : 10.3%
· Incrementally Modified Drug : Clanza®CR, Clavixin®Duo Cap, Cilostan®CR, Kalomin®Tab.
KUP is export-oriented company. KUP is aiming to be not only a local leader but also global leading company by offering wide range of generics as well as differentiated products, incrementally modified drugs.
KUP has broad and well balanced portfolio of 244 products and exports 416 different items to 32 countries through global marketing, and oversea manufacturing facilities in USA, Vietnam, and has a business alliance with oversea companies. Especially KUP established manufacturing facility in Alabama, US for manufacturing and distrubuting drugs and health functional foods in 2003. This facility have allowed KUP to expand markets in US, Japan, and Europe with know-hows of FDA regulatory processes.
KUP invested in Research&Development. KUP invested about 12% of net sales and 10% of total employees in R&D continuously. KUP is successful developing innovative drugs and commercializing it. As a result, KUP has launched four IMDs - Clanza®CR Tab., Calvixin®Duo Cap., Cilostan®CR Tab., Kalomin®Tab. In addition, KUP has well balanced R&D portfolio including differentiated products of anti-neoplastic, Anti-hypertensive, and Antithrombotic Dugs.
KUP has been acknowledged at home and abroad. KUP was nominated as Forbes’ ‘Asia’s 200 Best Under A Billion’ over two consecutive years. KUP is one and only pharmaceutical company in Korea nominated by the Forbes magazine as one of the ‘Asia’s 200 Best Under A Billion’ over two consecutive years (2009~2010). KUP was awarded the Best Drug Research Award in Korea for CilostanCR in 2015.
Company Profile
Korea United Pharm. Inc.RepresentativeHeadquarter Address
Foundation DateResearch Focus
Total StaffRepresentative PhoneRepresentative Fax Web
Duk-young Kang
22, Nonhyeon-ro 121-gil, Gangnam-gu, Seoul, Korea
Dec. 3. 1987
Drug delivery system - Novel Controlled Release Formulation - Novel Fixed Dose Combination
738
82-2-512-9981
82-2-548-4599
www.kup.co.kr
Contact PersonContact PhoneContact E-mail
Joosung Bae
82-2-558-8612
BD@kup.co.kr
123
Main Products
Product (Ingredient/Formulation) Remark
1. Clanza®CR Tab. (Aceclofenac 200mg / Controlled Release Formulation)
· Indication : Pain caused by rheumatism (Antiinflammatory Analgesic drug)· Improved dosing regimen from b.i.d. to q.d.· Less side effects of gastrointestinal
2. Cilostan®CR Tab.(Cilostazol 200mg / Controlled Release Formulation)
· Indication : Ischemic symptoms, Thrombosis (Antithrombotic drugs)· Improved dosing regimen from b.i.d to q.d.· Reduced side effects of headache & tachycardia
3. Clavixin®Duo Cap. (Clopidogrel 75mg and Aspirin 100mg / Fixed Dose Combination)
· Indication : Acute coronary syndrome (Antithrombotic drugs)· Improved patient compliance
4. Kalomin® Tab. (Pelargonium Sidoides(as dry extract) 20mg / New Dosage Formulation)
· Indication : Upper respiratory tract infections (Antitussive)· Improved patient compliance for adults
R&D Pipeline
Ingredient Code Use Stage of Development
Unigril®CR Tab. UI03SPG300CT Antithrombotic drugs Clinical Trial
Levonazine®CR Tab. UI04LDP090CT Antitussive Clinical Trial
Losasc® Tab. 5/50, Losasc® Tab. 5/100
UI15AML055MTUI18AML0510MT
Anti-hypertension Clinical Trial
DTX031 UI19DTX031IV Anti-neoplastic Clinical Trial
Gastin®CR Tab. UI05MSP015CT GI modulator Clinical Trial
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 134,816 136,885 151,485
R&D Expenditure 16,999 16,959 19,000
Capital 134,039 140,393 159,349
Financial Figures
2016 Directory of Korea Pharmaceutical Industry124
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 115,774 100,700 133,200
R&D Expenditure 179 236 206
Capital 46,790 55,646 63,256
Financial Figures
Specializing in production of infectious disease preventive medicine(Vaccine) and disposable medical devices, Korea Vaccine has contributed to people’s health since 1954.
Focus Area : Pediatric vaccine and disposable medical supply.
Company Profile
Korea Vaccine Co., Ltd.RepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Deok-Ho Choi
128, Mongnae-ro, Danwon-gu, Ansan-si, Gyeonggi-do, Korea
Jan. 1956
Vaccines
260
82-31-495-6397~8, 82-2-443-1961~5
82-2-2249-0363
www.koreavaccine.com
Contact PersonContact PhoneContact E-mail
Sungbae Ha
82-2-443-2008
sbha@koreavaooine.com
125
Product (Ingredient/Formulation) Use Exporting Countries Remarks
1. Freeze-dried BCG vaccine (percutaneous)
Prevention of TuberculosisGlobal
distributorship
2. Kovax Polio PF. Prevention of Poliomyelitis
3. Typhoid Kovax Inj.Prevention of Thphoid
bacillus
4. Kovax Influ PF (Influenza Vaccine)
Prevention of Influenza
5. IL-YANG Flu Vaccine (Influenza Vaccine)
Prevention of InfluenzaGlobal
distributorship
6. Vari-L Vaccine Inj. Prevention of VaricellaGlobal
distributorship
7. CD.JEVAX Inj.Prevention of Japanese
Encephalitis VirusGlobal
distributorship
Main Products
2016 Directory of Korea Pharmaceutical Industry126
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 43,900 41,555 45,392
R&D Expenditure 1,495 1,632 1,945
Capital 5,500 5,500 5,500
Financial Figures
We are a manufacturer, a distributor, an exporter and an importer of medicines, health functional foods and cosmetics related to human life. We have always been eager to be the most reliable and trustworthy pharmaceutical company that can bring the highest value to the society, clients and employees since its establishment in 1980. Our business has been focused on OTC medicines in the beginning and extended to ETC medicines after enforcement of the separation system of prescribing and dispensing drugs. Currently, we are concentrating on developing life style modification products.
We are opened to collaborate with anyone in any business field as we have been collaborating research projects with universities, governments and other research institutions. Regarding flexibility, we not only provide pharmaceuticals but also diagnostic tools, medical food, and cosmetics to help modifying life style.
We will cope actively by adopting changes of society and pharmaceutical circumstances. Also, to keep our promise of the forthcoming future, and work harder than ever had before. Running our business through differentiation and pliability, we expect to satisfy our customers, shareholders, and employees.
Focus Area : Central Nervous System Drugs
Company Profile
Korean Drug Co., Ltd.RepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Sang Hun Park
34, Nonhyeon-ro 28-gil, Gangnam-gu, Seoul, Korea
Jan. 1980
Central Nervous System Drugs
245
82-2-529-6100
82-2-529-6114
www.nicepharma.com
Contact PersonContact PhoneContact E-mail
Soon Ho, Bang
82-31-634-7100 (ext.610)
shbang@nicepharma.com
127
Product (Ingredient/Formulation) Use Exporting Countries Remarks
1. Neuromed (Oxiracetam/Tablet, Syrup, Inj)
Alzheimer’s-type dementia, multi-infarct dementia, Oraganic Brain Syndrome
China
2. Gabatin (Gabapentin/Tablet, Capsule)
Epilepsy, Neuropathic painSri Lanka, Vietnam, Philippines, Myanmar, Cambodia
3.Neurocept (Donepezil / Tablet)
Alzheimer’s-type dementi Vascular Dimentia
Philippines, Sri Lanka
4. Lukema (Montelukast / Tablet, Chewable Tablet)
Asthma, Allergic rhinitis Vietnam, Philippines
5. Zypeace OD (Olanzapin / OD Tablet)
Schizophrenia, Bipolar Disorder
6. Allertec (Cetirizine / Tablet)
Allergic rhinitis, Allergic conjunctivitis, chronic idiopathic urticaria, skin itching
Philippines, Vietnam, Cambodia, Sri Lanka, Singapore
7. Isotren (Isotretinoin / Soft Capsule)
Severe Acne Vietnam, Cambodia
8. Plamed (Clopidogrel / Tablet)
Improvement of atherosclerotic symptoms, decrease the risk of thromboembolism
Vietnam
9. Ginkgo-mexin (Ginkgo Biloba leaf ext. / Tablet, Soft Capsule)
Peripheral arterial circulatory disorders, dizziness, tinnitus
Vietnam
Main Products
Product (Ingredient) Use Approval Date
Neuromed (Oxiracetam) Brain metabolics 1992-03-11 / Korea
New Active Substances
Compound Name Code Use Stage of Development
crude extract KDC14-01 Osteophorosis Preclinical
crude extract KDC14-02 Atopic dermatitis Preclinical
R&D Pipeline
2016 Directory of Korea Pharmaceutical Industry128
Summary (1 Million Won)
Fiscal Year 2008 2009 2010
Sales 121,638 122,565 131,308
R&D Expenditure 2,710 2,177 1,769
Capital 65,248 71,936 75,942
Financial Figures
Under the company motto of “respect for human life”, we, Kukjepharm Ind. co., Ltd.
have devoted our constant attention to manufacturing various medicines of highest quality by using a state-of-the art synthesis technology and sophisticated facilities complying with GMP guideline recommended by WHO.
Company Profile
Kukje Pharm. Ind. Co., Ltd.RepresentativeHeadquarter Address
Foundation DateTotal StaffRepresentative PhoneRepresentative Fax Web
Jong-Hoon Ra
96-8, Yatap-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea
Jul. 27. 1959
461
82-31-781-9081
82-31-781-6040
www.kukjepharm.co.kr
129
Main Products
Product (Ingredient) Use Exporting Countries
1. cefminox Inj. Anti biotics China
2. spectinomycin Inj. Anti biotics Iran
3. Tricef cap. Anti biotics Vietnam
4. Netilmycin Inj. Anti biotics Vietnam
5. Cualone Eye-drop. Ophthalmic agents Vietnam
6. cefotaxime Inj. Anti biotics Vietnam
7. ceftriaxone Inj. Anti biotics Vietnam
8. ceftazidime Inj. Anti biotics Vietnam
9. Tronamycin Inj. Anti biotics Vietnam
10. Peratam Inj. Anti biotics Vietnam
R&D Pipeline
Ingredient Use Stage of Development
TG-1001 Diabetic Retinopathy Early stage
LM-1002 GERD Early stage
LP-1003 Lumbar spinal stenosis Early stage
RB-1004 acute, chronic gastritis Early stage
2016 Directory of Korea Pharmaceutical Industry130
Summary (1 Million Won)
Fiscal Year 2008 2009 2010
Sales 276,173 276,585 289,435
R&D Expenditure 6,500 6,630 6,150
Capital 52,400 52,400 52,400
Financial Figures
Kwang Dong Pharmaceutical Co., Ltd. has tried its utmost to manufacture superior medicines for the last half a century since it took the first step to supply medicines in Korea, a barren land for the medical industry in 1960’s. Kwang Dong has been advancing in to a top-ranking pharmaceutical company in the world through thee establishment of the most advanced factories in Pyungtaek City. We have been enjoying an excellent reputation in technology over forty years because of the goods quality and dependability of our goods. We are one of leading pharmaceutical manufacturer in Korea having GMP factory for ETC, OTC, drink and nutrition supplement. So, we have been exporting to our pharmaceutical products (Finished products) to sell all over the world.
Company Profile
Kwang Dong Pharm. Co., Ltd.Primary Logo Secondary Logo
Primary Signature Secondary Signature
Sung won choi
Gasan B/D, 85 Seochojungang-ro, Seocho-gu, Seoul, Korea
Oct. 16. 2012
Pharmaceutical
749
82-2-6006-7258~9
82-2-6006-7024
www.ekdp.com
RepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
131
Main Products
Product (Ingredient) Use Exporting Countries
1.Bicalude Tablet (Bicalutamide 50mg)
Advanced prostate cancer in combination with LHRH analogue therapy or surgical castration
Vietnam, Nigeria
2.Lenara Tablet (Letrozole 2.5mg) Breast cancer
3.Kwangdong Woohwang Chungsimwon
Stroke, Hypertension, Palpitation, Mental anxiety, Acute
Vietnam
4.Sedera ODF (Sildenafil citrate 50mg)
Treatment of erectile dysfunction
5.Cool strip ODF (Cetylpyridinium chloride 1.5mg)
Preventive treatment of pharyngitis, amygdalitis, stomatitis
6.KD-Fen Plaster (Diclofenac Diethylammonium 120.0mg)
Analgesia, anti-inflammatory : arthrosis deformans, tenontothecitis,tennis elbow, myalgia, post traumatic pain
Hong Kong
7. Clisia Solution(Clindamycin phosphate 1.188g/100mL (1g as Clindamycin)
acne vulgaris Hong Kong, Cambodia
8.Beaurasen Injection(placenta 100mg, Benzyl Alcohol 0.03mg)
menopausal disorder Malaysia, Hong Kong
9. Kwangdong Ceftriaxone Sodium Inj. (Ceftriaxone Sodium1g)
Treatment of community-acquired or mild to moderate health care-associated pneumonia
Afghanistan, Vietnam
10. Iritesin Injection(Irinotecan 20mg)
1. after 5-FU therapy recurrent, progressive metastatic rectal cancer, colon carcinoma
2. combined treatment with 5-FU or Leucovorin, progressive metastatic rectal cancer, colon carcinoma without other therapy
3. gastric cancer (incapable surgery or requrrent)
4. small cell lung cancer5. progressive small cell lung cancer
Georgia
R&D Pipeline Category Product
NameDevelopment
Phases indicantDosage
FormDevelopment
Type
Central Nervous System
KD501Clinical test
Phase II dementia oral
License in from Elcomscience (Kor)
Self developed
KD103 Developingdementia,
Alzheimer's diseaseconsidering Self developed
Metabolic disease
KD101 Pre clinical obesity oral Self developed
Endocrine System
KD802 Pre clinical short
statureInjection
License in from Genexine (Kor) /
joint research
Digestive trouble
Ramosetron ODF
INDantinauseant
medicineoral / film Self developed
2016 Directory of Korea Pharmaceutical Industry132
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 152,822 162,238 170,278
R&D Expenditure 4,408 4,724 5,357
Capital 10,758 10,758 10,758
Financial Figures
Kyongbo Pharm. has committed Contract Manufacturing Organization(CMO) business with sufficient technical and marketing resources. As one of major manufacturers of APIs and finished dosages in Korea, we will put utmost efforts along with the best staff of R&D and quality assurance to be a global pharmaceutical manufacturer. Our modern facilities and infrastructure guarantee that our products meet superior quality in accordance with cGMP standards.
Focus Area : General API, Anti-Cancer API, Cephalosporins API, Carbapenem API
Company Profile
Kyongbo Pharm. Co., Ltd.RepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Taewon Kang
174, Sirok-Ro, Asan-Si, Chungcheongnam-Do, Korea
Mar. 31. 1987
GENERIC
352
82-2-365-2301
82-2-2175-2388
www.kbpharma.co.kr
Contact PersonContact PhoneContact E-mail
Richard Kim
82-2-2175-2387
skarajjang@kbpharma.co.kr
133
Product (Ingredient/Formulation) Use Exporting Countries Remarks
1. ATORVASTATIN Hypolipidemic Japan
2. CEFTIZOXIME Anti-BioticChina, Japan, South
east Asia(SEA)
3. CEFTRIAXONE Anti-BioticEU, Japan, SEA, Russia
etc
4. CLARITHROMYCIN Anti-Biotic Japan
5. PRANLUKAST Anti-asthmatic Japan
6. Loxoprofen Anti-inflammatory Turkey
7. SULBACTAM β-lactamase inhibitor Japan, Russia
8. Cefroxadine Anti-Biotic Japan
9. Cefotaxime Anti-Biotic Russia, SEA etc
10. Clopidogrel Anti-platelet Japan
Main Products
Ingredient Code Use Stage of Development
Tenofovir Disoproxil HBV Pilot scale
Duloxetine HCl Antidepressant Pilot scale
Ezetimibe Hyperlipidemia Pilot scale
Cinacalcet HCl Hypercalcemia Completed Process validation
Dabigatran Etexilate Anticoagulant Pilot scale
Vildagliptin Diabetes Pilot scale
Sitagliptin Phosphate Diabetes Pilot scale
Memantine HCl Alzheimer'S Disease Completed Process validation
R&D Pipeline
2016 Directory of Korea Pharmaceutical Industry134
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 41,919 47,768 50,528
R&D Expenditure 1,097 1,925 3,623
Capital 2,000 2,000 2,000
Financial Figures
Korean affiliate of Kyowa Hakko Kirin Co., Ltd. Japan
A global specialty pharmaceutical company mainly focused on Hemato-oncology, Nephrology, Immunology and CNS area with world leading high technology on antibody.
Focus Area : Hemato-oncology, Nephrology, Immunology and CNS area
Company Profile
Kyowa Hakko Kirin Korea Co., Ltd.RepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Tae se Kwon
5F, Pungrim B/D, 124, Teheran-ro, Gangnam-gu, Seoul, Korea
May. 24. 1991
Hemato-oncology, Nephrology, Immunology, CNS
74
82-2-3471-4321
82-2-3471-4322
www.kyowa-kirin.com/kr/
Product (Ingredient/Formulation) Use Exporting Countries Remarks
1. Neulasta (Peg filgrastim) Neutropenia
2. Grasin (Filgrastim) Neutropenia
3. Nesp (Darbepoetin alfa) Anemia
4. Regpara (Cinacalcet HCl)Secondary
Hyperparathyroidism
5. Renagel (Sevelamer HCl) Hyperphosphatamia
6. Nplate (Romiplostim)Idiopathic Thrombocytopenic
Purpura
7. Mitomycin-C (Mitomycin) Cancer
Main Products
Contact PersonContact PhoneContact E-mail
Sang Heon Lee
82-2-2181-2926
sheon@kyowa-kirin-korea.com
135
Compound Name Code Use Stage of Development
Romiplostim AMG531Idiopathic Thrombocytopenic PurpuraAplastic anemia
LaunchedPhase II
Mogamulizumab KW0761
Leukemia/LymphomaCutaneous T-cell LymphomaPeripheral T-cell LymphomaAdult T-cell Leukemia/LymphomaSolid TumorAsthma
LaunchedPhase IIIPhase IIPhase IIPhase IPhase I
AntithrombinGamma
KW3357
Disseminated Intravascular Coagulation,Congenital Antithrombin DeficiencyDisseminated Intravascular Coagulation,Congenital Antithrombin
LaunchedPhase IPhase I
Granisetron Chemotheraphy induced Nausea and Vomiting
Launched
Tivantinib ARQ197 Hepatocellular Cancer Phase III
Benralizumab KHK4563 Asthma Phase III
Brodalumab KHK4827 Psoriasis Phase III
Istradefylline KW6002 Parkinson's Disease Phase III
Mesalazine Z206 Ulcerative Colitis Phase III
ASKP1240 Organ Transplant Rejection Phase II
BIW8962 Cancer Phase II
KHK4577 AtoPhase Ic Dermatitis Phase II
KHK7580 Secondary Hyperparathyroidism Phase II
BardoxoloneMethyl
RTA402 CKD in Patients with Type 2 Diabetes Phase II
KRN23
X-linked Hypophosphatemic Rickets(XLH) inpediatric patientsX-linked Hypophosphatemic Rickets/Osteomalacia(XLH) in adultpatientsX-linked Hypophosphatemic Rickets/Osteomalacia(XLH)in adult patients
Phase II
Phase I
Phase I
KHK2823 Cancer Phase I
KHK2898 Cancer Phase I
KHK4083 Autoimmune diseases Phase I
KHK2804CEP37250
Cancer Phase I
KHK6640 Alzheimer's Disease Phase I
Tivozanib KRN951 Cancer Phase I
R&D Pipeline
2016 Directory of Korea Pharmaceutical Industry136
Summary (1 Million Won)
Fiscal Year 2008 2009 2010
Sales 81,300 104,210 124,095
R&D Expenditure 4,111 4,657 4,017
Capital 13,575 13,575 13,575
Financial Figures
Kyung Dong Pharm. Co., Ltd. established a GMP factory in 1987 to manufacture medical products with good quality. Since we were approved as a designated KGMP company in 1991, we have been producing more than 80 items including tablets, capsules, injections, and solutions. We have approved BGMP manufacturer since 2001 and also have the cGMP and EU-GMP grade facilities for general finished product and API.
Company Profile
Kyung Dong Pharm. Co., Ltd.RepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Ryu Deokhee
9F, Kyungdong B/D, 1926 Nambusunhwan-ro, Gwanak-gu, Seoul, Korea
Sep. 1975
Circulatory system, Digestive system
435
82-2-570-6135
82-2-576-8815
www.kdpharma.co.kr
137
Main Products
Product (Ingredient) Use Exporting Countries
1. Cilostazol(API) Anti-platelet Japan
2. Cefmetazole sodium(API) Antibiotics China
3. Aclovir Inj. (Acyclovir) Antiviral Japan, Pakistan
4. Ceftisone inj. (Ceftriaxone sodium) Antibacterial Pakistan
5. Lihel Tab. (Biphenyl Dimethyl Dicarboxylate) Liver therapy Vietnam, Philippines
6. Rebamide Tab. (Rebamipide) Anti-peptic ulcer Japan
7. Cefpivo Tab. (Cefcapene pivoxil) Antibiotics
8. Atrovan Tab. (Atorvastatin Calcium) Hyperlipidemia
9. Cansata Tab. (Candesartan) Anti-hypertensive
10. Valtrep Tab. (Valsartan) Anti-hypertensive
New Active Substances
Product (Ingredient) Use Approval Date
Inhiplat Tab. (Clopidogrel Camsylate)
Anti-platelet 2008. 05. 07
Esoprazol Cap. (Esomeprazol base) Anti-peptic ulcer 2010. 03. 12
R&D Pipeline
Ingredient Use Stage of Development
Cilastatin sodium Antibiotics KFDA Approved
Telmisartan Anti-hypertensive KFDA Approved
Aripiprazole Antipsychotics R&D
Miglitol Anti-diabetic R&D
Celecoxib Antipyretic, Analgesic R&D
Entecavir Antiviral, Liver therapy R&D
Cefazedone sodium Antibiotics R&D
2016 Directory of Korea Pharmaceutical Industry138
Summary (1 Million Won)
Fiscal Year 2008 2009 2010
Sales 43,701 46,869 45,983
R&D Expenditure - - 337
Capital 11,192 14,692 15,350
Financial Figures
KyungNam Pharmaceutical has been representing the domestic vitamin C market by its steady seller ‘Lemona’ which has been receiving constant love for 28 years since the first release in 1983. As proving its popularity, it has been awarded “Brand Award of the Year for four consecutive years hosted by the Korean Consumers’ Forum and shown 73 percent of overwhelming public support in vitamin C product field in 2011. In addition, KyungNam has been occupying the unrivaled No.1 title in the Human placenta market, which is the origin of the life energy.
Moreover, KyungNam has been leading the general medicines market through its product such as PM, a typical athlete‘s foot medicine, and Minol Troche, a sore throat drug.
Company Profile
Kyung Nam Pharm. Co., Ltd.RepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Hee-Cheul Lee
17F, Keumkang Tower B/D, 410 Teheran-ro, Gangnam-gu, Seoul, Korea
Jun. 1. 1957
Vitamin & Human Placenta
244
82-2-3490-5105
82-2-3490-5129
www.kyungnampharm.co.kr
139
Main Products
Product (Ingredient) Use Exporting Countries
1. Lemona pulvis (vitamin B,C) vitamin America, Hong Kong,
Mongolia
2. KN vitamin C Tab. (vitamin B,C) vitamin
3. Lemo vita C Tab. (vitamin B,C) vitaminAmerica, Hong Kong,
Mongolia
4. Jahasaengryeok (Human Placenta) Tonic nutrition Hong Kong, Mongolia
5. Plagensia inj. (Human Placenta) relieve menopausal symptoms
6. PM Solution (Salicylic Acid) athlete's foot treatments
7. Minol troche (Cetypyridinium Chloride) relieve Throat inflammation
2016 Directory of Korea Pharmaceutical Industry140
About Laboratorios Cinfa S.A. in Spain (Headquarter)
Cinfa is a Spanish pharmaceutical company with more than 40 years of expertise in the industry. It has a professional team of more than 900 workers motivated by a common health project: giving people access to affordable and high quality treatments. In order to achieve this goal, it has the most advanced technologies and facilities. Cinfa provides the most pharmaceutical brands in Spanish homes. It is presented in 52 countries and currently expanding internationally. Its portfolio comprises five lines of products: prescription drugs, OTC products, orthopedic devices, dermo-cosmetics and nutraceutical solutions. Its commitment with innovation, international expansion and environmental issues are the mainstays of the company.
About Laboratorios Cinfa Ltd. in Korea
Cinfa Korea was established in 2012 as a business legal entity of Cinfa to provide quality products and services to Asian as well as Korean. Cinfa Korea is the first station in Asia region of Cinfa. Currently, Cinfa is continuously making progress of registration of generic products and OTC products. Respibien is the first OTC item marketed in Korea, which is distributed by Jeil Pharm. Furthermore, various medical devices and cosmetics are marketed in Korea. In case of medical devices, graduated compression stockings and various supporters including pregnancy belt are marketed under the brand name of “Farmalastic” via hospitals, clinics and pharmacies. In case of cosmetics, customized skin care solutions are provided under the brand name of “Be+[bemas]” mainly via hospitals and clinics. Cinfa Korea is always opened to discussion for any business development from Asian region as well as Korea.
Focus Area : OTCs, Medical Devices (Class 1) and Dermo-cosmetics
Company Profile
Laboratorios Cinfa Ltd.RepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Joo-Cheol Lee
7F, Medica B/D, 190, Hyoryeong-ro, Seocho-gu, Seoul, Korea
Aug. 21. 2012
Medicines, Cosmetics, Medical devices
20
82-2-3488-6400
82-2-3488-6401
www.cinfakorea.com
Contact PersonContact PhoneContact E-mail
Jihyun Kim
82-2-3488-6400
jihyun.kim@cinfa.com
141
Product (Ingredient/Formulation) Use Exporting Countries Remarks
1. Respibien (Oxymethazoline HCl)
Rhinitis Imported from Spain
2. Farmalastic compression stocking Thrombosis Imported from Spain
3. Farmalastic pregnancy belt Supporter Imported from Spain
4. Be+ 24h facial moisturizing calming deep revitalizing cream
moisturizer Imported from Spain
5. Be+ very dry nourishing face and body moisturizer
moisturizer Imported from Spain
Main Products
2016 Directory of Korea Pharmaceutical Industry142
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 30,100 27,887 27,000
R&D Expenditure 535 658 691
Capital 3,560 3,560 3,560
Financial Figures
Since 1976, Medica Korea has remained dedicated to achieving its business goals and enhancing social responsibility which is the improvement of human health through using better medicine. We produces all of the company’s products under the guidance and supervision of strict KGMP procedure. It also distributes its high-quality medicine to wholesalers, clinics and hospitals through exclusive sales channels.
Focus Area : Acne Treatment, Antihistamin, Antifungal agent, Gastrointestinal agent, Cardiovascular, Respiratory system agent, Neuropsychiatric drug. etc.
Target country : Vietnam, Philippines, Cambodia, Mongolia, Hongkong, Singapore, Chille, Myanma, etc.
Company Profile
Medicakorea Co., Ltd.RepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Duk Han Lee
2F, Medica B/D, 190, Hyoryeong-ro, Seocho-gu, Seoul, Korea
May. 20. 1976
ETC, OTC Drugs, Cosmetics, Food supplements
165
82-2-585-7799
82-2-585-9690
www.medicakorea.co.kr
Contact PersonContact PhoneContact E-mail
Jina Park
82-70-4018-8009
trade@medicakorea.com
143
Product (Ingredient/Formulation) UseExporting Countries
Remarks
1. NIMEGEN Soft cap.10/20 mg (Isotretinoin 10,20mg)
Cystic acne and acne conglobata treatment
Singapore, Hong kong
The first Bioequivalence
approval as of Isotretinoin formulation
2. GREEN PAM Cap. (Thymomodulin 80mg)
Supplementary treatment of bacterial and viral infections.
Vietnam, Cambodia
3. MEDICA RANITIDINE HCI Inj. 25mg (Ranitidine hydrochloride 25mg/2mL)
Short-term treatment of active duodenal ulcer, benign gastric ulcer, GERD
Philippines
4. POINTY Cap. (Diacerhein 50mg)Treatment of osteoarthritis disease
Vietnam
5. MUCOSTEN INJ. 10% (Acetylcysteine 100mg/mL)
Acute Chronic & Asthmatic bronchitis
Dominican Republic
6. Allutec Tab. (Cetirizine Hydrochloride 10mg)
Rhinitis, Conjunctivitis, Eczema, Dermatitis, etc
Hongkong, Philippines &
etc.
7. TABEL Inj. (Ketorolac tromethamine 30mg)
Non-narcotic analgesics.Short-term treatment of Moderate to severe acute pain
Philippines
8. RANITIDINE HCI MEDICA Inj. 25mg (Ranitidine hydrochloride 25mg)
Treatment of erosive esophagitis, Short-term treatment of active duodenal ulcer,benign gastric ulcer, GERD
Philippines
9. TOPASE Tab. (PancreatinⅠ 175mg Dimethicone 25mg Ox bile ext. 25mg Hemicellulase 50mg)
Indigestion, Overeating, Dyspepsia, etc
Cambodia
10. PIRACETAM Tab. 800mg (Piracetam 800mg)
Cerebral damage and Symptoms of cerebral wound, Post-cerebral operation, Severe renal impairment disease
Vietnam
Main Products
Compound Name Code Use Stage of Development
Nimegen Soft Cap. 10mg (Isotretinoin 10mg)
Cystic acne and acne conglobata treatment
Approved
SALBUTRON SR Cap.4mg (Salbutamol sulfate 8mg)
Asthmatic bronchitis, Chronic bronchitis, emphysema disease
Approved
NEWBORN Tab. 25 I.U.(Kallidinogenase 25 I.U.)
Hypertension, Meniere’s disease, Buerger’s disease, menopausal disorder, circulatory disturbance of chorioretinal disease
Approved
MUCOSTEN INJ. 10%(Acetylcysteine 100mg/mL)
Acute Chronic & Asthmatic bronchitisdisease
Approved
CALDIOL Soft Cap.20㎍(Calcifediol 20㎍)
Chronic renal failure, Metabolic bone disease
Approved
R&D Pipeline
2016 Directory of Korea Pharmaceutical Industry144
MG Co.,Ltd. is major manufacturer specialized in ‘Nutrition Infusion Therapy Products’ and our business market focuses on manufacturing of Parenteral and Enteral Nutrition Products and extends to its related areas.
Supplying nutrition at right time is mandatory for prompt curing a disease or illness, especially for following persons.
A surgical patient who is incapable of taking nutrition
Hypoproteinemia and Malnutrition patient
Wasting disease patient due to burn or gash
Immunosuppressive patient
With a long-term experience and accumulated technology, for the first time in Korea, we succeeded in localization of MG TNA which is 3-chamber bag product. Also we have provided 2-chamber bag product, MG Combi, and Lipid LCT(Lipid emulsion) etc. with our own technology. Furthermore, we recently developed the new products of FOMS Lipid and FOMS TNA, which are the combination of Fish oil, Olive oil, MCT oil and Soybean oil.
We, MG Co.,Ltd. and our employees promise our effort and endeavor to provide best quality products in Nutrition Therapy. Furthermore, we will hold an outstanding position for taking care of human health in 21st centuries
Focus Area : Nutrition infusion therapy products
Company Profile
MG Co., Ltd.RepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Chul-Soo Shin
27, Yongso-2-gil, Gwanghyewon-myeon, Jincheon-gun, Chungcheongbuk-do, Korea
Sep. 16. 2003
Nutrition infusion therapy products
85
82-2-2057-1002
82-2-2057-1003
www.medi-green.co.kr
Contact PersonContact PhoneContact E-mail
In-Soon Han
82-2-2057-1002
ishan@medi-green.co.kr
145
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 16,856 16,286 15,344
R&D Expenditure 460 437 546
Capital 6,712 7,252 9,164
Financial Figures
Product (Ingredient/Formulation) Use Exporting Countries Remarks
1. MG TNA inj. IVH for NPO inpatients VietnamUnder registration in Iran, Kazakhstan, Syria
2. MG TNA-peri inj. IVH for NPO inpatients Mongolia, VietnamUnder registration in Iran, Kazakhstan, Syria, Philippines
3. MG Combi-peri inj. IVH for NPO inpatients MongoliaUnder registration in Syria Kazakhstan
4. Lipid LCT inj. 10% / 20% Supply EFA & Calory MongoliaUnder registration in Iran
5. FOMS TNA inj. IVH for NPO inpatients -Under registration in overseas countries
6. FOMS TNA-peri inj. IVH for NPO inpatients -Under registration in overseas countries
7. FOMS Lipid inj. 20% Supply EFA & Calory -Under registration in overseas countries
Main Products
Compound Name Code Use Stage of Development
Amino acid solution including Glutamine (Non-PVC bag)
Glutamine Amino acids Nutrition
Stability
Selenium for injection Supply for Selenium Formulation
Zinc for injection Supply for Zinc Formulation
Multi-minerals for injection Supply for Zn, Se, Cu, Mn, Cr Formulation
Dextrose, Amino acids, Lipid(New formular for 3-chamber bag)
IVH for NPO inpatients Review the formular
Dextrose, Amino acids, Lipid, Vitamins, Elements etc.(The first 4-chamber bag product)
IVH for NPO inpatients Review the formular
R&D Pipeline
2016 Directory of Korea Pharmaceutical Industry146
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 1,907 4,586 10,558
R&D Expenditure 0 202 267
Capital
current assets: 1,733
current assets: 3,125
current assets: 5,323
non-current asset: 2,708
non-current asset: 3,218
non-current asset: 3,195
Financial Figures
MOTHER’S PHARMACEUTICAL CO., LTD. is a manufacturing plant of tablets, hard capsules authorized from Korea Food & Drug Administration. We took over a pharmaceutical company, which had manufactured oriental medicine more than 35 years. We have even expanded our business areas to chemical medicine based on natural product research experience. We have been rapidly developing to become the best pharmaceutical company.
Focus Area : Oriental Medicine, Digestive System Drug
Company Profile
Mother’s Pharmaceutical co., LtdRepresentativeHeadquarter Address
Foundation DateTotal StaffRepresentative PhoneRepresentative Fax Web
Si-Eun Lee
703-ho, 1-dong, (Lotte Itcastle,) 98, Gasan digital 2-ro, Geumcheon-gu, Seoul, Korea
Dec. 19. 2011
57
82-2-2026-8890
82-2-2026-8094
www.motherspharm.com
Contact PersonContact PhoneContact E-mail
Sun-young Jung
82-70-7457-8819
shine@mtspharm.com
147
Product (Ingredient/Formulation) Use Exporting Countries Remarks
1. STOEM Tab. (Artemisia Asiatica 95% Ethanol ext. 60mg)
Chronic gastritis, acute gastritis improvement
ETC
2. BENZNAL Tab. (Trimebutine Maleate 100mg)
Gastroesophageal reflux disease
OTC
3. TRILOCIN Tab. (Bromelain 40mg, Trypsin Crystalline)
Inflammation reduction OTC
4. RANITIEM Tab. (Ranitidine Hydrochloride 84mg)
Hypergastric acidity, heartburn
OTC
5. DIGEST Tab. (Dimethicone 25mg, Hemicellulase 50mg, Ox Bile Extract 25mg, Pancreatin 175mg)
Dyspepsia, sense of stomach distension release
OTC
6. LEBCETIN Tab. (Levocetirizine HCl 5mg)
Allergic coryza, dermatitis and eczema
ETC
7. AFELAC Tab. (Aceclofenac 100mg) Ostarthritis, backache ETC
8. ATOTIN M Tab. (Atorvastatin 10mg) Hypertension ETC
9. LAXOFEN M Tab. (Loxoprofen 60mg)
Analgesic anti-inflammatics, rheumatoid arthritis
ETC
10. ALKILL Tab. (Albendazole 400mg) Roundworm, threadworm OTC
Main Products
Compound Name Code Use Stage of Development
Oriental Medicine Osteo-arthrosis Formulation Development Stage
Atorvastatin Blood pressure Research stage
Rosuvastatin Hyperlipidemia Research stage
Itraconazole Onychomycosis, Pityriasis versicolor Research stage
Esomeprazole GERD
(gastroesophageal reflux disease)Research stage
Chemical Medicine Chronic hepatitis B Formulation Development Stage
R&D Pipeline
2016 Directory of Korea Pharmaceutical Industry148
Summary (1 Million Won)
Fiscal Year 2008 2009 2010
Sales 86,000 98,000 100,000
R&D Expenditure
Capital
Financial Figures
Myung-In Pharmaceutical Company (Myung-InI) is the Korea located pharmaceutical company.
Myung-In is engaged in the development, production and marketing of pharmaceuticals and active pharmaceutical ingredients. The company’s comprehensive therapeutic produt’s range include anti-psychotics, cardiovascular drugs, neurological drugs, anti-diabetics and several OTCs. Myung-In conducts its most operations in Korea and about to start business in China. Myung-In headquartered in Seoul and the plant is located in Gyeongi province. We have 341 employees.
The company recorded revenue over $100 billion during the financial year (FY) ended December 2010, which is 10 times as much as that of 1995.
Company Profile
Myung In Pharm. Co., Ltd.RepresentativeHeadquarter Address
Foundation DateTotal StaffRepresentative PhoneRepresentative Fax Web
Hang-Myung Lee
Myungin B/D, 95, Banpo-daero, Seocho-gu, Seoul, Korea
Apr. 1. 1985
341
82-2-587-9060
82-2-585-0352
www.myunginph.co.kr
149
Main Products
Product (Ingredient) Use Exporting Countries
1. Igatan Gum disease
2. Disgren Anti-thrombosis China
3. Rispen Schizophrenia
4. Coniel Hypertension
5. Carmazepine Epilepsy
6. Zanapam Anxiety disorder
7. Proctin Depression
8. Traline Depression
9. Newpram Major depressive disorder
10. Parox Major depressive disorder
New Active Substances
Product (Ingredient) Use Approval Date
Disgren (Triflusal) Anti-thrombosis 13.12.1993
Glibomet Diabetes 20.08.2001
Almiride Parkinson's disease 13.02.2003
R&D Pipeline
Ingredient Use Stage of Development
Pregabalin Neuropathic pain Approved
Amisulpride Schizophrenia Approved
Levitiracetam Epilepsy Waiting for approval from MFDS
Methylphenidate HCl ADHD Waiting for approval from MFDS
Clopidogrel + Aspirin Antiplatelet Waiting for approval from MFDS
Propafenone Arrhythmia Preparing BE
Oxacarbazepine Epilepsy Preparing BE
2016 Directory of Korea Pharmaceutical Industry150
In 1983, Myungmoon Pharm. Co., Ltd. was established for the improvement of national health. It is achieving remarkable development via research and development, production, and sales based on its founding principle: Advancement, Harmony, and Creation.
Myungmoon Pharm. Co., Ltd. is an acknowledged manufacturer to produce the finished medicines; Injection, Tablet, Capsule, Patches, Solution and Creams.
Nowadays, Myungmoon Pharm. Co., Ltd. produces more than 250 specialized and general medicines and has more than 400 specialized and general medicine licenses to be able to manufacture. Myungmoon Pharm. Co., Ltd. is focusing on our research and development efforts so that Myungmoon Pharm. Co., Ltd. is launching more than 20 new products every year.
Myungmoon Pharm. Co., Ltd. established the new plant for API in 2008. Myungmoon Pharm. Co., Ltd has Gabapentin(USP) and the other 8 API products now, how ever, Myungmoon Pharm. Co., Ltd. would have many new API products in the foreseeable future.
To gain a foothold on biomedicine products, outsourcing strategies are preceding the use of trusted clinical agency CRO and production agency CMO, and Myungmoon Pharm. Co., Ltd has already started to develop human growth hormones through a bio-venture corporation. Within 2 or 3 years, Myungmoon Pharm. Co., Ltd. should be launching bio-similar, including EPO and the processing of the complement of plants for biomedical products as well as the development of advanced medical bioethics, including monoclonal antibodies.
Myungmoon Pharm. Co., Ltd. is sharply developing to be a professional and global treatment company in the world.
Company Profile
Myung Moon Pharm. Co., Ltd.RepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Kyu Huok Lee
Myungmoon B/D, 7, Gangnam-daero 54-gil, Gangnam-gu, Seoul, Korea
Sep. 1983
Medicines, Bio-Product
450
82-2-6711-2000
82-2-572-5137
www.mmpharm.co.kr
151
Summary (1 Million Won)
Fiscal Year 2008 2009 2010
Sales 77,390 92,246 100,914
R&D Expenditure 1,401 1,741 1,789
Capital 5,100 5,293 5,500
Financial Figures
Main Products
Product (Ingredient) Use Exporting Countries
1. Kimite Patch (Scopolamine 1.5mg) Motion sickness Vitenam, China, Hong-Kong
2. Dobutamine Inj. (Dobutamine HCl 280.3mg/5ml)
Cardiac stimulants Vietnam, Pakistan, Nigeria
3. Inopan Inj. (Dopamine HCl 200mg/5ml) Cardiovascular drug Vietnam, Pakistan, Nigeria
4. Ketocin Inj. (Ketorolac tromethamine 30mg/1ml)
Nonsteoidal Anti-inflammatory drug
Vietnam, Philippines, Dominican Rep.
5. Bupivacaine HCL Heavy Inj. 0.5% (Bupivacaine HCL 21.12mg/4ml)
Local Anesthetics Vietnam, Nigeria, Dominican Rep.
6. Pyrinol Tab. (Pyridostigmine Bromide 60mg)
Parasympathomimetics Chile, Malaysia
7. Levonia Tab. (Levonorgestrel 1.5mg) Contraceptive Vietnam, Mexico
8. Tipem Inj. (Imipenem 500mg, Cilastatin 500mg)
Antibiotics Vietnam
9. Esgen Vaginal Cream (Estropipate 1.5mg/g)
Hormons Guatemala
10. Neocoline Inj. 500mg (Citicoline 500mg/2ml)
Parkinson’s diease Uzbekistan, Vietnam
R&D Pipeline
Ingredient Use Stage of Development
Sonatropin-PEG conjugate (Bio-Product)
GROWTH Hormone Finished Process(Lab Scale)
Erythropoietin(Bio-Product) Erythrogenesis Finished Process(Lab Scale)
Flumanzenil Inj. 0.5mg Antidote for Midazolam Launching on April, 2012
Valsartan 160mg, 80mg Hypertension Launching on April, 2012
Lansoprazole 30mg Antipeptic ulcer drug Launching on August, 2012
Sildenafil 100mg Erectile dysfunction Launching on August, 2012
Raloxifene 60mg Osteoporosis Launching on July, 2013
2016 Directory of Korea Pharmaceutical Industry152
Summary (1 Million Won)
Fiscal Year 2008 2009 2010
Sales 20,879 25,847 31,263
R&D Expenditure 1,164 1,228 1,611
Capital 28,515 30,146 38,915
Financial Figures
Pharmaking is the leader of pharmaceutical industry in the field of hepatoprotective medicine. We have been investing more than 20% of its total sales into R&D for the development of new medicines. As a result, the first hepatoprotective medicine in Korea named “Nissel” was developed in July 1990. Furthermore, after obtaining a patent for a new hepatoprotective medicine and completing the phase Ⅱ, III clinical trials, “Pennel” was launched in Feb. 1998. Pharmaking Co., Ltd. has been exporting the flagship hepatitis medicine “Pennel” to Egypt for more than 10 years. Its superiority has been internationally recognized, driving the expansion of overseas sales in numerous countries, including Vietnam, Cambodia, Malaysia, Turkey and the UAE.
Company Profile
Pharmaking Co., Ltd.RepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Wan Bae Kim
4, Sujeong-ro 306beon-gil, Sujeong-gu, Seongnam-si, Gyeonggi-do, Korea
May. 14. 1975
liver/GI diseases
145
82-31-739-3300
82-31-739-3392
www.pharmaking.co.kr
153
Main Products
Product (Ingredient) UseExporting Countries
1. PENNEL capsule (Garlic oil 50mg, Biphenyl dimethyl dicarboxylate 25mg)
Acute and chronic hepatitis followed by the increase of transaminase
Egypt
2. NISSEL (Biphenyl dimethyl dicarboxylate 25mg)
For Hepatitis followed by the increased number of transaminase caused by chronic hepatitis with the continuously increased number of SGPT or by drugs
Vietnam, Mongolia
3. EUROCEL(Health food) (Eurocel Ext. Powder* 96.7%: Patriniae Radix 35%, Phellodendron amurense 35%, Yin-Chen Wormwood 20%, Schisandrae Fructus 10%), Sucrose ester of fatty acid 1.92%,Silicon Dioxide 1.38%
Acute and chronic hepatitis C USA
4. UDB (Biphenyl dimethyl dicarboxylate 12.5mg, Ursodesoxycholic acid 50mg)
chronic hepatitis followed by the continuously increased number of SGPT
5. RABET Tab. (Rabeprazole sodium 10mg)
Gastric ulcer, Duodenal ulcer, Oesophagitis erosiva
6. REVODRO Tab. (Levodropropizine 60mg)
Cough: Acute and Chronic Bronchitis
7. ITO Tab. (Itopride HCl 50mg) Functional dyspepsia
8. SIMVAMAX Tab. (Simvastatin 20mg)
1) To reduce the risk of coronary attack of patients with coronary artery disease, peripheral vascular disease, stroke or cerebrovascular disease2) Primary Hyperlipidemia
9. ROZAPLUS Tab. (Losartan potassium 50mg, Hydrochlorothiazide 12.5mg)
Diabetic nephropathy; Hypertension; Cardiac failure
10. PHARMAKING REBAMED Tab. (Rebamipide 100mg)
Gastric ulcer, Erosion, bleeding, flare, edema of gastric mucous membrane by acute gastritis and exacerbation of chronic gastritis
New Active Substances
Product (Ingredient) Use Approval Date
NISSEL(Biphenyl dimethyl dicarboxylate 25mg)
Acute and chronic hepatitis followed by the increase of transaminase
1990.07.10
UDB(Biphenyl dimethyl dicarboxylate 12.5mg, Ursodesoxycholic acid 50mg)
chronic hepatitis followed by the continuously increased number of SGPT
1997.12.30
PENNEL(Garlic oil 50mg, Biphenyl dimethyl dicarboxylate 25mg)
For Hepatitis followed by the increased number of transaminase caused by chronic hepatitis with the continuously increased number of SGPT or by drugs
1998.07.25
R&D Pipeline
Ingredient Use Stage of Development
New chemicalNAFLD(Non-Alcoholic Fatty Liver
Disease)Phase 2 clinical trial in process
New combination drug ASH(Alcoholic steatohepatitis) Phase 2 clinical trial IND approved
New herbal medicine Acute Bronchitis Phase 2 clinical trial IND approved
New chemical Gastritis Application of phase 1 clinical trial
New modified chemical Asthma, Allergy Pre-clinical trial(PK/PD) in process
New herbal medicine Inflammation Pre-clinical trial(in vivo) in process
2016 Directory of Korea Pharmaceutical Industry154
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 32,700 39,300 44,200
R&D Expenditure 1,500 2,700 3,300
Capital 20,680 34,065 40,020
Financial Figures
Pharmbio Korea Co., Ltd. is an emerging, innovative company established in 1999, specializing in registration, ex/importing, manufacturing, and marketing of innovative pharmaceutical products in Korea. It is one of the most influential companies in many therapeutic areas.
Focus Area : Urology, gastroenterology, neurosurgery, orthopedics, general surgery, immunology, etc.
Company Profile
Pharmbio Korea Co., LtdRepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Bong Kil Nam
7F, Samho B/D A, 83 Nonheyon-ro, Seocho-gu, Seoul, Korea
May. 1. 1999
25
170
82-2-587-2551~4
82-2-529-7454
www.pharmbio.co.kr
Contact PersonContact PhoneContact E-mail
Jun Sang Nam
82-10-4558-8033
bd@pharmbio.co.kr
155
Product (Ingredient/Formulation) Use Exporting Countries Remarks
1. Picolight (Sodium Picosulfate, Magnesium Oxide(light), Citric Acid(anhydrous)/Powder)
Pre-colonoscopic preparation
Discussing out-licensing in in Vietnam, etc.
2. Urocitra-K (Potassium citrate/Tablet)
Uric acid lithiasis MyanmarDiscussing out-licensing in Vietnam, etc.
3. Urocitra-C (Potassium Citrate, Citric Acid Hydrate/Powder)
Uric acid lithiasis Discussing out-licensing in Cambodia, etc.
4. Endonse (Pronase B/Powder)Pre-endoscopic
preparation
5. Ribon (Risedronate Sodium Hydrate/Tablet)
Postmenopausal osteoporosis
Discussing out-licensing in Singapore, Hong Kong, etc.
6. Gagron (Pentasan Polysulfate Sodium/Capsule)
Interstitial Cystitis
7. Movilax (Polyethylene Glycol3350, Electrolytes/Powder)
Chronic constipation
8. Zinkistin (Zinc Histidine Dihydrate/Capsule)
Zinc deficiency
9. Acupan Capsule (Nefopam Hydrochloride/Capsule)
pain controller Discussing out-licensing in Nigeria, etc.
Main Products
2016 Directory of Korea Pharmaceutical Industry156
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 18,981 23,276 27,323
R&D Expenditure 1,228 1,327 1,283
Capital 1,510 1,580 1,786
Financial Figures
PMG Pharm has been a leading pharm in the market for treatments of rheumatoid arthritis, osteoarthritis, anti-osteoporosis and related diseases and its main business has been focused on the development of DMARDS, DMOADS and NSAIDs etc. At 13 Mar 2012, a Layla Tab has been registered as a new treatment for the osteoarthritis. Layla is consisted of 12 medicinal plants which has been recognised as traditional herbal medicines for arthrosis. PMG Pharm is ready to expand its business by licensing out Layla.
Focus Area : DMARD, DMOAD, NSAID
Company Profile
PMG PHARM Co., LtdRepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Young Chin Chun
21 Sinangbukro 4-gil, Sangnok-gu, Ansan-si, Gyeonggi-do, Korea
Dec. 2001
DMARDS, DMOADS, NSAIDS
101
82-31-439-5470
82-31-439-5471
www.pmgpharm.co.kr
Contact PersonContact PhoneContact E-mail
Ji-Won Kim
82-31-439-5470
jwkim@pmgpharm.co.kr
157
Product (Ingredient/Formulation) Use Exporting Countries Remarks
1. Layla Tab (12 herbal extracts 405.4mg) Osteoarthritis
2. Rheumakin Tab 10, 20mg (leflunomide)
Rheumatoid arthritis
3. Duroc Tab 100, 200, 400mg (Hydroxychloroquine sulfate)
Rheumatoid arthritis
4. Admin Forte Tab (cholecalciferol, VitD 1000IU)
VitD deficiency
5. SynflexSafe Tab (Naproxen /Esomeprazole 500/20mg)
NSAID
6. Indometa Cap 25mg (Indomethacin) NSAID
7. Morix Cap 7.5, 15mg (meloxicam) NSAID
8. PMG Loxiprofen 60mg (loxoprofen) NSAID
9. Cenatone Tab 500mg (nabumetone) NSAID
10. Droban Tab 150mg (Ibandronate) anti-osteoporosis
11. Risena Tab 35mg (Risedronate Na) anti-osteoporosis
Main Products
Product (Ingredient) Use Approval Date
Layla Tab(12 herbal extracts 405.4mg) Osteoarthritis 2012.03.13/Korea
New Active Substances
Ingredient Code Use Stage of Development
PMG1001 Blood circulation Development of bioassay
PMG1003 Benign prostatic hyperplasia Screening active ingredients
PMG1203 DepressionPartial purification & identification of active ingredients
PMG1301 DMARD In-vitro test
PMG1401 Anti-osteoporosis Screening active ingredients
R&D Pipeline
2016 Directory of Korea Pharmaceutical Industry158
Summary (1 Million Won)
Fiscal Year 2008 2009 2010
Sales 25,192 32,744 41,414
R&D Expenditure 950 1,229 1,589
Capital 500 500 500
Financial Figures
Richwood Pharmaceutical Co., Ltd. a reliable CMO company with global standards in pharmaceutical manufacturing, has competitive advantages such as holding specialized formulation technologies using a 3-layer tablet machine and a GPCG series, a strategic partnership with CRO, and development pipelines of herbal medicine.
Company Profile
Richwood Trading Co., Ltd.RepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
JeongSuk Lee
16F, Danam B/D, 10, Sowol-ro, Jung-gu, Seoul, Korea
Mar. 1974
Finished drug, Herbal medicine
146
82-2-778-2351
82-2-756-5402
www.richwood.net
159
Main Products
Product (Ingredient) Use Exporting Countries
1. Acetracet Tab. (acetaminophen, tramadol HCl)
Pain relief
2. Ebaco SR Cap. (pseudoephedrine, ebastin)
Allergic rhinitis
3. Gli-M Tab. 2/500mg (glimepiride, metformin)
Type II diabetes
4. Limaprost 0.17mg (limaprost)Buerger's disease, acquired spinal
canal stenosis
5. Cetirizine Tab. (cetirizine) Allergic rhinitis
6. Livaduet Tab. (atrovastatine,amlodipine besylate)
Hypertension
R&D Pipeline
Ingredient Use Stage of Development
Oxycodone hydrochloride Opioid analgesic Clinical trial
2016 Directory of Korea Pharmaceutical Industry160
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 76,650 80,391 91,518
R&D Expenditure 1,360 1,787 1,978
Capital 10,000 10,000 10,526
Financial Figures
SamChunDang(SCD) Pharm. Co., Ltd. is one of the leading pharmaceutical company specializing in all kinds of ophthalmic products including multi-dose and mono-dose certified by MHRA, UK (EU GMP certificate) in 2015. SCD is a well known company as a manufacturer and distributor of quality pharmaceuticals in Korea as well as global markets. With our prior experience to work with more than 25 overseas countries for more than 20 years, we are now supplying our eye drops to most of Asian countries, Central America, Latin America and Middle East Countries with high quality and reasonable price on a long term basis.
Focus Area : Ophthalmic product
Company Profile
Sam Chun Dang Pharm. Co., Ltd.RepresentativeHeadquarter AddressFoundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Jeon Kyo, Park
351 Hyoryeong-ro, Seocho-gu, Seoul, Korea
Dec. 29. 1943
Ophthalmic Product
335
82-2-2046-1100
82-2-2046-1102
www.scd.co.kr
Contact PersonContact PhoneContact E-mail
Brian Kim
82-2-2046-1255
silluet75@scd.co.kr
161
Product (Ingredient/Formulation) Use Exporting Countries Remarks
1. Hameron Eye Drops (Sodium Hyaluronate 0.1%)
Artificial TearsVietnam, Jordan, Philippines, etc.
Modo-dose & Multi-dose
2. Tobaren Eye Drops (Tobramycin 0.3%, Dexamethasone 0.1%)
AntibacterialVietnam, Hong Kong,
Myanmar, etc.
3. Moxista Eye Drops (Moxifloxacin 0.5%)
Antibacterial Vietnam, etc.
4. Tolon Eye Drops (Fluorometholone 0.1%)
Anti-Inflammatory
China, Costa Rica, etc.
5. Tetzoline Eye Drops (Tetrahydrozoline HCl 0.05%)
Artificial Tears (Redness relief )
USA
Main Products
Compound Name Code Use Stage of Development
Tranilast 0.5% Eye DropsAllergic
conjunctivitisFormulation development
Loteprednol Etabonate 0.5% Eye Drops Anti-Inflammatory Test method development
Fluorometholone 0.1%, Tetrahydrozoline HCl 0.025% Eye Drops
Anti-InflammatoryManufacturing process
development
Diquafosol Sodium 3% Eye Drops Artificial Tears Formulation development
R&D Pipeline
2016 Directory of Korea Pharmaceutical Industry162
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 56,572 54,637 59,894
R&D Expenditure 3,849 3,821 4,100(E)
Capital 144,788 147,045 145,864
Financial Figures
SAMA is Korea’s number one pediatrics company, and also one of the top leaders in the respiratory and ENT segments. Founded in 1945, we have our own GMP-certified manufacturing plant, R&D center, and over 140 sales reps within our own nation-wide sales and marketing network. We are also expending into new therapeutic fields via R&D and licensing deals. In addition, SAMA is one of the first companies in Korea to start an international licensing business.
SAMA’s credibility as a trust-worthy business entity and partner is unparalleled both internationally and domestically due to our solid financial status and transparent management. Given this reputation, SAMA has been able to maintain decades-long partnerships with major companies in Japan such as Astellas, Dainippon-Sumitomo, and Kowa, as well as some European companies. We are trying to expand into other fields such as Gastrointestinal(GI) and cardiovascular(CV) drugs.
Focus Area : Pediatrics, Respiratory, ENT, Dermatology, GI, and CV
Company Profile
SamA Pharm. Co., Ltd.RepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Jun Hur
49 Dongwha gongdan-ro, Munmak-eup, Wonju-si, Gangwon-do, Korea
Oct. 4. 1945
Pediatrics, Respiratory, ENT, Dermatology, GI and CV
320
82-2-2056-7200
82-2-2056-7210
www.samapharm.co.kr
Contact PersonContact PhoneContact E-mail
Soojin Lee
82-2-2056-7283
sjlee@samapharm.co.kr
163
Product (Ingredient/Formulation) UseExporting Countries
Remarks
1. SETOPHEN (Acetaminophen / tablets ER tablets & Dry syrup & suspension)
NSAIDs (Fever, Pains, Headache, Menstrual pain etc.)
2. CODENAL (Dihydrocodeine, etc ./ tablets & syrup)
Cough, Phlegm Hong Kong
3. ATOCK (Formoterol fumarate/tablets & dry syrup)
Acute & chronic bronchitis, Bronchial asthma
4. LIDOMEX (Prednisolone valeroacetate / topical lotion & cream)
Eczema, Dermatitis,Prurigo, Psoriasis, etc.
5. CITUS (Pranlukast/ dispersible tablets & dry syrup)
Bronchial asthma, Perennial allergic rhinitis
6. TANTUM (Benzydamine HC l/ gargle solution & nebulizer)
Gingivitis glossitis,Pharyngitis, Laryngitis, Tonsillitis etc.
7. HEBRON (Ivy leaves extract/tablets & syrup)
Chronic inflammatory bronchial disease, acute inflammation of respiratory tract
8. BEPORIN (Bepotastatine salicylate/tablets)
Anti-histamines
9. COBIAN-S(Chlorpheniramine maleate, Phenylephrine HCl/ tablets & syrup)
Improvement of all symptoms due to common cold or allergic rhinitis cough
10. NOMA (Multivitamins, Minerals /gummies & chewable tablets)
Growth promotion, nutritional deficiency, supply for vitamins & minerals
Main Products
Compound Name Code Use Stage of Development
TD13 TDIQ Erectile dysfunction NDA filing (MFDS)
SA09012 SA09012 Bronchial Asthma, Allergic rhinitis Phase 2 clinical trudy
PR13 PRIT Bronchial Asthma, Allergic rhinitis Discovery
PR13 PRIC Bronchial Asthma, Allergic rhinitis Discovery
R&D Pipeline
2016 Directory of Korea Pharmaceutical Industry164
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 35,000 37,000 40,000
R&D Expenditure 778 956 904
Capital 702 702 702
Financial Figures
Since established in 1973, Samik has been focusing all our efforts to improve the Quality of Life with natural scientific value through the production and quality development of a number of OTC and ETC. Also we have exported medicines to several countries in asia, and expanded the market territory constantly.
Focus Area : Drug for circulatory system disease
Company Profile
Samik Pharm. Co., Ltd.RepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Lee Choong Whan
4F, Dongbo B/D, 413, Jong-ro, Jongno-gu, Seoul, Korea
1973
Circulatory system diseases
137
82-2-928-0661~4
82-2-924-3749
www.samik.co.kr
Contact PersonContact PhoneContact E-mail
Yu Li Kim
82-2-928-0661(Etx.555)
web@samik.co.kr
165
Product (Ingredient/Formulation) Use Exporting Countries Remarks
1. CEZAR TAB. (Losartan potassium 50mg/100mg)
Antihypotensive
2. CEZAR PLUS TAB. (Losartan potassium 50mg, Hydrochlorothiazide 12.5mg)
Antihypotensive
3. TAMITRA TAB. (Acetaminophen 325mg, Tramadol hydrochloride 37.5mg)
NSAID’s
4. SERODIN SYR. (Loratadine 5mg) Antihistamine
5. HEPA-WORLD (Caraus marianus extract 100mg, Thiamin Hydrochlorid 4mg, Riboflavin 4mg, Pyridoxin Hydrochlorid 4mg, Nicotinamide 12mg, Calcium Pantothenate 8mg, Cyanocobalamin 0.1% 1.2mg)
Hepatic disorder Vietnam
6. T-MODUVAX CAP. (Thymomodulin 80mg)Immune
enhancementVietnam
7. PHARTINO TAB. (Bromelain 40mg, Crystallized trypsin 1mg)
Anti-inflammation Vietnam
8. SONA-TIUM TAB. (Alendronate 70mg) Osteoporosis Vietnam
Main Products
Compound Name Code Use Stage of Development
SIP-1101 Erectile dysfunction BE Test
SIP-1102 Allergic rhinitis Clinical Test
SIP-1103Liver function improvement
Clinical Test
R&D Pipeline
2016 Directory of Korea Pharmaceutical Industry166
Company overview
· 1947 - The establishment of Samil Pharm. Co., Ltd.
· 1969 - Technical alliance with Boots Co. of the UK for Brufen
· 1985 - Korea stock exchange IPO (000520)
· 1985 - Completion of KGMP (Korean Good Manufacturing Practice) in Ansan
· 1987 - Establishment of Central R&D Center / Set up ophthalmic business division
· 2003 - Newly established Thea business division
· 2008 - Joint Venture contract with Allergan Inc, of USA
· 2011 - Joint Venture contract with Mon-samil LLC of Mongolia
· 2014 - $9 Million export contract with Iran
Export country
Hong Kong, Japan, Myanmar, Mongolia, Philippines, USA, Vietnam, Yemen
Subsidiary company
Samil H&T Co., Ltd., Samil Medical Co., Ltd. (detistry, medical device)
Focus Area : Ophthalmology, Gastro-intestinal, Respiratory, Circulatory, Cardiovascular, Dermatology
Company Profile
Samil Pharm. Co., Ltd.RepresentativeHeadquarter Address
Foundation DateResearch Focus
Total StaffRepresentative PhoneRepresentative Fax Web
Kang Huh
155, Hyoryeong-ro, Seocho-gu, Seoul, Korea
Oct. 7. 1947
Ophthalmology, Gastro-intestinal, Respiratory, Circulatory, Cardiovascular, Dermatology
396
82-2-520-0300
82-2-588-5924
www.samil-pharm.com
Contact PersonContact PhoneContact E-mail
Shin-ku Kang
82-2-520-0324
skkang@samil-pharm.com
167
Product (Ingredient/Formulation) Use Exporting Countries Remarks
1. Ofloxacin 3mg/mL Ophthalmic Soln. & Oint.
Susceptible strains of the microorganisms
Asia, Mid-East under registration (Asia, Mid-East, Europe)
2. Tobramycin 3mg/mL / Ophthalmic Solution & Ointment
Susceptible strains of the microorganisms
Asia, Mid-Eastunder registration (Asia, Mid-East)
3. Polymyxin B sulfate 6,000IU, Neomycin sulfate 3mg (potency), Dexamethasone 1mg Ophthalmic Suspension & Ointment
conjunctivitis, blepharitis, and keratitis
Asia, Mid-Eastunder registration (Asia)
4. Levofloxacin 5mg/mL Ophthalmic Solution
Susceptible strains of the microorganisms
Asiaunder registration (Asia, Mid-East)
5. Sodium Hyaluronate 1mg/mL Ophthalmic Solution
Sjogren's syndrome, Stevens-Johnson Syndrome, dry eye syndrome, drug-induced, injury, contact lenses
Asiaunder registration (Asia, Mid-East)
6. Diclofenac sodium 1mg/mL Ophthalmic Solution
a nonsteroidal anti-inflammatory product
Asia, Mid-Eastunder registration (Mid-East)
7. Povidone 20mg/mL Ophthalmic Solution
a lubricant alleviating dry eyes
Asiaunder registration (Mid-East)
8. Acyclovir 30mg/g Ophthalmic Ointment
keratitis caused by herpes simplex virus
Asiaunder registration (Asia, Mid-East)
9. Fluorometholone 1mg/mL Ophthalmic suspension
corticosteroid-responsive inflammation of outer and anterior segments of the globe
Asiaunder registration (Asia, Mid-East)
10. Losartan Potassium, HCTZ 50mg, 50/12.5mg, 100/12.5mg Tablets
hypertension Asia
Main Products
Compound Name Patent No. Title Date of patent
Trimebutine 1020100002507Stable pharmaceutical composition comprising Trimebutine and prokinetic agent
12 JAN. 2010
Limaprost alfadex 1020100068304Pharmaceutical composition in tablet form for oral administration comprising Limaprost
15 JUL. 2010
Sulglycotide 1020110013635
Multi layer pharmaceutical tablet with improved stability comprising Sulglycotide and H2 antagonists and preparation method thereof
16 FEB. 2011
Telmisartan 1020120079809Pharmaceutical composition comprising Telmisartan with improved stability and preparation method thereof
23 JUL. 2012
Telmisartan & Hydrochlorothiazide
1020120114062Pharmaceutical composition comprising Telmisartan and HCTZ
15 OCT. 2012
R&D Pipeline
2016 Directory of Korea Pharmaceutical Industry168
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 185,702 192,007 201,305
R&D Expenditure 11,030 12,397 13,855
Capital 13,900 13,900 13,900
Financial Figures
All human beings have the right to enjoy a healthy and happy life.
However, the complicated social structure of modern society and the development of material civilization cause the advent of new diseases.
In order to protect human health from these diseases and fundamentally get rid of diseases, Samjin pharm Co., Ltd secures excellent personnel and latest equipment and continues to challenge the development of excellent pharmaceutical drug by utilizing advanced pharmaceutical information and technology.
Samjin pharm Co., Ltd always strives for a better future on the basis of dignity of human life and company philosophy.
The company pioneering a healthy life of people and challenging the prosperous future with mind of creation.
Focus Area : Cardiovascular system drugs, Analgesics & Antipyretics, etc.
Company Profile
Samjin Pharm. Co., Ltd.RepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Sung-Woo Lee
121 Wawoosan-Ro (Seogyo-dong), Mapo-Gu, Seoul, Korea
Apr. 18. 1968
AIDS, Dry eye, etc.
626
82-2-3140-0700
82-2-5312-2001
www.samjinpharm.co.kr
Contact PersonContact PhoneContact E-mail
Seo-Yeon Yang
82-2-3140-0708
ysy6043@samjinpharm.co.kr
169
Product (Ingredient/Formulation) Use Exporting Countries Remarks
1. PLATLESS TAB.Antithrombotics, Antiplatelet Agents
Philippines, Cambodia, Singapore
2. NEUSTATIN-A TAB. Antilipidemic Agents
3. NEURACETAM TAB. Nootropics & Neurotonics
4. NEUTOIN TAB. Nootropics & Neurotonics
5. TIROXIN CAP. Cephalosporins.
6. BAMEDN TAB. Antiulcerants Cambodia
7. SYNERJET TAB. Analgesics & Antipyretics Philippine
8. MAROBIVEN-A. Inj. Antiinflammatory Enzymes
9. GEWORIN TAB. Analgesics & AntipyreticsVietnam, Cambodia
Mongolia, PhilippinesOTC
10. TRESTAN CAP. Appetite Stimulants OTC
Main Products
Compound Name Code Use Stage of Development
SJ-3366 AIDS Phase1/Preclinical
SA001 Dry eye Preclinical
SA002 Obesity Preclinical
SA003 Arthritis Preclinical
SJ001M Tissue Protection Preclinical
SJ3548 Diabetes Biological Test
SJ2395 Alzheimer’s Disease Biological Test
R&D Pipeline
2016 Directory of Korea Pharmaceutical Industry170
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 44,130 50,672 57,186
R&D Expenditure 7,494 7,819 7,748
Capital 101,288 207,129 210,810
Financial Figures
Samyang Biopharmaceuticals Corporation (SYB), with its central research center has been engaged in development and marketing of novel drug delivery systems and medical devices. SYB has been focusing its efforts on healthcare as its core strategic business of the 21st century.
After the recent merger with its sister company, Samyang Genexbio Corporation, SYB is now a fully integrated company with R&D, GMP facility for APIs as well as finished dosage forms (injections & patches), and Medical devices. SYB has been expanding its relationship with excellent partners in many markets, and is looking to find more potential companies that would create a good synergy.
Focus Area : Oncology, GMP Manufacturing(APIs, Injections, Patches), DDS Technology
Company Profile
Samyang Biopharm. Corp.RepresentativeHeadquarter Address
Foundation DateResearch Focus
Total StaffRepresentative PhoneRepresentative Fax Web
Taeung Eom
31, Jong-ro 33-gil, Jongno-gu, Seoul, Korea
Nov. 1. 2011
Novel drug delivery systems and medical devices
200
82-2-740-7163
82-2-740-7269
www.samyangbiopharm.com
Contact PersonContact PhoneContact E-mail
Jae-Wook Joo
82-2-740-7163
jaewook.joo@samyang.com
171
Product (Ingredient/Formulation) Use Exporting Countries Remarks
1. GenexolⓇ Inj. (Paclitaxel) Anti-CancerEurope, Asia, Midddle-East
2. Genexol-PMⓇ Inj. (Paclitaxel) Anti-Cancer Asia, Africa
3. NanoxelⓇ-M Inj. (Docetaxel) Anti-Cancer
4. PemedⓇ Inj. (Pemetrexed) Anti-Cancer
5. ZolenicⓇ Inj. (Zoledronic Acid) Bone metastasis
6. RheumastopⓇ Transdermal patch (Diclofenac Diethylamine)
Rheumatoid arthritis
Middle-East,Asia
7. Tulobuterol Transdermal Patch Asthma acute bronchitis
8. FentadermⓇ Transdermal Patch (Fentanyl)
Severe Pain
9. Rivastigmine Transdermal Patch Anti-Alzheimer
Main Products
Ingredient Use Stage of Development
Polymeric Micelle InjectionGenexol-PMⓇ Marketed
NanoxelⓇ-M Marketed
Polymeric Nano-Particle InjectionDocetaxel-PNP Clinical (Phase I)
Voriconazole-PNP Clinical (Phase I)
Polymeric Micro-Particle Injection hGH-PMP SR Non-clinical
TDS(Transdermal Drug Delivery
System)Transdermal Capsaicin Clinical (Phase II)
R&D Pipeline
2016 Directory of Korea Pharmaceutical Industry172
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 46,377 42,043 43,816
R&D Expenditure 5,505 4,734 4,175
Capital 25,384 32,252 31,100
Financial Figures
Seoul Pharma Co., Ltd. founded in 1976, has engaged in the pharmaceutical manufacturing and distribution business, and in 1997, established the R&D Center and has researched and developed new drug delivery technology since then. The sales revenue was 40 Million USD in 2014.
Being focused its R&D on the innovative and creative DDS technology such as special formulations, the company has developed a new platform technology (named as SmartFilmⓇ Technology) to produce Orally Disintegrating Film (ODF) products and planned to penetrate the global market through SmartFilmⓇ Technology with a new cGMP/EU-GMP factory that was built in Osong city. ODF means a pharmaceutical formulation which makes drug with a shape like thin square film, so drug can be dissolved within 3 minutes, ideally 10 seconds, with maximal expansion of its surface area in tongue.
Focus Area : ED, CNS
Company Profile
Seoul Pharma Co., Ltd.RepresentativeHeadquarter AddressFoundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Younha Lee
21, Banpo-daero, Seocho-gu, Seoul, Korea
Aug. 1976
NME, IMD, ODF
226
82-2-3470-2300
82-2-3470-2395
www.seoulpharma.com
Contact PersonContact PhoneContact E-mail
Dong-churl Seo
82-2-3470-2386
pharmseo@seoulpharma.com
173
Product (Ingredient/Formulation) Use Exporting Countries Remarks
1. Auclatin tab./Dry syrup (amoxicillin + K clavulanate)
antibiotics
2. Diflu cap. (fluconazole) antifungal Tanzania
3. Sebron cap./syrup (acetylcysteine)
mycolytics
4. Levobacter tab. (levofloxacin) antibiotics Mongolia
5. Duvelac cap. (bacillus licheniformis)
probiotics
6. Ossobone tab. (ossopan substance)
Ca supplement
7. Lead-Me cap. (green tea ex.) anti-obesity
8. Aliver susp. (l-leucine, l-isoleucine, l-valine)
hypoalbuminemia
9. Vultis ODF (Sildenafil citrate) erectile dysfunctionLaunched as
Viagra L in Korea
10. Vulteum ODF (Tadalafil) erectile dysfunction
Main Products
Compound Name Code Use Stage of Development
SPC-702 COPD Preclinical
SPX-601 Arthritis Phase IIa clinical
Artpezil ODF (Donepezil HCl) SPO-1112 Dementia Registered
Aripiprazole ODF SPO-1113 Schizophrenia Registered
SPO-1107 Anti-emetic Formulation Research
SPO-1411 Dementia Formulation Research
SPO-1307 Hepatitis Formulation Research
SPO-1109 NSAID Formulation Research
SPO-1405 Obesity Formulation Research
R&D Pipeline
2016 Directory of Korea Pharmaceutical Industry174
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 212,010 206,471 209,584
R&D Expenditure 7,925 8,797 9,395
Capital 185,644 185,886 185,485
Financial Figures
Under the management philosophy of ‘for the health of the people’, Shin Poong Pharm.Co.,Ltd specializes in manufacturing remedy drugs with sincere efforts put into producing every single tablet of life-saving drugs ranging from ingredients to finished products based on our state-of-the-art manufacturing facilities and quality assurance system. We are committed to realizing the spirit of Shin Poong 3V (Vision, Venture and Victory) with top-notch competitiveness based on in-house ingredient synthesizing technologies obtained through rigorous R&D efforts and to further developing the company into the one that receives confidence from our customers and that contributes to promoting the wellbeing of human beings. In 2011, Shin Poong developed PYRAMAX¢ç in cooperation with Medicines for Malaria Venture and approved by Korean FDA. PYRAMAX® is the first artemisinin-based combination therapy to receive an Article 58 positive Scientific opinion from EMA for the treatment of both strains of malaria: P.falciparum and P.vivax, in adults and children over 20kg and was listed on WHO prequalified medicines in May, 2012.
Focus Area : Prescription drugs in the Surgery market
Company Profile
Shin Poong Pharm. Co., Ltd.RepresentativeHeadquarter AddressFoundation DateResearch Focus
Total StaffRepresentative PhoneRepresentative Fax Web
Jei Man Ryu
161, Yeoksam-ro, Gangnam-gu, Seoul, Korea
Jun. 9. 1962
New Drugs, Incrementally Modified Drugs, Generics
841
82-2-2189-3400
82-2-557-4372
www.shinpoong.co.kr
Contact PersonContact PhoneContact E-mail
Paul Choen
82-2-2189-3471
jung1@shinpoong.co.kr
175
Product (Ingredient/Formulation) Use Exporting Countries Remarks
1. Pyramax (Artesunate, Pyronaridine / Inj) Anti-malaria NME
2. Loxfen CR (Loxoprofen / Tab) Analgesic IMD
3. Hyal Forte (Sodium Hyaluronate / Inj) Arthritis Generic
4. Clamoxin (Amoxicillin Sodium / Tab) Anti-biotics Generic
5. Medicurtain (Sodium Hyaluronate, HES / Inj)
Adhesion Barrier Medical device
Main Products
Compound Name Code Use Stage of Development
SP-8203 SP4C001 Stroke Phase I
SP-35454 SP-35454 Osteoporosis IND approval
SP-2236 SP-2236 Heart failure Candidates
SP5M001 SP5M001 Osteoarthritis IND applications
Free Wink SP5V003 Anti-wrinkle Non-clinical
Pyramax granule SP1P001 Anti-malaria NDA applications
CR tablet SP3R001 Anti-histamine Phase I
R&D Pipeline
Product (Ingredient) Use Approval Date
Pyramax Tab Anti-malaria2011.8 / Korea
2012.2 / EU
New Active Substances
2016 Directory of Korea Pharmaceutical Industry176
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 9,376 8,704 8,631
R&D Expenditure
Capital
Financial Figures
In the year 1959, few years after Korean war, SINSIN Pharmaceutical Company was established during the reconstruction of post-war period for the purpose of improving the national health. Amidst the devastating conditions of the 1950’s SINSIN committed to the development of top professional staff, research and development of new products and to the improvement of the Korean pharmaceutical market. SINSIN’s efforts were successful in replacing the expensive Japanese Plaster and through superior quality management became the #1 Plaster company in Korea. SINSIN began to export it’s products in 1971 and at present time it ships to over 30 different countries worldwide with trememdous success. SINSIN has been given various awards including the Outstanding Company Award and the Presidential award. These awards have motivated SINSIN to work harder to promote national health, which is both our responsibility to society and our original goal as a leading pharmaceutical company. From environmental concerns to national health SINSIN Pharmaceutical will continue to diligently work for the improvement of life.Thank you for all of your support.
Focus Area : Pain reliving patches, Liniment, Aerosol, Wound care product.
Company Profile
Sinsin Pharm. Co., Ltd.RepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Hanki Kim
Korea Bio Park C-4F, 700, Daewangpangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea
1955
Pain reliving and wound care etc.
240
82-31-776-1111
82-31-776-1117
www.sinsin.com
Contact PersonContact PhoneContact E-mail
Woongjin Han
82-31-776-1141
wjhan@sinsin.com
177
Product (Ingredient/Formulation) Use Exporting Countries Remarks
1. SINSINPAS-RX Active ingredient : Out of 1 sheet (10x14cm, 2,301.24mg) L-menthol 90.9mg, dl-camphor 34.1mg, Mentha oil 45.46mg, Methyl salicylate 90.90mg, Vanillyl Nonylamide 0.114mg
IndicationMuscular pain, Joint pain, Shoulder pain, backache, Bruise, Sprain
U.S.A, Asian countries Pain Relief Patch
2. SINSIN PAS Pain relief Patch Active ingredient : Out of 1 sheet (6.2x 4.1cm, 453.29mg) Methyl salicylate 29.98mg, Thymol 0.77mg, L-menthol 36.32mg, DL-camphor 15.63mg, Borneol 1.20mg
IndicationMuscular pain, Joint pain, Shoulder pain, backache, Bruise, Sprain
U.S.A, EU, Asian countries.
Pain Relief Patch
3. SINSIN CAPSICUM PATCH Active ingredient : Out of 1 sheet (13x18cm, 2,400mg) Capsicum extract 0.025%
IndicationMuscular pain, Joint pain, Shoulder pain,Neuralgia, Rheumatism, backache
U.S.A, Middle East, Asian countries.
Pain Relief Patch
4. ICE COLD PAIN RELIEF PATCH Active ingredients (out of 8x12cm, 5.2g) • L-Menthol 5%
Indication• Muscular pain• Joint pain• Shoulder pain • backache• Bruise • Sprain
Exporting countryOver 15 countries including :• U.S.A (CVS, Wal green)• Poland• U.K (Boots )• Asia• RussiaICE COLD PAIN RELIEF PATCHPAIN RELIEF HYDRO GEL PATCHCode :SSP 3405
Pain Relief Patch
5. KETOCLIN PLASTER Active ingredients (out of 10×7cm, 0.7g ) • Ketoprofen 30mg
Indication• Arthritis Deformans • Peri-arthritis of shoulder• Tendinitis• Peri-tendinitis• Myalgia
Exporting countryOver 10 countries including :• HK• Vietnam• Macao• Iran• Guatemala
Pain Relief Patch,Transdermal Drug Delivery System (TDDS).
Main Products
2016 Directory of Korea Pharmaceutical Industry178
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 258,952 303,383 350,270
R&D Expenditure 24,500 30,621 34,910
Capital
Financial Figures
SK Chemicals is a member company of SK Group, the third largest company group in Korea.
Since founded in 1969, SK Chemicals has focused on the development of drug products targeting the diseases with unmet treatment needs in order to fulfill its vision; “Healthcare and Earthcare”.
The R&D area of SK Chemicals covers a broad range of product lines, including new chemical entities, new herbal extract drugs, reformulated generics, vaccines and blood products. Owing to its continuous efforts on R&D, SK Chemicals was able to develop three new chemical entities (NCEs), novel drug delivery system (DDS) flat foam technologies, recombinant DNA technology and in-house premium vaccines.
On the basis of this strong R&D capability together with its outstanding marketing operations, SK Chemicals was selected as a member of the Korea Innovative Pharmaceutical Company.
Company Profile
SK Chemicals Life ScienceRepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
In-Serk Lee
310, Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea
Jul. 1. 1969.
NCE, Herbal, Biologics
1593
82-2-2008-2008
82-2-2008-2959
www.skchemicals.com
179
Main Products
Product (Ingredient) Use Exporting Countries
1. OMED Tab. (Omeprazole) Gastric Ulcer EU
2. SID710 Patch (Rivastigmine) Alzheimer's Disease EU
3. SK Albumin Inj. 20% (Human Albumin) Albumin DeficiencyEgypt, India, China, Hong Kong, Mongolia Dominican Republic
4. LIV-Gamma Inj. (Human IgG) IgG Deficiency Thailand, Peru, India, Egypt
5. Trast Patch (Piroxicam) Arthritis Saudi Arabia, China, Philippines
6. Ginexin Tab. (Ginko biloba) Blood Circulation Enhancer Saudi Arabia
7. Joins Tab. Arthritis Australia
8. SID530 Inj. (Docetaxel) Anti-cancer EU
9. SID820 Cap. (Esomeprazole) Gastric Ulcer EU
10. MvixS ODF (Mirodenafil) Erectile Dysfunction N/A
New Active Substances
Product (Ingredient) Use Approval Date
SUNPLA (Heptaplatin) Anti-cancer 1999
JOINS (Herbal Extracts) Arthritis 2002
Mvix (Mirodenafil) Erectile Dysfunction 2007
R&D Pipeline
Ingredient Use Stage of Development
NCE 401 Fibrosis Pre-clinical
NCE 403 Endometriosis Pre-clinical
HMP 301 Asthma Phase III
HMP 302 Alzheimer's Disease Phase III
HMP 304 Irritable Bowel Disease Phase II
NBP 606Prevention of infection caused by
Pneumococcal bacteriaPhase I
NBP 607 Prevention of infection caused by Influenza virus Phase I
2016 Directory of Korea Pharmaceutical Industry180
Summary (1 Million Won)
Fiscal Year 2008 2009 2010
Sales 101,606 107,816 124,860
R&D Expenditure 748 505 547
Capital 5,902 6,084 6,084
Financial Figures
Since Establishment in 1973, Suheung Capsule Co., Ltd have sought to produce only the highest quality capsules and thus grown to be one of the world’s leading manufacturers
and exporters of empty hard gelatin, fish and HPMC capsules.
Company Profile
Suheung Capsule. Co., Ltd.RepresentativeHeadquarter Address
Foundation DateTotal StaffRepresentative PhoneRepresentative Fax Web
Joo Hwan, YANG
Jung-An B/D 6F, 40, Janghan-ro, Dongdaemun-gu, Seoul, Korea
1973
500
82-2-2210-8193
82-2-2217-2356
www.suheung.com
181
Main Products
Product (Ingredient) Use Exporting Countries
1. Empty hard gelatin capsules more than 40
2. Empty hard fish capsules more than 40
3. Empty hard HPMC capsules more than 40
2016 Directory of Korea Pharmaceutical Industry182
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 95,043,027 94,325,508 90,905,789
R&D Expenditure 4,836,463 6,355,765 7,686,165
Capital 92,603,127 101,850,598 91,917,685
Financial Figures
Taejoon Pharm., founded in 1978, is a global pharmaceutical company accomplished in exporting aseptic eye drops to Europe for the first time in Korea. In addition, we are the first specialized company to have technologies to make all three fields of contrast media products: X-ray, MRI, and CT. Taejoon Pharm’s Yongin plant, which was built in October, 2005, became Korea’s first EU-GMP certified plant to produce qualified pharmaceutical products that export to Europe.
Taejoon is implementing a marketing strategy, targeting countries of the world and continuously reinforcing pioneering movement by actively participating in internationally renowned academies and exhibitions. As a result, we were able to create a strong sales network among more than 50 countries, including 30 European countries. On this basis, we plan to strengthen the sales network with the goal of simultaneous release into the world in the event of global product launch. We expect to increase the company’s brand value by establishing the sales network through localized sales marketing in particular countries, such as the U.S., China, Russia, and Europe.
Focus Area : Ophthalmology, Gastrointestinal agents, Contrast media, etc.
Company Profile
Taejoon Pharm. Co., Ltd.RepresentativeHeadquarter Address
Foundation DateResearch Focus
Total StaffRepresentative PhoneRepresentative Fax Web
Tae Young Lee
8 Daesagwan-ro 31-gil, Yongsan-gu, Seoul, Korea
1978
Ophthalmology, Gastrointestinal agents, Contrast media, etc
385
82-2-799-0072
82-2-798-6665
www.taejoon.co.kr
Contact PersonContact PhoneContact E-mail
Andy Lee
82-2-799-0072
jhlee2@taejoon.co.kr
183
Product (Ingredient/Formulation) UseExporting Countries
Remarks
Ophthalmic solution
1. Cyporin N ophthalmic solution (Cyclosporine)
The increase of tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca
2. MC Free ophthalmic solution (Sodium carboxymethylcellulose)
Dry eyes for the temporary relief of burning, irritation and discomfort EU, USA
3. Hyaluni ophthalmic solution (Hyaluronic acid)
Bond and repair corneal epithelial cells, helps cure corneal injuries and retain and stabilize tears, dysfunction tear syndrome
4. Taejoon Ultra ophthalmic solution(Polyethylene Glycol)
Temporary relief of irritation and burning due to dryness of the eye USA
5. Xalost Plus ophthalmic solution (Latanoprost + Timolol maleate)
Reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension
EU, Russia, China
6. Xalost ophthalmic solution (Lataonoprost)
Reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension
EU, Russia, China
7. Alpaday ophthalmic solution (Olopatadine HCl)
Relief of allergic conjunctivitis
8. Fluvin ophthalmic solution (Fluorometholone)
Inflammatory diseases of the anterior/external segment of the eye (blepharitis, conjunctivitis, keratitis, etc)
Gastrointestinal agents
9. Coolprep (PEG 3350) Preparation for colonoscopy
10. Lamina G (Sodium Alginate)Hemostasis and remission of subjective symptom in gastric & duodenal ulcer, erosive gastritis
11. Gasocol Susp. (Simethicone) For elimination of gastric bubble for gastroendoscopy
12. Colyte (PEG 3350) Preparation for colonoscopy
13. Colyte F (PEG 3350) Preparation for colonoscopy
Contrast Media14. MRbester injection (Gadopentetate dimeglumine)
Contrast medium for cranial and spinal MRI/ whole body MRI Asia
15. Iobrix injection (Iohexol)Myelography, angiography, urography, contrast enhancement of computerized tomography
Asia
16. Radisense injection (Iopamidol)
Angiography throughout the cardiovascular system, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, pediatric angiocardiography, selective visceral arteriography and aortography, peripheral venography (phlebography), and adult and pediatric intravenous excretory urography and intravenous adult and pediatric contrast enhancement of computed tomographic (CECT) head and body imaging
Asia
17. Iversense injection (Ioversol)For cerebral angiography and peripheral arteriography, contrast enhanced computed tomographic imaging of the head and body, venography, and intravenous excretory urography
18. Visisense injection (Iodixadol)
1. Intra-arterial intra-arterial digital subtraction angiography angiocardiography (left ventriculography and selective coronary arteriography), peripheral arteriography, visceral arteriography, and cerebralarteriography
2. Intravenous CECT imaging of the head and body, excretoryurography, and peripheral venography.
19. Solotop-HD (Barium sulfate)
Contrast enhanced x-rays or computed tomographic imaging (CAT scan, CT scan; a type of body scan that uses a computer to put together x-ray images to create cross-sectional or three dimensional pictures of the inside of the body) of the esophagus (tube that connects the mouth and stomach), stomach, and intestine
Asia
Main Products
Compound Name Code Use Stage of Development
Age-related Macular Degeneration (New Biological Entity)
AMD Phase 2/3
Antibiotic product (New Chemical Entity)
Bacterial conjunctivitis Pre-clinical
Dry eye product(New Chemical Entity)
Dry eye Pre-clinical
Combination or Improved drugs Ophthalmic/GI indications Phase 3 ~ Pre-clinical
R&D Pipeline
2016 Directory of Korea Pharmaceutical Industry184
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 38,000 43,000 50,000
R&D Expenditure 160 190 420
Capital 16,000 17,000 20,000
Financial Figures
“Supply best quality pharmaceutical products to customer.” Since established in 1957, Tai Guk Pharm. Co., Ltd. has been manufacturing pharmaceutical products. We have focused on development of OTC products such a hydroquinone cream and professional and leading manufacturer of ointments(ointment, cream, gel) in Korea. We have largest plant in Korea for ointments at Buyeo and pushing to FDA approved Buyeo plant. We can also undertake contact manufacturing Tablet, Capsule, Internal & External liquid, and specially Ointments. We are export to USA and many other countries.
Focus Area : Ointment & Cream
Company Profile
Taiguk Pharm. Co., Ltd.RepresentativeHeadquarter Address
Foundation DateTotal StaffRepresentative PhoneRepresentative Fax Web
Chang Koo Lee
123, Jeyakgongdan 3-gil, Hyangnam-eup, Hwaseong-si, Gyeonggi-do, Korea
1957
284
82-2-3474-7761
82-2-2051-2597
www.taiguk.co.kr
Contact PersonContact PhoneContact E-mail
You Mi Kim
82-2-3474-7761
taiguk3@korea.com
185
Product (Ingredient/Formulation) Use Exporting Countries Remarks
1. Highrosone Cream (Hydrocortisone / Cream) Dermatitis Cambodia
2. Paracool Cream (Methyl Salicylate, l-Menthol, dl-Camphor / Cream)
Pain Relief Vietnam
3. Pramyxin Ointment (Bacitracin Zinc, Neomycin sulfate , Polymyxin B Sulfate, Pramoxine HCl / Ointment)
Antibiotics Hongkong
4. Partygel Suspension (Almagate / Gel) Hyperacid Vietnam
5. Miobi soft cap. (Vitamin A and other ingredients / Capsule)
Multi Vitamin Ecuador
Main Products
2016 Directory of Korea Pharmaceutical Industry186
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 65,757 56,398 52,244
R&D Expenditure 5,710 3,914 2,815
Capital 13,627 13,887 13,887
Financial Figures
THERAGEN ETEX CO., LTD. is a leading pharmaceutical company to develop innovative and personalized new drugs having a world class analysis technology of individual genome.
Excellent System : We have manufactured outstanding pharmaceuticals by controlling all lines at GMPs factory from manufacturing to quality controls in compliance with WHO/ICH Guideline.
Best Bio center : Our laboratory having the best analysis technology and excellent analysts of the genome in Korea. The first and the best results of studies to be recognized in the world - Whole genome mapping of woman, tigers and whales(the first in the world) - Commercialized personal genome analysis service(the first in Asia)
Innovative New drug : THERAGEN ETEX CO., LTD. has built databases and infrastructures to develop personalized pharmaceuticals by analysing individual’s disease genes as the only pharmaceutical manufacturing facilities and genome analysis service in Korea.
Focus Area : E.N.T & Cardiovascular
Company Profile
Theragen Etex Co., Ltd.RepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Kyu won Ji
5F, 32, Nonhyeon-ro 30-gil, Gangnam-gu, Seoul, Korea
Oct. 1. 1990
First Generic & Slow release type drug
216
82-2-3463-7111
82-2-3463-8111
www.thera-gen.com
Contact PersonContact PhoneContact E-mail
Sun-Hee, Kim
82-2-3463-7111
k37818@etexpharm.com
187
Product (Ingredient/Formulation) Use Exporting Countries Remarks
1. ETEXCITICOLINE Tab. (Cilticoline 500mg)Memory disorderIschemic stroke
Vietnam
2. CELEMIN Cap. 200mg (Celecoxib 200mg) NSAID Vietnam
3. NEXON Tab. 20mg/40mg (Esomeprazole 20mg/40mg)
Gastritis Vietnam
4. RABEZOLE 10mg/20mg (Rabeprazole 10mg/20mg)
Gastritis Vietnam
5. EXPERA Tab. 5/80 (Amlodipine 5mg + Valsartan 80mg)
Hypertension Philippines
6. ATOSEN Tab. (Atorvastatin 10mg) Hyperlipidemia Vietnam
7. ETEX ROSUVASTATIN Ca Tab. (Rosuvastatin Ca 5mg/10mg/20mg)
Hyperlipidemia Philippines
8. ZAKUTEX Dry syrup 156.25mg/5mL (Amoxicillin hydrate 21.6248g + Diluted potassium calvulanate 10.8124g)
Chronic branchitis Myanmar
9. ZAKUTEX Neo Dry syrup (Amoxicillin hydrate 54.5454g + Diluted potassium calvulanate 7.8g)
Acute otitis media for children
Vietnam
10. CLAROCIN Tab. (Clarithromycin 250mg) Antibiotics Vietnam
11. UMCKAMAX Syrup (Pelargonium sidoides 11%EtoH ext.17.16mg)
BronchitisLaryngopharyngitis
Vietnam
12. CRANTOL Syrup (Ambroxol HCl 150mg + Clenbuterol HCl 0.1g)
Cough Nigeria
13. CITLEN Solution (Citrulline maleate 1g) Fatigue recovery Vietnam
14. ETEX CYCLOSERINE Cap. (Cycloserine 250mg)
Tuberculosis Vietnam
15. ZENTOX Tab. (Albendazole 400mg) AnthelminthicUzbekistanAzerbaijanKyrgyzstan
16. OEANZIL Vaginal Soft Cap. (Neomycin 35,000IU, Nystatin 10,000IU, Polymyxin B sulfate 35,000IU)
Vaginal infectionMyanmarCambodia
17. SIMTUM-TWO Tab. (Acetaminophen 325mg, Phenylphrine HCl 5mg, Dextromethorphan hydrobromide 10mg, Chlorpheniramine maleate 2mg)
Cold Hongkong
Main Products
2016 Directory of Korea Pharmaceutical Industry188
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 42,294 40,467 48,715
R&D Expenditure 781 987 712
Capital 2,100 2,100 2,100
Financial Figures
Union Korea Pharma is pharma manufacturing company, certificated GMP compliance of tablet, capsule, injection(ample, vial) and cephalosporin powder from MFDS Korea.
We have exported to Vietnam, Cambodia, Philippines, Hongkong, Mongo, Peru, Chile, Bolivia, Yemen, Azerbaijan etc, and we had received Presidental Award by small and medium enterprise export support center in 2009.
Focus Area : Antibiotics(Cepha inj.), Cardiovascular, Degenerative Disease, Contrast media, Ophthalmology
Company Profile
Union Korea Pharm. Co., Ltd.RepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Sung Jun Kim
6F, ABN Tower B/D, 331, Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea
Nov. 1956
Infectious disease
220
82-2-489-3611
82-2-487-3611
www.ukp.co.kr
Contact PersonContact PhoneContact E-mail
Jeongsu Ock
82-2-489-3611(Ext.311)
jsock@ukp.co.kr
189
Product (Ingredient/Formulation) Use Exporting Countries Remarks
1. Unitiaxone Inj. (Ceftriaxone Sodium 1g)
Respiratory system infection, infection related otolaryngology renal and urinary tract infection, septicemia meningitis, prophylactic of pre/post operation infection, osteoarthritis, skin and soft tissue infection, cholecystitis, G.I. tract infection.
Vietnam, Philippines,
Yemen
2. Uni-Infusion Inj. (L-Ornithine-L-Aspartate 500mg)
Hepatic dysfunction - Acute and chronic hepatitis, alcoholic liver disease; post hepatitis convalescence, cirrhosis, along with hepatotoxic drugs.
Vietnam, Mongol
3. Union Cefuroxime Sodium Inj. (Cefuroxime Sodium 750mg)
Acute or chronic bronchitis, bronchiectasis, bacterial pneumonia, pneumonial abscess, post-operational chest infection, sinusitis, tonsilitis, pharyngitis, nephropyelitis, cystitis, cellulitis, eryspelas
Vietnam, Philippines
4. Climycin Inj. (Clindamycin phosphate 600mg)
Infections caused by susceptible anaerobic bacteria
Vietnam, Philippines
5. Unifenac Inj. (Diclofenac Sodium 75mg)
Fever and pain due to cold, headache, neurodynia, muscle ache, menstrual cramps, rheumatoid arthritis, arthralgia, toothache
Vietnam
Main Products
Compound Name Code Use Stage of Development
Combined antibiotics with beta-lactamase
bacterial infections (upper respiratory tract infections).
Phase III trial
R&D Pipeline
2016 Directory of Korea Pharmaceutical Industry190
Summary (1 Million Won)
Fiscal Year 2008 2009 2010
Sales 92,915 99,387 105,687
R&D Expenditure 4,534 4,385 5,995
Capital 97,843 108,436 124,881
Financial Figures
We are pursuing a healthy society through supplying good medicines to medical profession. Having established in 1978 as a specialized manufacturer of psychotherapeutics, we have been devoting ourselves to become a leading specialty company in Korea by satisfying the needs in the following areas where we have special competencies :
- CNS disorders & Neurodegenerative diseases
- Age related disorders
- New areas of unmet medical needs
Company Profile
Whan In Pharm. Co., Ltd.RepresentativeHeadquarter Address
Foundation DateResearch Focus
Total StaffRepresentative PhoneRepresentative Fax Web
WonBum Lee
117, Saemal-ro, Songpa-gu, Seoul, Korea
Jun. 5. 1978
CNS disorders & Neurodegenerative diseases, Age-related disorders and new areas of unmet medical needs
407
82-2-405-3000
82-2-405-3182
www.whanin.com
191
Main Products
Product (Ingredient) Use Exporting Countries
1. RIPERIDONE (Risperidone) Antipsychotics
2. QUETAPINE (Quetiapine) Antipsychotics
3. ALPRAM (Alprazolam) Tranquilizer
4. URANTAC (Ranitidine) Pepticulcer
5. ZOLPILAM (Zolpidem) Anxiolytics & Hypnotics
6. WI ACAMPROSATE (Acamprosate) Alcohol dependence
7. WI GRANDAXIN (Tofisopam) Anxiolytics
8. METADATE CD (Methylpenidate) ADHD
9. NUREPTOL (Gabapentin) Anticonvulsants
10. WI DONEPEZIL (Donepezil) Antidementia
New Active Substances
Product (Ingredient) Use Approval Date
NEPONID (Nemonapride) Antipsychotics Jan. 1994
R&D Pipeline
Ingredient Use Stage of Development
WIN-34B Osteoarthritis under PhaseⅡ
WIP-901C Osteoarthritis Pre-clinical
WIN-901X Asthma Pre-clinical
WIN-902A Anti-obesity Pre-clinical
WIN-1001X Anti-parkinsonism Pre-clinical
2016 Directory of Korea Pharmaceutical Industry192
Summary (1 Million Won)
Fiscal Year 2008 2009 2010
Sales 2,790,000,000 3,125,000,000 3,567,000,000
R&D Expenditure 4,500 3,600 3,200
Capital 3,000,000,000 3,000,000,000 3,000,000,000
Financial Figures
Founded by Wonkwang University on the basis of Bohwadang, a pharmacy established in 1934 under the slogan ”Save all living things from distress and sickness” Wonpharm Co., Ltd. manufactures over 180 medicines, lncluing Gyeongokgo under strict quality control, and over 20 health foods, incluing Wonkwang Bohwaokgo and Hyosam Forte, at its KGMP-certified factory equipped with clean facilities.
Wonpharm CO., Ltd., which has been designated as cooperative business for research in pharrmaceutical resources as well as the practice factory for Pharmacy College, Wonkwang University, devotes itself to technical development for a society free from disease.
it has aiso established a solid educational industrial research system with medical College, Oriental Medical Center of Wonkwang University.
Company Profile
Won Kwang Pharm. Co., LtdRepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Yong Jeong Park
165, Seogam-ro 11-gil, Chunpo-myeon, Iksan-si, Jeollabuk-do, Korea
May. 1934
Save all livings from distress and sickness
40
82-80-359-3333
82-63-833-4114
www.wonpharm.co.kr
193
Main Products
BoHwa KyungOkKo is composed of Korean Ginseng Hoelen, Rehmannia juice, and sweet honey based on the prescription of the korean traditional medical book known as Dong Eui Bo Kam (UNESCO recognizes as a world legacy of the record). This product is well recognized as a restorative enforcing the vitality of whole organs, and also as elimination fatigues, exhaustion followed by weariness. Because of the special properties that had no any interferences against any foods, this product has been used by the ancient royal family and the nobles. Especially this product improves the growth of children and the
recovery from weariness due to illness of stress.
Product (Ingredient) Use Exporting Countries
1. Bohwa Kyungokgo
2. Bohwa Sohap won
3. Woohwang chungsimwon Suspension liquid
2016 Directory of Korea Pharmaceutical Industry194
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 74,169 75,372 85,651
R&D Expenditure 3,535 2,640 3,418
Capital 3,000 3,000 3,000
Financial Figures
Yooyoung has established a foothold for growth through consistent increasing sales, and we are growing as a leading pharmaceutical company in Korea by fulfilling our medium and long term mission.
Focus Area : Arthritis, Anti-Thrombosis, Mixed-Dylipidemia, etc.
Company Profile
Yoo Young Pharm. Co., Ltd.Woo-Pyoung Yoo
Yooyoung B/D, 93, Hyoryeong-ro, Seocho-gu, Seoul, Korea
Dec. 23. 1981
New Drug & IMD
320
82-2-6207-6114
82-2-6202-7067
www.yypharm.co.kr
RepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Contact PersonContact PhoneContact E-mail
Mr. Choi
82-2-6202-7116
khchoi2@yypharm.co.kr
195
Product (Ingredient/Formulation) Use Exporting Countries Remarks
1. Atri InjectionArthritis, Scapular periarthritis
Poland, Syria, UAE, Russia, Vietnam, Japan
CTD Dossier Available
2. Atri Plus InjectionArthritis, Scapular periarthritis
Poland, UAE, Russia, Malaysia
CTD Dossier Available
3. Cnoxane InjectionLMWH : Anti-Coagulant
Russia, Syria, Philippines, Vietnam
CTD Dossier Available
4. Asasulfan Tablet Ulcerative colitis Japan
Main Products
Compound Name Code Use Stage of Development
Stem cell Neuronata-R ALS On Market
IMD/DDS Artis-FR Gastric ulcer Registration
Monoclonal Antibody YYB101 Anti-cancer Phase 1
IMD/DDS YY1201 OA Phase 1
IMD/New combination YYC301Neuropathic
PainPreclinical
IMD/Release control YYD601 GERD Preclinical
IMD/New HA filter YYD701 Dermal Filler Preclinical
Fusion Protein YYB102 Anti-cancer Discovery
R&D Pipeline
2016 Directory of Korea Pharmaceutical Industry196
Summary (1 Million Won)
Fiscal Year 2008 2009 2010
Sales 595,720 630,347 649,324
R&D Expenditure 34,317 35,495 41,208
Capital 862,941 967,425 1,072,464
Financial Figures
Founded in 1926 with the mission of supporting South Korea by enhancing the quality of life for all people, Yuhan has been providing high quality medicines for the last 85 years as one of the leading pharmaceutical companies in South Korea.
Since its foundation, Yuhan has set the foremost priority to provide the best medicines by building its R&D. In 2005, Yuhan moved its central research to Giheung, Gyeonggi-do, and opened the largest R&D center in the South Korean pharmaceutical industry. With state-of-the-art facilities, Yuhan is committed to deliver advanced and innovative medicines to enhance quality of life.
Yuhan is focusing its R&D capabilities on developing new chemical entities, herbal medicines, market-oriented IMDs(Incrementally modified drugs), and APIs/intermediates for overseas markets.
Company Profile
Yuhan Corp.RepresentativeHeadquarter AddressFoundation DateResearch Focus
Total StaffRepresentative PhoneRepresentative Fax Web
Yoon Searb Kim
74, Noryangjin-ro,Dongjak-gu, Seoul, Korea
Dec. 1926
Gastrointestinal disease, Cardiovascular disease, Metabolic disease
1,480
82-2-828-0429
82-2-828-0080
www.yuhan.co.kr
197
Main Products
Product (Ingredient) Use Exporting Countries
1. Piperacillin Monohydrate Antibiotic USA, Europe
2. CMO-HIV New Drug (API 1) HIV USA, Europe
3. CMO-HIV New Drug (API 2) HIV USA, Europe
4. CMO-HIV New Drug (API 3) HIV USA, Europe
5. Ribavirin HCV USA, Europe
6. Cilostazol Anti-platelet USA
7. CMO-HCV New Drug (API4) HCV USA
8. PEG-Thiol Coagulant USA
9. PEG-NHS Coagulant USA
10. Levofloxacin Antibiotic Canada, Japan
New Active Substances
Product (Ingredient) Use Approval Date
Revanex (Revaprazan) Duodenal Ulcer, Gastiric Ulcer, Gastritis Sep. 2005
R&D Pipeline
Ingredient Use Stage of Development
IMD1 Anti-platelet Phase I
IMD2 Cardiovascular Disease Phase I
IMD3 Pain Phase I
IMD4 NERD Phase II
YHD1044 Premature Ejaculation Phase II
YH14617 Diabetes Phase II
YH14642 Periodontal Disease Phase II
YHD1023 Erectile Dysfunction Phase II
YHD001 Asthma/Bronchitis Phase II
YH4808 GERD Phase II
YH14618 Degenerative Disc Phase I/II
YH14619 Osteo Arthritis Phase I
YH14810 Cancer (Immune modulator) Phase I
YHB1411-2 Rheumatoid Arthritis Phase I
YH**** Diabetes Phase I
YH**** Irritable Bowel Syndrome Phase I
2016 Directory of Korea Pharmaceutical Industry198
Summary (1 Million Won)
Fiscal Year 2008 2009 2010
Sales 45,014 47,900 52,027
R&D Expenditure 1,023 1,421 487
Capital 64,591 70,458 70,642
Financial Figures
Yuyu Pharma Inc, established in 1941, is a company that sales, markets and manufactures pharmaceutical products in Korea and has developed its business through not only in-house developed new drugs but also various partnerships with global companies such as Sanofi-Aventis, Pfizer, GSK and Novartis by incensing in their original products for the Korean market.
Yuyu Pharma has focused on how to serve the aging population, as people are living longer and searching for ways to live a healthier life. This has led us to be a specialist in the fields of neurology, osteoporosis, cardiovascular and nephrology. Yuyu’s treatment in these areas has proven to be fruitful and we will continue to focus on these therapeutic categories. In order to expand the business, we are also expanding our presence in the field of gastrointestinal diseases and antibiotics.
Also, Yuyu has completed new state-of-art factory in 2006. The factory designed in accordance with cGMP and EU GMP. Tablets, capsules and cream are manufactured with advanced equipment under cGMP compliance.
We would like to have an opportunity for the business relationship with your company who is dealing with imported finished pharmaceutical products.
Company Profile
Yuyu Pharma, Inc.RepresentativeHeadquarter AddressFoundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Seungpil Yu
Yuyu B/D, 197, Dongho-ro, Jung-gu, Seoul, Korea
1941
New Drug, Botanical Drug
257
82-2-2253-6600
82-2-2253-6200
www.yuyu.co.kr
199
Main Products
Product (Ingredient) Use Exporting Countries
1. Maxmarvil tablet (Alendronate, Calcitriol) Osteoporosis Thailand
2. Yuclid tablet (Ticlopidine, Ginkgo biloba) Antithrombotics
3. Bonky soft capsule (Calcitriol) Osteoporosis Malaysia, Vietnam
4. Bonky Injection (Calcitriol) Hypocalcemia Malaysia, Pakistan
5. Yupan-C tablet Vitamin-C Philippines
6. Venoforte Injection (Aesculus hipp. ext.) post-operative swelling Syria
7. Venoforet gel (Heparine,Aescine,Glycol) Swelling Hongkong
8. Mycobutin tablet (Rifabutin) Antitubercular agent
9. Yucezone Injection (Cefezone) Antibiotic Vietnam
10. Yuroxim Injection (Cefuroxime) Antibiotic Vietnam
R&D Pipeline
Ingredient Use Stage of Development
Ginkgo Blood circulation Launched
Alendronate Osteopoeosis Launched
vitamin D3 Osteodystrophy Launched
Ticlopidine Ischemic stroke Launched
Ginseng, Ginkgo ADHD Phase Ⅲ
2016 Directory of Korea Pharmaceutical Industry200
C&R ResearchRepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Moon Tae Yoon
Daechi MS B/D, 412, Yeoksam-ro, Gangnam-gu, Seoul, Korea
1997
Contract Research Organization
+220
82-2-6251-1500
82-2-6251-1504
www.cnrres.com
C&R Research Inc. (hereinafter “C&R”), the first CRO (Contract Research Organization) in South Korea was established in 1997 leading the development of Korean CRO industry with a market share of over 30% in the past five years (2011~2014).
From accumulated proven capability, C&R is the No. 1 CRO in the field of regulatory clinical trials encompassing clinical development phase I-III in South Korea with the most extensive experience and know-how. C&R has conducted more than 750 clinical trial projects in various global therapeutic areas with over 140 customers around the world successfully.
More than 50% of all clinical trials being performed is a global type and C&R is getting regular system audit and being confirmed of competency and qualification constantly from the global sponsor and has secured an excellent global clinical trial execution capabilities accordingly.
In 2008 C&R was awarded as “South Korea Clinical Research Organization of the year” from Frost & Sullivan which was awarded for the first time in CRO companies in Korea.
Also, C&R has been selected as MAIN-BIZ / INNO-BIZ certificated for business innovation and technology, and established C&R R&D Center (Research Laboratory) that provides data analysis and publishes trend analysis and forecast report about clinical trial in South Korea.
C&R is running a specialized Oncology & Biology team and Marketing & LPS (Late Phase Study) team. Oncology & Biology team have been dedicated to the oncology and biology clinical trials. It was selected as a CRO partner of National Onco Venture, a
government agency focusing on R&D for anticancer drugs, which is being currently operated. Marketing & LPS (Late Phase Study) team is specialized division for the enhancement of the Phase IV stage providing services of consulting, planning and clinical services targeting for Phase IV, Observational Study and Post Market Surveillance.
C&R Research China Inc. was established in Beijing in 2010 by focusing on the Chinese market providing drug registration, clinical trial services and China market entry strategy consulting services, and C&R is planning to set up additional subsidiaries in China in 2015.
In 2012, an Asia CRO alliance called, A-PACT (Alliance for Pac-Asia Clinical Trials) was established with the founding members including C&R Research, performing its role as a leading CRO community in Asia-Pacific region. Through strong network relationships with competitive global CROs and regional CROs over five, C&R can provide a multinational clinical trial service including Asia-Pacific regions.
Moreover, C&R has implemented a consistent internal training to strengthen the recruitment and staff competencies by operating training & Operations practice team and also have contributed to the development of clinical experts through C&R Academy.
C&R has the largest QA organization among Korea CRO which was established C&R QA separately from C&R Research in Aug 2014. It has been providing a variety of professional QA services with more than five auditors.
Company Profile
Contact PersonContact PhoneContact E-mail
Bomi Jeon
82-70-4033-3010
jeon.bomi@cnrres.co.kr
201
Introduction of C&R Academy
Introduction
C&R Academy was founded in May 2010 aimed at being a clinical trial training center in Northeast Asia, offering a wide range of training programs related clinical trials.Now C&R Academy provides professional, comprehensive and practical “hand-on” clinical research training and continuous education programs to researchers (PI) and research nurses (CRC) as well as CRA, PM, CRM to improve the quality of clinical trials.Training programs of C&R Academy is consists of Fundamental Course, Basic Course, Monitoring Practice, Clinical Project Management, GCP Training, Oncology Clinical Trial, Early Phase Study, Introduction to Clinical Trial and so on. All training programs can expect the effect of intensive training workshop conducted in the form of a small two-way communication.In addition, since 2011, C&R Academy introduced LMS (Learning Management System) and have been strived to improve the validation and quality of educational services for all C&R Academy as ISO9001 certified company. C&R Academy will to be oriented to international standards of clinical training services continuously.
Training programs
Instructor-led Courses - Fundamental of Clinical Research & Practice - Basic Course of Clinical Research & Practice - Clinical Project Management - Monitoring Practice for Clinical Research - Introduction to Clinical Trial - Good Clinical Practice Training
- Oncology Clinical Trial - Early Phase StudyOnline Training Courses - Clinical Trial Guidance - Monitoring in Clinical Research, GCP Guidelines,
Overview of Drug DevelopmentIn-Company Training Courses
Contact information Help Desk: +82 70 4033 3017 e-mail: cnracademy@cnrres.co.kr Web: www.cnracademy.org
Introduction of C&R QA
Introduction
C&R QA Inc. (hereinafter C&R QA), founded in Aug 2014, is the first company specialized in quality assurance of clinical trials in South Korea. C&R QA is established for the purpose of enhancing the professionalism of the quality assurance work of clinical trials independently from C&R Research that had provided quality assurance services such as audits in a variety of therapeutic areas, education and preparation for government authority inspection. As the importance of quality assurance of clinical trials has been increasingly emphasized, C&R QA is aiming to provide quality assurance services of clinical trials to customers with credibility. All auditors of C&R QA have a membership of RQA (Research Quality Assurance) and Auditor certificates, especially lead auditors have a certificate of ‘Registered Quality Assurance Professional’ by SQA(Society of Quality Assurance). C&R QA will continue to devote itself to be the best partner for customers in the field of quality assurance of clinical trials by ensuring that the clinical trial is performed and the data are generated, documented (recorded), and reported in compliance with Good Clinical Practice (GCP) and the applicable regulatory requirement(s).
Services
- Risk-based Quality Management - Good Clinical Practice Audit - Good Laboratory Practice Audit - Good Pharmacovigillance Practice Audit
- Due Diligence Audit - Mock Inspection - Quality Assurance Consultation - Standard Operation Procedure Development - Training
Contact information Contact Person: Jiyeon Hwang TEL: +82 70 4033 3054 E-mail: hwang.jiyeon@cnrqa.com Web: www.cnrqa.com
Main Service
Regulatory Affairs Services IMPD prep. & Consulting, IRB submission, IND submission, NDA submission & approval
Medical Affairs Services Protocol development, CRF development, ICF development, CSR writing, Medical translation
Statistical Analysis Services Statistical programming/ analysis, Randomization, Sample size calculation
Clinical Operation Services Site feasibility & contract, Project management, Monitoring, Budget management, Inspection
Data Management Services DB design, Paper & EDC based data management (manual & programming), Clinical Coding , AE report to KIDS etc
Electronic Data Capture Services EDC system develop. & maintenance (Medidata RAVE, Oracle Inform GTM, etc, ...), IWRS
Medical Translation Services Medical document translation & verification
Quality Assurance Services External audit, GCP & GLP & GPP Audit, CQMS, Due diligence, Mock inspection, SOP development
C&R China Services Multinational Trial Consulting-Market Feasibility Assess in China, CRO service, Pharmaceutical Licensing
Asia Pacific Clinical Trial Services Multinational Trial Consulting-Market Feasibility Assess in China, CRO service, Pharmaceutical Licensing
Global Clinical Trial Services US FDA pre-IND consulting/IND Submission, US Phase I & II Trial
2016 Directory of Korea Pharmaceutical Industry202
CrystalGenomics, Inc. is a commercial stage biopharmaceutical company that is dedicated to the discovery and development of novel pharmaceuticals with innovative platform technologies to address significant unmet medical needs in the therapeutic areas of infectious disease, oncology and inflammatory diseases. The Company is headquartered in Korea and has a US presence for multi-national clinical development in California, and is publicly traded on the KOSDAQ exchange.
CrystalGenomics’ first product, Acelex® (polmacoxib), has recently been approved by the Korean MFDS and is expected to be launched within the first half of 2015. Acelex is a next generation NSAID for the relief of signs and symptoms of osteoarthritis.
CrystalGenomics has two therapeutic programs in the clinic. The first program is CG400549, a first-in-class antibiotic candidate for MRSA where its phase 2a skin infection study in the US had been completed with an excellent positive outcome of 100% clinical cure rate. The second program is CG200745, a molecular targeted anti-cancer therapeutic for various types of liquid and solid tumors of which is ready for a phase 1b/2 MDS (Myelodysplastic Syndromes) study in Korea.
The business model of CrystalGenomics is to independently conduct discovery through clinical proof-of-concept phase and then out-license the ex-Korea rights to either multi-national or local pharmaceutical companies for specific regions for further development and commercialization outside of Korea, while independently conducting development and commercialization for the Korean market. By leveraging its capabilities and the know-how in novel drug R&D, CrystalGenomics will continue to strive in making significant contributions in the improvement of human health.
Focus Area : Infectious disease, oncology and inflammatory diseases
Company Profile
CrystalgenomicsRepresentativeHeadquarter Address
Foundation DateResearch Focus
Total StaffRepresentative PhoneRepresentative Fax Web
Joong Myung Cho
5F, Korea Bio Park A, 700 Daewangpangyoro, Bundanggu, Seongnamsi, Gyeonggido, Korea
Jul. 7. 2000
Discovery and development of novel therapeutics in unmet medical need areas
80
82-31-628-2700
82-31-628-2701
www.cgxinc.com
Contact PersonContact PhoneContact E-mail
Steven Kim
82-31-628-2720
skim@cgxinc.com
203
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 3,719 4,796 4,536
R&D Expenditure 7,029 6,646 6,558
Capital 22,514 36,931 55,729
Financial Figures
New Active Substances
Product (Ingredient) Use Approval Date
Acelex® (polmacoxib)Indicated for the relief of signs and symptoms of osteoarthritis
February 5, 2015 / Korea
R&D Pipeline
Compound Name Code Use Stage of Development
HDAC Inhibitor CG200745Various solid and liquid tumors including MDS, AML, pancreatic and liver cancer
Phase 1b/2 ready
FabI Inhibitor CG400549
MRSA (Methicillin Resistant Staphylococcus aureus) and other serious infections associated with Staph aureus
Phase 2a completed
BTK/FLT3 Inhibitor CG026806 AML Preclinical
Product (Ingredient/Formulation) Use Exporting Countries Remarks
Acelex® (polmacoxib)
Indicated for the relief of signs and symptoms of osteoarthritis
Currently none
Currently in discussions with multiple potential partner companies from the Emerging markets including China, Russia, Turkey and South America
Main Products
2016 Directory of Korea Pharmaceutical Industry204
GL PharmTech (GLPT ) has focused on developing improved vers ions of the cur rent ly mar keted pharmaceutical products with reduced side effects, greater therapeutic efficacy and better patient compliance using our proprietary drug formulation and delivery technologies since 2002.
We have provided more than 50 pharmaceutical companies in Korea with value-added drug formulations and delivery technologies for generic and improved version of marketed drug.
We are now transitioning from a being a technology transfer-based operat ion to being a specialty pharmaceutical company capable of developing and delivering new product lines by ourselves from 2010. We are doing this based on intensive investment in various clinical studies of products currently in our pipelines and using our already-established drug delivery platform technologies.
*Technology - GLARS(Geometrically Long Absorption Regulated System)
Conventional sustained release drug delivery systems such as ALZA’s OROS (Osmotic Release Oral System) and Skyepharma’s Geomatrix, have enjoyed great success in the field of a drug dosage form reformulation. Although these systems extend the drug release up to 24 or 48 hours, the simple extension of drug release time would be meaningless because a practical absorption site of overall drugs is generally limited to a small intestine consider the total transit time along the small intestine with absorption will be only 4 to 6 hrs. This means that
relatively large amounts of the incorporated drug would pass out without a sufficient practical absorption. To overcome the shortcomings of the currently existing sustained release drug delivery technologies we have recently developed a novel drug delivery system to enable a drug to be dissolved irrespective of the surrounding environment and further absorbed up to colon. We coined this “Geometrically Long Absorption Regulated System (GLARS)”. Basically, this system is a triple-layered tablet, comprised of upper and lower layers that swell and draw a sufficient amount of water, plus a highly water-soluble middle layer that rapidly draw water into the tablet core simultaneously.
As the middle layer induces a rapid water draw into the tablet core, the penetrated water also diffuses to the upper and lower layers, which makes the tablet to rapidly swell and controls drug release. At virtually the same time, the swollen upper and lower layers form to surround a lateral side of the middle layer, which can, in turn, further control drug release. This relatively rigid swollen matrix structure makes drug release not affected by surrounding mechanical flux, which can provide relatively consistent in vivo drug release irrespective of degree of gastrointestinal motility. The water drawn into the tablet (about 3 to 5 times the weight of the tablet itself ) functions as an additional media which enables additional and later drug release out of the dosage form. This serves to overcome the shortage of surrounding media that has been reported to be one of the key reasons for mal-absorption of a drug in colon.
Focus Area : IMD(Incrementally Modified Drugs)
Company Profile
GL Pharm TechRepresentativeHeadquarter Address
Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web
Hunsik, Wang
#714 Jungang Induspia V, 137, Sagimakgol-ro, Jungwon-gu, Seongnam-si, Gyeonggi-do, Korea
Aug. 2002
IMD(Incrementally Modified Drugs)
27
82-31-739-5220~3
82-31-739-5224
www.glpt.co.kr
Contact PersonContact PhoneContact E-mail
Jun Sang Park
82-31-739-5220(Ext. 324)
jspark@glpt.co.kr
205
Main Products
Product (Ingredient/Formulation) Use Exporting Countries Remarks
1. G-soren Tab. (Artemisiae Argyi Folium Isopropanol ext.(20→1))
Gastritis
2. GL2803(Glimepiride plus Metformin XL) Diabetes
3. GL1203(Tamsulosin)BPH (Benign Prostatic Hyperplasia)
4. GL1204(Felodipine ER) Hypertension
5. GL1314(Ramipril) Hypertension
6. GL1317(Pantoprazole) Gastric ulcer
7. GL1319(Nifedipine SR) Hypertension
8. GL1320(Doxazosin XL) BPH
9. GL1405(Paroxetine CR) Depression
10. GL1502(Limaprost) Buerger's disease
11. GL1505(Tolterodine LA) BPH
12. GL1507(Rabeprazole) Gastric ulcer
13. GL1606(Tramadol plus acetaminophen) Pain
14. GL1608(Atorvastatin) Hyperlipidemia
15. GL1712(Tacrolimus) Immunosuppressant
R&D Pipeline
Compound Name Code Use Stage of Development
Tamsulosin plus Finasteride FDC GL2701 BPH Phase III
Tamsulosin new QD GL2702 BPH Phase III
Oxycodone XL GL2907 Pain Phase I
Pregabalin QD GLA5PR Pain Phase I
Paroxetine CR GLE3PA Vasomotor Symptoms Phase III
Ropinirole XL GL1901 Parkinson's disease BE test
Summary (1 Million Won)
Fiscal Year 2012 2013 2014
Sales 4,021 3,765 7,301
R&D Expenditure 1,007 1,088 1,158
Capital 1,162 1,162 1,162
Financial Figures
No Company Phone Fax Address Homepage
1 Aestura Corporation 100 Cheonggyecheon-ro, Jung-gu, Seoul www.aestura.com/
2 Ahn-Gook Pharm. Co., Ltd. 82-2-3289-4200 82-2-847-8867 993-75 Daelim-dong, Yeongdeungpo-gu, Seoul www.ahn-gook.com
3 Aju Pharm Co., Ltd. 82-2-2630-0700 82-2-2636-7519 413-13 Shindolim-dong, Guro-gu, Seoul www.asiapharm.co.kr
4 Alcon Korea Ltd. 82-2-2007-5000 82-2-2007-5001 Glasstower, Teheran-ro 534, Gangnam-gu, Seoul 135-708 www.alcon.com
5 Alpha Pharm. Co., Ltd. 82-54-552-5381 82-2-54-552-5385 662 Jinjeong-ri, Sanyang-myeon, Mungyeong-si, Gyeongsangbuk-do www.alphapharm.co.kr
6 Arlico.co.Ltd. 82-2-520-6943 82-2-3474-3281 Alico Building, 70-5 Yangjae-dong, Seocho-gu, Seoul www.arlico.co.kr
7 ASTELLAS Pharm Korea, Inc 82-2-3448-0504 82-2-3448-0510 GumHa B/D 6F 41-2 Chungdam-dong, Gangnam-gu, Seoul www.astellas.com/kr
8 B. Braun Korea. Co., Ltd 82-2-3459-7800 82-2-3453-3060 Posco center 13F, 892 Daechi-dong, Gangnam-gu, Seoul www.bbraun.co.kr
9 Baxter Inc. 82-2-6262-7100 82-2-6272-7101 KNTO B/D 5F,10 Da-dong, Jung-gu, Seoul www.baxter.co.kr
10 Bc world pharm. Co.,Ltd. 82-2-2182-0403 82-2-574-5064 Kyung B/D .Gaepo-dong 1184-8 , Gangnam-gu, Seoul www.bcwp.co.kr
11 Binex Co., Ltd. 82-6710-7235 82-2-6710-7299 Ilshin B/D, Dohwa-dong 541, Mapo-gu, Seoul www.bi-nex.com
12 Bolak. Co., Ltd. 82-31-352-6455 82-31-352-4341 307-1 Songsan-ri, Yanggam-myeion, Hwaseong-si, Gyeonggi-do www.bolak.co.kr
13 Boryung Pharm. Co., Ltd. 82-2-708-8000 82-2-708-8439 Boryung B/D, 66-21 Wonnam-dong, Jongno-gu, Seoul www.boryung.co.kr
14 BTO Pharm. Co., Ltd. 82-2-501-4720 82-2-543-8401 3F Daebo Building, 102-6 Munjeong-dong, Songpa-gu, Seoul www.btopharm.com
15 Bukwang Pharm. Co., Ltd. 82-2-828-8114 82-2-828-8029 398-1 Daebang-dong, Dongjak-gu, Seoul www.bukwang.co.kr
16 Celltrion Pharm. Inc 82-32-850-5000 82-32-850-4309 13-6, Songdo-dong, Yeonsu-gu, Incheon www.celltrionph.com
17 Chemtros Co., Ltd 82-31-491-0653 82-31-491-0881 7 Neungan-ro, Danwon-gu, Ansan-si, Gyeonggi-do www.chemtros.com
18 Cho-a Pharm. Co., Ltd. 82-2-2166-4000 82-2-2166-4111 Ace Techno Town 1F, 55-7 Moonrae-dong 3 ga,Youngduengpo-gu, Seoul www.choa.co.kr
19 Chodang Pharm. Co., Ltd. 82-2-869-0181 82-2-869-1192 44 Guro 5-dong, Guro-gu, Seoul www.chodang.com
20 Chong Kun Dang Pharm. Corp. 82-2-2194-0300 82-2-2194-0369 Chong Kun Dang B/D 368, Chungjeongno 3-ga,
Seodaemun-gu, Seoul www.ckdpharm.com
21 Chunhedang Pharm. Co., Ltd. 82-31-675-5561 82-31-676-6320 246-47 Dodang-dong, Wonmi-gu, Pucheon-si, Gyeonggi-Do
22 CJ Healthcare CJ Cheiljedang Center, 330, Dongho-ro, Jung-gu, Seoul 100-400, Korea www.cjp.co.kr/
23 CMG Pharmaceutical CO.,Ltd. 82-2-3453-8816 82-2-3453-8819 7F MJL Building, 204-5 Nonhyun-dong, Gangnam-
gu, Seoul www.cmgpharma.co.kr
24 Cmic CMO Korea Co.,Ltd. 82-32-678-5771 82-32-675-3385 157-3 Dodang-dong, Wonmi-gu, Pucheon-si, Gyeonggi-Do www.cmic-cmo.co.kr
25 Crown Pharm. Co., Ltd. 82-31-443-3922 82-31-443-3921 218-7 Anyang7-dong Manan-gu, Anyang si, Gyeonggi-Do www.crownpharm.co.kr
26 CTCBIO, Inc 82-2-70-4033-0200 82-2-449-6966 CTC Building, 13 Jungdaero 40 gil, Songpa-gu, Seoul www.ctcbio.com
27 C-Tri 82-31-557-0001 82-31-557-6622 778-1 Ilpae-dong, Namyangju-si, Gyeonggi-do www.c-tri.co.kr
28 Dae Lim Pharm Co., Ltd. 82-2-232-1819 82-2-232-7018 164-98, Annyung-dong, Hwaseog-si, Gyeonggi-Do
29 Dae Woo Pharm. Ind. Co., Ltd. 82-51-204-3831 82-51-202-3397 153 Dadaero, Saha-gu, Busan www.daewoopharm.com
30 Daebong LS 82-32-712-8800 82-32-817-8808 122B-9L, 692-8, Gojan-dong, Namdong-gu, Incheon www.daebongls.co.kr
31 Daehwa Pharm. Co., Ltd. 82-33-342-5140 82-33-342-0576 308 Masan-ri, Heongseong-gun, Gangwon-do www.dhpharm.co.kr
32 Daewon Pharm. Co., Ltd. 82-2-2204-7000 82-2-498-9108 229-3 Yongdap-dong, Seongdong-gu, Seoul www.daewonpharm.com
33 Daewoong Pharm. Co., Ltd. 82-2-550-8800 82-2-550-3530 163-3 Samsung-dong, Gangnam-gu, Seoul www.daewoong.co.kr
34 Dai Han Pharm. Co., Ltd. 82-2-2678-8445 82-2-2671-9636 8-3 Yangpyeong-dong 4-ga, Yeongdeungpo-gu, Seoul www.daihan.com
Regular Members(2015. 4)
2016 Directory of Korea Pharmaceutical Industry206
No Company Phone Fax Address Homepage
35 Daiichi Sankyo Korea Co.,Ltd. 82-2-3453-3300 82-2-3452-9756 Posco West 3F, Daechi4-dong, Kangnam-gu, Seoul www.daiichisankyo.co.kr
36 Dalim Biotech Co., Ltd. 82-31-535-6091 82-31-535-6093 907-5 Sangsan-ri, Hyangnam-eup, Hwaseong-si, Geonggi-do www.dalimmedical.co.kr
37 DHP Korea Co., Ltd. 82-43-239-3303 82-43-239-3308 491 Mansu-ri, Gangwoe-myeon, Cheonggwon-gun, Chungcheongbuk-do www.dhpkorea.co.kr
38 Dong In Dang Pharm. Co., Ltd. 82-31-319-1990 82-31-319-1995 Shiwah Complex 1 Ra No.603,1248-8 Jungwang-
dong, Siheung-si, Gyeonggi-do www.dongin-dang.co.kr
39 Dong Koo Pharm. Co., Ltd. 82-2-2688-5421 82-2-2681-1880 195-2 Gocheok 2-dong, Guro-gu, Seoul www.dongkoo.co.kr
40 Dong Kook Pharm. Co., Ltd. 82-2-2191-9900 82-2-566-8542 997-8 Daechi 3-dong, Gangnam-gu, Seoul www.dkpharm.co.kr
41 Dong Kwang Pharm. Co., Ltd. 82-2-776-7641 82-2-777-4874 Yeongak tower 12F, 25-5 Chungmuro 1-ga, Jung-gu,
Seoul www.dkpco.co.kr
42 Dong Wha Pharm. Ind. Co., Ltd. 82-2-2021-9300 82-2-778-2336 5 Sunwha-dong, Jung-gu, Seoul www.dong-wha.co.kr
43 Dong-A Pharmaceutical 64 Cheonhodaero, Dongdaemun-gu, Seoul en.dapharm.com
44 Dong-A ST 64 Cheonhodaero, Dongdaemun-gu, Seoul en.donga-st.com/
45 Dongsung Pharm. Co., Ltd. 82-2-6911-3600 82-50-5191-69081 703-14 Banghak-dong, Dobong-gu, Seoul www.dongsung-pharm.co.kr
46 Dongwoo Syntech Co., Ltd. 82-43-882-7280 82-43-882-7283 152-1, Bondae-Ri, Geumwang-Eup, Eumsung-
Gun, Choongcheongbook-Do www.dongwookr.com
47 Dream Pharma Corp. 82-2-729-4115 82-2-729-4127 Hanwha B/D 13F, 1 Jangkyo-dong, Jung-gu, Seoul www.dreampharma.co.kr
48 Eisai Korea Inc. 82-2-3451-5500 82-2-3451-5599 Revessant B/D 10F, 147-17Samseong-dong, Gangnam-gu, Seoul www.eisaikorea.com
49 Elyson Pharmaceutical Co. Ltd. 82-2-6342-7001 82-2-6342-7003 2F Kyungpung Building, 788-26 Yeoksam-dong,
Gangnam-gu, Seoul www.elyson.co.kr
50 Estech Pharma Co., Ltd. 82-2-3471-2078 82-2-3471-2079 Daekwan B/D 5F, 15-1 Yangjae-dong, Seocho-gu, Seoul www.estechpharma.com
51 Ferring Pharm. Korea Co.,Ltd. 82-2-534-2761 82-2-534-2956 Songwon B/D 7F, 59-5 Banpo-dong, Seocho-gu,
Seoul www.ferring.co.kr
52 Fresenius Kabi Korea Ltd. 82-2-3484-0900 82-2-3484-0957 SaemaeulUndong B/D 3F, 1008-4 Daechi-dong, Gangnam-gu, Seoul www.fresenius-kabi.com
53 Fresenius medical care korea co.,Ltd 82-2-2112-8800 82-2-2112-8804 Landmarktower 7F, 837-36 yeoksam-dong,
Gangnam-gu, Seoul www.fmc-korea.co.kr
54 Galderma Korea Ltd. 82-2-6717-2000 82-2-6717-2001 Bando B/D 7F, 48-1 Banpo-dong, Seocho-gu, Seoul www.galdermakorea.com
55 GlaxoSmithKline Korea 82-2-709-4116 82-2-796-4710 Kukjecenter B/D 9F, 191 Hangangno 2-ga, Yongsan-gu, Seoul www.gsk-korea.co.kr
56 Green Pharm. Co., Ltd. 82-2-842-1301 82-2-842-1302 2F, 4159 Shingil 6-dong, Yeoungdeungpo-gu, Seoul
57 Greencross Corporation 82-31-260-9300 82-31-260-9413 303 Bojeong-dogn, Giheung-gu, Yongin-si, Gyeonggi-do www.greencross.com
58 Guerbet Korea. Ltd. 82-2-3453-1212 82-2-3453-2634 IS B/D 6F, 719-35 Yeoksam-dong, Gangnam-gu, Seoul www.guerbet.co.kr
59 Guju Pharm. Co., Ltd. 82-2-2672-1122 82-2-2679-7569 94-119 Yeoungdeungpo-dong 2-ga, Yeongdeungpo-gu, Seoul www.gujup.co.kr
60 Hamsoa Pharm. Co., Ltd. 82-2-2176-2180 82-2-3443-0825 8F Joil Building 62 Nonhyeon-dong, Gangnam-gu, Seoul www.hamsoapharm.com
61 Han Kook Korus Pharm. Co., Ltd. 82-33-264-5771 82-33-264-5774 1181 Geodu-ri, Dongnae-myeon, Chuncheon-si,
Gangwon-do www.koruspharm.co.kr
62 Hana Pharm. Co., Ltd. 82-2-577-7667 82-2-577-6003 Rocket B/D 6~7F, 747-29 Yeogsam-dong, Gangnam-gu, Seoul www.hanaph.co.kr
63 Hanall Bio Pharm. Co., Ltd. 82-2-2204-1928 82-2-2414-7474 Jamsil I-Space 6F, 11-10 Shinchon-dong, Songpa-gu, Seoul www.hanall.co.kr
64 Handok Pharm. Co., Ltd. 82-2-527-0114 82-2-527-5001 132 Teheran-ro, Gangnam-gu, Seoul www.handok.co.kr
65 Hankooksinyak Pharm. Co., Ltd. 82-41-740-8900 82-41-740-8849 805-15 Jungsan-ri, Yangchon-myeon, Nonsan-si,
Chungcheongnam-do www.hsp.co.kr
66 Hanlim Pharm. Co., Ltd. 82-2-3489-6000 82-2-3489-6101 1656-10 Seocho-dong, Seocho-gu, Seoul www.hanlim.com
67 Hanmi Pharm. Co., Ltd. 82-2-410-9114 82-2-410-9259 Hanmi Tower, 45 Bangi-dong, Songpa-gu, Seoul www.hanmi.co.kr
207
No Company Phone Fax Address Homepage
68 Hanpoong Pharm. Co., Ltd. 82-2-586-5211 82-2-583-8584 981-52 Banbae-dong, Seocho-gu, Seoul www.hanpoong.co.kr
69 Hansol Pharm. Co., Ltd. 82-43-881-6333 82-43-881-6332Chungpyeong-gil 2-11 (Docheong-lee 33-32), Geumwang-eup, Eumsung-gun, Choongcheongbook-Do
www.hansolpharm.com
70 Hanwha Pharma. Co., Ltd. 82-2-959-3161 82-2-959-3621 261 Seokkwan 2-dong, Seongbuk-gu, Seoul www.hwpharm.com
71 Hanzung Pharm. Co., Ltd. 82-42-936-5858 82-42-936-2525 165-7, Sangseo-dong, Daedeok-gu, Daejeon www.hzpharm.co.kr
72 Hawon Pharm. Co. 82-2-554-2012 82-2-554-4557 788-1 Yeogsam-dong, Gangnam-gu, Seoul www.hawonpharm.co.kr
73 Hospira, Inc 82-2-3497-1870 82-2-2009-4801 8F IKP Building, 300-6 Yeomgok-dong, Seocho-gu, Seoul www.hospira.co.kr
74 Humedix. Co., Ltd. 82-70-7492-5600 82-31-420-5650 Room 502 Anyang-megavalley, 268 Hagui-ro, Dongan-gu, Anyang-si, Gyeonggi-do humedix.com
75 Huniz. Co., Ltd. 82-51-831-1030 82-51-831-1040 1529-4, Songjeong-dong, Gangseo-gu, Busan www.huniz.kr
76 Huons Co., Ltd 82-31-854-4700 82-31-6455-0740 C-901 PangyoInoBelly, 621 Sampyeong-dong, Bundang-gu, Seongnam-si, Gyeonggi-do www.huons.com
77 Hutecs Korea Co., Ltd 82-31-377-7900 82-31-377-7911 555-2 Yeongchun-ri, Dongtan-myeon, Hwaseong-si, Gyeonggi-do www.hutecs.co.kr
78 Hyundai Pharm. Ind. Co., Ltd. 82-2-2600-3813 82-2-2693-7628 Hyungai pharm B/D, 204-4 Nonhyeon-dong,
Gangnam-gu, Seoul www.hyundaipharm.co.kr
79 Icure Pharm. Inc. 82-31-776-3776 82-31-776-3770 Room 1305 Technopark Techcentre, 190-1 Sangdaewon-dong, Jungwon-gu, Seongnam-si www.icure.co.kr
80 Ik-Su Pharm. Co., Ltd. 82-2-416-1112 82-2-416-1118 Iksoo B/D, Amsa-dong 488-20, Kangdong-gu, Seoul www.iksu.co.kr
81 Il Dong Pharm. Co., Ltd. 82-2-526-3114 82-2-526-3030 60 Yangjae-dong, Seocho-gu, Seoul www.ildong.com
82 Ilsung Pharm Co., Ltd. 82-2-3271-8800 82-2-2701-6335 44-7 Wonhyoro1-ga, Yongsan-gu, Seoul www.ilsung-ph.co.kr
83 Ilwha Co., Ltd. 82-31-550-0100 82-31-550-0105 437 Sutaek1-dong, Guri-si, Gyeonggi-Do www.ilhwa.co.kr
84 Il-Yang Pharm. Co., Ltd. 82-2-570-3700 82-2-570-3708 544-5, Dogok-dong, Gangnam-gu, Seoul www.ilyang.co.kr
85 Ipsen Group 82-2-512-6693 82-2-512-6692 13F Sesin Building, 129-11 Cheongdam-dong, Gangnam-gu, Seoul www.ipsen.com
86 Isu Abxis Co., Ltd. 82-2-2227-8888 82-2-2227-8887 Yeonse medical school 6F, Sinchon-dong 134, Seodaemoon-gu, Seoul www.abxis.com
87 Janssen Korea Ltd. 82-2- 2094-4500 82-2- 538-5632 25F LG Yongsan Tower B/D, 191 Hangang-ro 2ga , Yongsan-gu, Seoul www.janssenkorea.com
88 Je Il Pharm. Co., Ltd. 82-53-583-6226 82-53-583-5775 Daechun-dong 739, Dalseo-gu, Daegu city www.jeilphar.co.kr
89 Jeil Pharm. Co., Ltd. 82-2-549-7451 82-2-549-4045 343, Sapyeong-daero, Seocho-gu, Seoul www.jeilpharm.co.kr
90 Jin Yang Pharm. Co., Ltd. 82-2-3470-0300 82-2-3470-0390 1532-9 Seocho-dong, Seocho-gu, Seoul www.jinyangpharm.com
91 JRP Co., Ltd. 82-31-353-6551 82-31-354-1539 900-2, Sangsin-ri, Hyangnam-myeon, Hwaseong-si, Gyeonggi-do www.ejrp.co.kr
92 JW Pharmaceutical 82-2-840-6777 82-2-841-1213 698 Shindaebang-dong, Dongjak-gu, Seoul www.jw-pharma.co.kr
93 JW Shinyak 82-2-2109-3300 82-2-2109-3388 3F 13cha Daeryung Techno Tower, Gasan-dong, Geumcheon-gu, Seoul www.jw-shinyak.co.kr
94 KMS Pharm Co., Ltd. 82-31-215-5456 82-31-215-5925 492-12, Maetan 3-dong, Yeongtong-gu, Suwon-si, Gyeonggi-do www.kmspharm.com
95 Kolmar Korea 82-41-862-1057 82-41-862-7637 170-7 Seojeong-ri, Jeonui-myeon, Yeongi-gun, Chungcheongnam-do www.kolmar.co.kr
96 Kolmar pharma 82-43-640-0088 82-43-640-0007 93 Biovalley 2-ro, Jecheon-si, Chungcheongbuk-do www.kolmar.co.kr
97 Kolon Pharma 82-2-2120-8300 82-2-2120-8301 6F Annex to Kolon Tower, 1-22 Byeoryang-dong, Gwacheon-si, Gyeonggi-do www.kolonpharm.co.kr
98 Korea Atomic Energy Research Institute 82-42-868-4641 82-42-868-2106 Advanced Reactor Development Institute, Daedeok-
daero 989-11, Yuseong-gu, Daejeon www.kaeri.re.kr
99 Korea Global Pharm. Co., Ltd. 82-41-951-4300 82-41-951-4344 417-4, Seokchon-ri, Jongcheon-myeon, Seocheon-
gun, Chungcheongnam-do www.globalpharm.co.kr
100 Korea INS Pharm. Inc. 82-61-371-3000 82-61-371-3015 1065 Daepo-ri ,Dong-myeon ,Hwasun-gun, Jeollanam-do www.inspharm.co.kr
2016 Directory of Korea Pharmaceutical Industry208
No Company Phone Fax Address Homepage
101 Korea Jinseng Corp. 82-2-2189-6500 82-2-2189-6559 Cosmo tower, Daechi-dong 1002, Kangnam-gu, Seoul www.kgc.or.kr
102 Korea Kowa Company Ltd. 82-2-6930-4800 82-2-6930-4808 7F Gookmin-1 B/D, 302 Yeongdong-daero,
Gangnam-gu, Seoul www.kowakorea.com
103 Korea mcnulty. Co., Ltd. 82-31-378-1460 82-31-378-1468 713-2, Jung-ri, Dongtan-myeon, Hwaseong-si, Gyeonggi-do www.koreamcnulty.co.kr
104 Korea Otsuka Pharm. Co., Ltd. 82-2-3287-9000 82-2-3287-9019 770-9 Yeoksam-dong, Gangnam-gu, Seoul www.otsuka.co.kr
105 Korea Pharma Co., Ltd. 82-2-558-1277 82-2-558-1677 Baeklim B/D 8F, 823-33 Yeogsam-dong, Gangnam-gu, Seoul www.koreapharma.co.kr
106 Korea Prime Pharm. Co., Ltd. 82-62-233-1110 82-62-233-3298 Daein Building, 158-3 Daein-dong, Dong-gu,
Gwangu www.koreaprime.co.kr
107 Korea United Pharm. Inc. 82-2-512-9981 82-2-548-4599 154-8 Nonhyun-dong, Gangnam-gu, Seoul www.kup.co.kr
108 Korea Vaccine Co., Ltd. 82-2-443-1961 82-2-443-4484 Doowon B/D, 87-3 Garak-dong, Songpa-gu, Seoul www.koreavaccine.com
109 Korean Drug Co., Ltd. 82-2-529-6100 82-2-529-6114 423-2 Dogok-dong, Gangnam-gu, Seoul www.nicepharma.com
110 Kuhnil Pharm. Co., Ltd. 82-2-714-0091 82-2-719-0493 Osong B/D 27-11Jeong-dong, Jung-gu, Seoul www.kuhnil.com
111 Kukbo Science Co., Ltd. 82-43-264-7765~8 82-43-267-7769 49 Sandan-ro, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do www.kukboscience.co.kr
112 Kukje Pharm. Ind. Co., Ltd. 82-31-781-9081 82-31-781-6040 513-2 Yatap-dong, Bundang-gu, Seongnam-si,
Gyeonggi-do www.kukjepharm.co.kr
113 Kunwha Pharm. Co., Ltd. 82-2-2047-7700 82-2-443-0589 1002 Yangjae-daero, Songpa-gu, Seoul www.kunwha.com
114 Kwang Dong Pharm. Co., Ltd. 82-2-6006-7777 82-2-6006-7024 1577-4 Seocho-dong, Seocho-gu, Seoul www.ekdp.com
115 Kyongbo Pharm. Co., Ltd. 82-41-545-0456 82-41-546-8427 345-6 Silok-dong, Asan-si, Chuncheongnam-do www.kbpharma.co.kr
116 Kyowa Hakko Kirin Korea Co. Ltd. 82-2-3471-4921 82-2-3471-4322 5F Poonglim Building, 823 Yeoksam-dong,
Gangnam-gu, Seoulwww.kyowa-kirin-korea.com
117 Kyung Dong Pharm. Co., Ltd. 82-2-576-6121 82-2-577-5195 1659-5 Inheon-dong, Gwanak-gu, Seoul www.kdpharma.co.kr
118 Kyung Nam Pharm. Co., Ltd. 82-2- 3490-5105 82-2- 3490-5129 889-13 Daechi-dong ,Gangnam-gu, Seoul www.kyungnampharm.
co.kr
119 Laboratorios Cinfa Ltd. 82-2-3488-6400 82-2-3488-6401 7F Medica Building, 1489-2, Seocho-dong, Seocho-gu, Seoul www.cinfakorea.com
120 LG Life Sciences, Ltd. 82-2-3773-1114 82-2-6924-3051 LG Gwangwamoon Building, 92 Sinmun-ro 2ga, jongno-gu, Seoul www.lgls.co.kr
121 Medicakorea Co., Ltd. 82-70-4018-8000 82-2585-9689 3, 8F Medica Building, 1489-2 Seocho 3 dong, Seocho-gu, Seoul www.medicakorea.com
122 MG Co., Ltd. 82-2-2057-1002 82-2-2057-1003 Yangjae B/D, Yangjae-dong 261, Seocho-gu, Seoul www.medi-green.co.kr
123 Mirae Pharma. Korea 82-2-583-9077 82-2-583-7421 174 Saimdang-ro, Seocho-gu, Seoul www.miraepharmkorea.co.kr
124 Mitsubishi Tanabe Pharma Korea Co., Ltd 82-2-579-0121 82-2-579-0125 R902 9F Yookyung Building, 239-1 Nonhyeon-dong,
Gangnam-gu, Seoulwww.mt-pharma-korea.com
125 Mother's Pharmaceutical co., Ltd 82-2-2026-8890 82-2-2026-8094 1-702 Gasandigital 2-ro, Geumcheon-gu, Seoul www.motherspharm.com
126 Mundipharma Korea 82-2-568-5689 82-2-568-5634 541 Namdaemoon-ro 5, Jung-gu, Seoul www.mundipharma.co.kr
127 Myung In Pharm. Co., Ltd. 82-2-587-9060 82-2-585-0352 Myungin B/D, 1539-9 Seocho-dong, Seocho-gu, Seoul www.myunginph.co.kr
128 Myung Moon Pharm. Co., Ltd. 82-2-6711-2000 82-2-572-5137 Myungmoon B/D, 946-18 Dogok-dong, Gangnam-
gu, Seoul www.mmpharm.co.kr
129 Nelson Korea Pharm Co.,Ltd. 82-2-588-0941 82-2-588-0170 Nelson B/D 3F, Seocho-dong 1462-17, Seocho-gu,
Seoul www.nelsonkorea.co.kr
130 Nensys Co., Ltd. 82-31-232-5285 82-31-234-4410 836 Seryu3-dong, Gwonsun-gu, Suwon-si, Gyeonggi-Do www.nensys.co.kr
131 Newgenpharm Inc. 82-2-580-5900 82-2-580-5999 BK Tower 11F, 942-2 Daechi 2, Gangnam-gu, Seoul www.newgenpharm.com
132 Novo Nordisk Pharma Korea Ltd. 82-2-2188-8947 82-2-2188-8980 16F Korea AD Culture Center, Sincheon-dong
,Songpa-gu, Seoul www.novonordisk.co.kr
133 Ono Pharma Korea Co., LTD. 82-2-928-8423 82-2-925-2151 13F, The-K twin towers B, 50 Jong-ro 1-gil, Jongno-
gu, Seoul www.ono.co.jp/eng/
209
No Company Phone Fax Address Homepage
134 Pharmaking Co., Ltd. 82-43-882-3501 82-43-882-3502 363 Ogung-ri, Gamgok-myeon, Eumseong-gun, Chungcheongbuk-do www.pharmaking.co.kr
135 Pharmbio Korea Co., Ltd 82-2-587-2551 82-2-587-2552 7F Samhomulsan Building A, 275-1 Yangjae-dong, Seocho-gu, Seoul www.pharmbio.co.kr
136 Pharvis Bio Tech Korea Corp. 82-2-579-6262 82-2-579-0880 517-9 Doggok-dong, Gangnam-gu, Seoul www.pharvis.co.kr
137 PMG PHARM Co., Ltd 82-31-439-5470 82-31-405-5471 726-4 Bugok-dong, Sanrok-gu, Ansan-si, Gyeonggi-do
138 Reyon Pharm. Co., Ltd. 82-2-793-5557 82-2-798-7538 38-6 Dongbinggo-dong, Yongsan-gu, Seoul www.reyonpharm.co.kr
139 Richwood Trading Co., Ltd. 82-2-757-3071 82-2-3789-6993 Danam B/D 22F, 120 Namdaemoonno 5-ga, Jung-gu,
Seoul www.richwood.net
140 RP corp., Inc 82-2-568-0051 82-2-554-0871 163-3 Samsung-dong, Gangnam-gu, Seoul www.rpskorea.com
141 Sae Han Pharm. Co., Ltd. 82-2-533-7417 82-2-553-7416 Samoh B/D 4F, Yeoksam1-dong 751-10, Kangnam-gu, Seoul www.shpharm.co.kr
142 Sam Chun Dang Pharm. Co., Ltd. 82-2-2046-1100 82-2-2046-1101 Seocho-dong 1606-1, Seocho-gu, Seoul www.scd.co.kr
143 SamA Pharm. Co., Ltd. 82-2-2056-7200 82-2-2056-7300 Sama B/D, 80-18 Cheongdam-dong, Gangnam-gu, Seoul www.samapharm.co.kr
144 Samik Pharm. Co., Ltd. 82-2-928-0661 82-2-924-3749 Dongbo B/D 4F, 1253 Sungin-dong, Jongno-gu, Seoul www.samik.co.kr
145 Samil Pharm. Co., Ltd. 82-2-520-0300 82-2-588-5924 990-1 Bangbae1-dong, Seocho-gu, Seoul www.samil-pharm.com
146 Samjin Pharm. Co., Ltd. 82-2-3140-0605 82-2-338-8032 338-8 Seokyo-dong, Mapo-gu, Seoul www.samjinpharm.co.kr
147 Samnam Pharm. Co., Ltd. 82-41-754-3771 82-41-752-0086 99-1 Sang-ri, Geumsan-eup, Geumsan-gun, Chuncheongnam-do www.samnam51.com
148 Samsung Pharm. Ind. Co., Ltd. 82-2-3408-4500 82-2-3408-4702 614-4 Junggok-dong, Gwangjin-gu, Seoul www.sspharm.co.kr
149 Samyang Biopharm. Corp. 82-2-740-7116 82-2-743-6626 263 Yeonji-dong, Jongno-gu, Seoul www.samyangbiopharm.
co.kr
150 Samyang Chemical Co., Ltd. 82-2-3488-5592 82-2-521-3100 1500-10 Seocho 3-dong, Seocho-gu, Seoul www.samyangchem.com
151 SANDOZ Korea Co., Ltd 82-2-768-9300 82-2-753-1287 Yonsei severance B/D 18F, 84-11 Namdaemonn-ro 5ga, Junggu, Seoul www.sandoz.com
152 Santen Pharm. Korea Co., Ltd. 82-2-754-1434 82-2-754-2929 1678-4 Seocho-dong, Seocho-gu, Seoul
153 SBP 82-41-857-3686 82-41-857-7854 533-2 Bongkok-ri, Banpo-myun, Gongju-si, Chungchungnam-do www.sbp.com
154 Schnell BioPharmaceuticals., Inc 82-2-561-4011 82-2-561-4012 L2 Hanrasigmavalley 442-2 Sangdaewon-dong,
Jungwon-gu, Seongnam-si, Gyeonggi-do www.schnell.kr
155 Seoul Pharma co. Ltd. 82-31-497-1931 82-31-431-0715 Kyungje-ro 59, Siheung-si, Gyeonggi-do www.seoulpharma.com
156 Sewon Cellontech Co.,Ltd 82-2-2167-9000 82-2-2167-9157 11F GooodmorningShinhan Tower, Yeouidae-ro 70, Yeongdeungpo-gu, Seoul www.sewoncellontech.com
157 Shin Poong Pharm. Co., Ltd. 82-2-2189-3426 82-2-2189-3439 748-31 Yeoksam-dong, Gangnam-gu, Seoul www.shinpoong.co.kr
158 Sinil Pharm. Co., Ltd. 82-2-2211-6700 82-2-2212-6539 Sinil B/D, 315-18 Jangan 2-dong ,Dongdaemun-gu, Seoul www.sinilpharm.com
159 Sinsin Pharm. Co., Ltd. 82-31-491-6151 82-31-491-6153 776-6 Wonsi-dong, Danwon-gu, Gyeonggi-do www.sinsin.com
160 SK Chemicals Life Science 82-2-2008-2008 82-2-2008-2009 686 Sampyung-dong, Bundang-gu, Seongnam-si, Gyeonggi-do www.skchemicals.com
161 SS Pharm Co.,Ltd 82-31-491-6311 82-31-491-4797 533-2 Bongkok-ri, Banpo-myun, Gongju-si, Chungchungnam-do www.susungpharm.co.kr
162 Suheung Capsule. Co., Ltd. 82-2-2210-8116 82-2-2217-2357 435-5 Jangan 3-dong, Dongdaemun-gu, Seoul www.suheung.co.kr
163 Sung Kwang Pharm. Co., Ltd. 82-41-566-8283 82-41-566-8322 555-42 Baekseok-dong, Seobuk-gu, Cheonan-si,
Chungcheongnam-do www.skpharm.net
164 Sungwon Adcock Pharm. Co., Ltd. 82-2-3665-2872 82-2-3665-2874 Room 302 Gayang-technotown, 1487 Gayang
3-dong, Gangseo-gu, Seoul www.swpharm.com
165 Taejoon Pharm. Co., Ltd. 82-2-798-6601 82-2-795-8873 657-87 Hannam-dong, Yongsan-gu, Seoul www.taejoon.co.kr
2016 Directory of Korea Pharmaceutical Industry210
No Company Phone Fax Address Homepage
166 Taiguk Pharm. Co., Ltd. 82-80-3474-7761 82-2-3472-5501 Seowoo B/D 6F, Yeoksam-dong 837-12, Kangnam-gu, Seoul www.taiguk.co.kr
167 Takeda Pharmaceuticals Korea Co., Ltd. 82-2-3484-0800 82-2-3484-0808 12F KT&G Cosmodaechi Tower, 945-10 Daechi-dong,
Gangnam-gu, Seoul www.takeda-asia.com
168 Teva-Handok. Co., Ltd. 82-2-521-5501 82-2-527-5510 132 Teheran-ro, Gangnam-gu, Seoul
169 Theragen Etex Pharm. Inc. 82-2- 3463-7111 82-2- 3463-8111 Kyunghee B/D 5F, 517-5 Dogok-dong, Gangnam-gu,
Seoul www.etexpharm.com
170 UK Chemipharm Co., Ltd. 82-31-310-1983 82-31-310-1985 R38 6F Asandigital Park, 1123 Shingil-dong, Danwon-gu, Ansan-si, Kyunggi-do www.ukchemipharm.com
171 Unimed Pharm. Inc. 82-2-2240-5100 82-2-2240-5115 Unimed B/D, 250-8 Jamsilbon-dong, Songpa-gu, Seoul www.unimed.co.kr
172 Union Korea Pharm. Co., Ltd. 82-2-489-3611 82-2-487-3611 Wonwae B/D 5F, 389-1 Poongnap 2-dong, Songpa-
gu, Seoul www.ukp.co.kr
173 Whan In Pharm. Co., Ltd. 82-2-405-3000 82-2-404-2518 84-1 Munjeong-dong, Songpa-gu, Seoul www.whanin.com
174 White Global Pharmaceutical Corp. 82-2-541-4884 82-2-541-8448 621, Yeongdong-daero, Gangnam-gu, Seoul www.whpharma.com
175 Won Kwang Pharm. Co., Ltd 82-63-832-3114 82-63-833-4114 827 Shindong-ri, Chunpo-myeon, Iksan-si,
Jeonrabuk-do www.wonpharm.co.kr
176 YD Diagnostics Co., Ltd. 82-31-329-2000 82-31-329-2002 Seo-ri 173, Idong-myun, Cheoin-gu, Yongin-si, Kyunggi-do www.yd-diagnostics.com
177 Yoo Young Pharm. Co., Ltd. 82-2-6207-6114 82-2-6207-6135 915-9 Bandbae 1-dong, Seocho-gu, Seoul www.yypharm.co.kr
178 Young Poong Pharm. Co., Ltd. 82-2-823-3251 82-2-821-2913 402-1 Daebang-dong, Dongjak-gu, Seoul www.yppharm.co.kr
179 Yuhan Corp. 82-2-828-0181 82-2-828-0300 49-6 Daebang-dong, Dongjak-gu, Seoul www.yuhan.co.kr
180 Yuhan Medica Corp. 82-43-215-9435 82-43-215-1738 807-1 Yangcheong-ri, Ochang-eup, Cheongwon-gun, Chungcheongbuk-do www.yuhanmedica.co.kr
181 Yuhan-clorox Co., Ltd. 82-2-702-6561 82-2-702-6606 Sungwoo B/D 6F, 51-1 Dohwa-dong, Mapo-gu, Seoul www.yuhanclorox.co.kr
182 Yuil Pharm Tech. Co., Ltd. 82-43-537-2161 82-43-537-2163 365-1 Shinwon-ri, Iwol-myeon, Jincheon-gun, Chungcheongbuk-do
183 Yungjin Pharm. Co., Ltd. 82-2-2041-8200 82-2-2041-8219 451-20 Chonho 3-dong, Gangdong-gu, Seoul www.yungjin.co.kr
184 Yuyu Pharma, Inc. 82-2-2253-6600 82-2-2253-6200 Yu Yu B/D, 358-9 Shindang-dong, Jung-gu, Seoul www.yuyu.co.kr
211
No Company Phone Fax Address Homepage
1 Abnoba Korea Co.,Ltd 82-2-6340-5114 82-2-6340-5588 Room1704 Ace High-end Tower2, 222-14 Guro3-dong, Guro-gu, Seoul www.krabnoba.com
2 Bioland 82-41-564-8615 82-564-8619 394 Songjeong-ri, Byungcheon-myeon, Dongnam-gu, Cheonan-si, Chungcheongnam-do www.biolandkorea.com
3 BioLeaders 82-42-934-7671 82-42-934-7670 13 Techno8-ro, Yuseong-gu, Daejeon, Korea www.bioleaders.co.kr
4 C&R Research 82-2-6251-1500 82-2-6251-1504 3F Leeyangwon Building, 63-7 Kyungwoon-dong, Jongno-gu, Seoul www.cnrres.co.kr
5 Crystalgenomics 82-31-628-2700 82-31-628-2701 5F, Tower A, Korea Bio Park 700, Daewangpangyo-ro, Bundang-gu, Seongnam-si, Cyeonggi-do www.crystalgenomics.com
6Daegu-Gyeongbuk Medical Innovation Foundation
82-53-790-5113 82-53-790-5119 2387 dalgubeol-daero, Suseong-gu, Daegu www.medivalley.re.kr
7 DreamCIS Inc. 82-2010-4500 82-2-720-5385 R1010 Jeokseon-Hyundai Building, 80 Jeokseon-dong, Jongno-gu, Seoul www.dreamcis.com
8 Genexine Co.,Ltd. 82-31-628-3200 82-31-628-3229 B-4F Korea Bio Park, 694-1, Sampyeong-dong, Bundang-gu, Seongnam-si, Gyeonggi-do www.genexine.com
9 Glpharmtech.corp. 82-31-739-5220~3 82-31-739-5224 R714 Chungang Induspia 5th, Sangdaewon-dong, Jungwon-gu, Seongnam-si, Gyeonggi-do
10 Korea Institute of Toxicology 82-42-610-8250 82-42-610-8085 141 Gajeong-ro, Yuseong-gu, Daejeon 305-343 www.kitox.re.kr
11 KT&G Life Sciences Corp. 82-31-303-8831 82-31-303-5831B-1004~6 Digital Empire BLDG, 16, Deogyeong-daero 1556beon-gil, Yeongtong-gu, Suwon-si, Gyeonggi-do
www.ktngls.com
12 Medihelpline 82-2-2026-0707 82-2-2026-0708 R1207 Woorim Lions Building B, 371-28 Gasan-dong, Geumcheon-gu, Seoul www.medihelpline.co.kr
13 Modern Cell & Tissue Technology 82-2-3446-8884 82-2-3445-1380 R519 Seoul Technopark, 172 Gongneung 2-dong,
Nowon-gu, Seoul www.mctt.co.k
14 PHARMICELL Co.,Ltd 82-2-3496-0114 82-2- 3496-0159 12F Chungho Building, 120 Dosandae-ro, Gangnam-gu, Seoul www.pharmicell.com
15 Samsung Bioepis Co., Ltd 82-32-455-3114 82-32-455-6119 107, Cheomdan-daero, Yeonsu-gu, Incheon www.samsungbioepis.com
16 YD Global Life Science Company 82-2-576-9331 82-2-576-9334 R212 Dongseoul Onette, 339-1 Gil-dong, Gangdong-
gu, Seoul www.bioyd.co.kr
Associated Members(2015. 4)
2016 Directory of Korea Pharmaceutical Industry212